VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 25 (22-31 octubre / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

VACYT

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

CUBA

Noticias en la Web

Under-twos hit hard by pneumococcal disease

Oct 23. And overall cases are expected to surpass last year's figures, according to figures from the National Notifiable Diseases Surveillance System. More than 900 cases were reported in the first half of this year, compared with 698 cases over the same period last year.

"Children under two are among the most affected by the surge in invasive pneumococcal disease, which has rebounded after a dip during covid lockdowns."

Recently released 2022 figures show the most affected groups were children under age two, adults between the ages of 60 and 70, and children between age two and five.

While exact figures for the under-two age group haven't yet been released for this year, there were 144 cases of invasive pneumococcal disease in under-fives in the first half of this year compared to 122 cases in the first half of last year.

Similar jumps have been seen in the 60-to-70 age group, with 121 cases in the first half of this year, compared with 88 cases in the same period last year.

Dr Rod Pearce, South Australian GP and chair of the Immunisation Coalition, said pneumococcal vaccines were evolving and improving, making it important to check whether older patients had recently been vaccinated.

"They may need the latest pneumococcal vaccine," he told TMR.

The PneumoSmart vaccination tool could identify which vaccine patients needed based on their vaccination history, he said.

Dr Pearce said community acquired pneumonia should be treated "early and appropriately" with antibiotics.

Professor Robert Booy, Sydney infectious diseases paediatrician, said it was concerning that Streptococcus pneumoniae serotype 3 was again the most dominant serotype. This is despite its inclusion in the pneumococcal vaccine given to infants.

Serotype 3 had been the most dominant serotype since 2014, and in 2022 it remained the most dominant serotype in children under five years, including the most vulnerable cohort of children under two years, the University of Sydney expert said.

"We've also seen a rise in serotype 33F to become the second most prevalent serotype in 2022 among infants under two years followed by serotypes 19F, 15B and 22F together with 38," he said.

"Throughout the first two years of the pandemic, invasive pneumococcal disease cases fell largely due to covid non-pharmaceutical intervention … and the current resurgence of invasive pneumococcal disease cases was expected."

There are more than 100 Streptococcus pneumoniae serotypes which can cause different clinical presentations of pneumococcal disease, including meningitis, pneumonia and bacteraemia, but 23 serotypes cause most infections.

Professor Booy said last year more than half the cases of empyema – a serious complication of pneumonia

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

caused by Streptococcus pneumoniae – were in children under five years. Of those, 58% were caused by serotype 3.

“From an epidemiological perspective serotype 3 has always been a serotype of concern given its unique polysaccharide coat structure and its ability to cause breakthrough disease despite its inclusion in pneumococcal vaccines.”

Because current vaccines were, at best, only partially protective, Professor Booy said more effective and immunogenic vaccines to protect against serotype 3 needed to be developed.

Professor Booy told TMR that pneumococcal pneumonia caused by serotypes not covered by the vaccine were again a threat.

“Now that covid is on the wane and mixing and crowding are on the up, we’ve got as much pneumonia as we had before covid.”

The overall number of bacterial and viral infections were rising, and that increase could continue into summer and the new year, he said.

While pneumococcal vaccine offered some protection, Professor Booy said it was “less than optimal”.

“We’re seeing pneumonia again, and we’re seeing it at the extremes of life. Even if you’re vaccinated, be aware it could still be pneumonia caused by a serotype not protected by the vaccine.”

Public health and infectious diseases epidemiologist Professor Paul Van Buynder said both vaccine-covered and non-vaccine covered serotypes appeared to be on the rise.

“As invasive pneumococcal disease cases return to pre-pandemic levels it’s advisable young children, Indigenous Australians and older adults keep up with the pneumococcal NIP schedule,” said the Griffith University professor.

Fuente: Medical Republic. Disponible en https://acortar.link/y2Bvj0

Pfizer Meningococcal Vaccine Nabs FDA Nod, Offering More Convenient Dosing

Oct 23. The FDA approved Pfizer’s Penbraya for vaccinating against five bacterial groups that can cause meningococcal disease. Pfizer already has vaccines covering those groups, but Penbraya addresses all of them in a single vaccine, making dosing easier for patients.



Photo: BSIP/Universal Images Group, via Getty Images

The FDA has approved a new Pfizer meningococcal vaccine whose simpler dosing schedule is expected to make it easier for children and young adults to get fully vaccinated to protect against a rare infection that can quickly become fatal within 24 hours.

Five groups of Neisseria meningitidis bacteria are the most common cause of meningococcal disease, which causes infections of the lining of the brain and spinal cord as well as the blood. For those who survive serious cases of the infection, the effects can still be long lasting.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

Pfizer already had four of the culprit bacterial groups covered with a vaccine called Nimenrix. Another Pfizer vaccine called Trumenba covers the fifth group of bacteria. Penbraya, the meningococcal vaccine approved by the FDA on Friday, combines Nimenrix and Trumenba in a single shot. The regulatory decision covers use of this new vaccine in those ages 10 through 25. Penbraya is administered as two intramuscular injections given six months apart.

Penbraya is a bacterial vaccine. It works by what's called active immunization, in which the immune system is prompted to produce antibodies against target pathogens. FDA approval of the new Pfizer vaccine is based on the results of clinical trials that compared Penbraya to currently available meningococcal vaccines. Results showed this vaccine was "noninferior," meaning it was not worse at eliciting an immune response versus the comparator vaccines.

"In a single vaccine, Penbraya has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots," Annaliesa Anderson, senior vice president and head, vaccine research and development at Pfizer, said in a prepared statement.

The Phase 3 study for Penbraya enrolled more than 2,400 patients from the U.S. and Europe. The most common adverse reactions were pain at the injection site, fatigue, headache, injection site redness, muscle pain, injection site swelling, joint pain, and chills. The vaccine's label also cautions that Guillain-Barré syndrome, an immune response that damages nerves, has been reported after dosing of other meningococcal vaccines.

The next step for Penbraya is a recommendation from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. This vaccine is the first agenda item for the committee's next meeting, scheduled for this Wednesday.

Pfizer isn't the only company trying to offer protection against meningococcal infection with fewer shots. GSK's pentavalent meningococcal vaccine candidate is a combination of that company's approved vaccines, Bexsero and Menveo. In March of this year, the British pharmaceutical giant reported Phase 3 results showing this vaccine candidate, administered as two doses six months apart, was non-inferior to the two approved GSK meningococcal vaccines.

Fuente: Med City News. Disponible en https://acortar.link/Fr6Pl0

López Obrador defiende vacuna cubana Abdala al aplicarse refuerzo contra el COVID-19

24 oct. El presidente mexicano Andrés Manuel López Obrador se aplicó el martes la vacuna cubana Abdala durante un acto en el que defendió los biológicos de Cuba y Rusia que utilizará su gobierno como refuerzo contra el COVID-19 y cuya efectividad ha sido cuestionada por algunos especialistas.

"No se dejen confundir", dijo López Obrador tras aplicarse el refuerzo cubano y otra vacuna contra la influenza durante un acto en el palacio de gobierno donde también fue vacunado el secretario de Salud, Jorge Alcocer.

El mandatario, que se contagió hace seis meses de COVID-19 por tercera vez, consideró "absurdos gigantescos" los comentarios que se han hecho contra la eficacia de las vacunas cubanas y rusas y sostuvo que las críticas responden a intereses, pero no ofreció detalles.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

"Ha habido desinformación, todo por interés o mala fe", dijo López Obrador al defender las evaluaciones que realizó la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) para la aprobación de los inoculantes y adelantó que próximamente se autorizará la venta en el país de las vacunas Pfizer, AstraZeneca y Moderna.

El subsecretario de Prevención y Promoción de la Salud, Ruy López, anunció el martes que ya se emitió una opinión favorable para las vacunas de Pfizer y Moderna y que se solicitó más información en el caso de AstraZeneca.

López Obrador informó que la vacuna Patria, que desarrolló México, ya está lista y podría estar disponible para noviembre. Algunos analistas han señalado que el biológico mexicano no está diseñado para las nuevas variantes del coronavirus.

ARCHIVO - El presidente mexicano Andrés Manuel López Obrador habla durante una conferencia en el Zócalo, en la Ciudad de México, el 1 de julio de 2023. (Aurea Del Rosario/AP)

El gobierno mexicano anunció en septiembre que se utilizarían más de nueve millones de dosis de la vacuna rusa Sputnik y de Abdala como parte de un plan nacional de refuerzo contra el COVID-19 que se aplicará en los hospitales públicos a la población mayor de 60 años, embarazadas y personas con comorbilidades y enfermedades de alto riesgo.

En ese momento Alcocer dijo que México contaba con más de 5,38 millones de dosis de la vacuna cubana y que se esperaba la llegada de cuatro millones de unidades de la vacuna rusa.

El gobernante, de 69 años, se contagió de COVID-19 a principios de 2021 y un año después se enfermó nuevamente con el virus. Tras el segundo contagio López Obrador, que sufrió en 2013 un infarto, se sometió a un cateterismo.

Fuente: Los Angeles Times. Disponible en https://acortar.link/9nK4bN

CDC advisers vote to recommend routine use of the mpox vaccine to protect people at high risk of infection

Oct 26. Men who have sex with men and others who are at high risk of mpox infection should get two doses of the Jynneos vaccine, even now that the recent public health emergency in the United States has passed, according to an independent panel of experts that advises the US Centers for Disease Control and Prevention on its vaccine decisions.

CDC's Advisory Committee on Immunization Practices, or ACIP, voted unanimously on Wednesday to recommend that certain individuals ages 18 and older who are at high risk for getting mpox continue to get the vaccine as a routine part of their sexual health care. Previously, the CDC had recommended vaccination of high-risk individuals during the outbreak.

The recommendations now move to CDC Director Dr. Mandy Cohen, who must sign off.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

More than 31,000 Americans were diagnosed with mpox in the 2022-2023 outbreak, including 55 who died, according to CDC data. Most of those who were infected were gay men.

According to the CDC, people at high risk for catching mpox include gay, bisexual, and other men who have sex with men, transgender and non-binary people who in the past six months have had at least one of the following: a new diagnosis of at least one sexually transmitted disease; more than one sex partner; sex at a commercial sex venue or in conjunction with a large public event in an area where mpox is spreading; sexual partners of people who have those risks; and people who plan to participate in any of the previous activities.

The Advisory Committee on Immunization Practices voted 14-0 on Wednesday to recommend people at high risk of mpox infection get two doses of the Jynneos vaccine. Mario Tama/Getty Images .

More than 2 million people in the United States are eligible for vaccination against mpox under the new recommendations, according to the CDC. To date, approximately 23% of this group has received the recommended two doses of Jynneos.

Bavarian Nordic, the manufacturer of the vaccine, says it's preparing for a commercial launch of Jynneos in the United States in the first half of 2024.

Fuente: CNN. Disponible en https://acortar.link/uez598

Quebec could reevaluate baby vaccines as post-pandemic viruses change needs

Oct 27. Quebec is evaluating whether part of its vaccination schedule for babies and toddlers needs modification in the wake of the COVID-19 pandemic, which saw different diseases and viruses thrive.

For example, Quebec currently offers babies two doses of the vaccine Synflorix, which fights against 10 strains of pneumococcal disease.

These doses are given at the two- and four-month appointments. Additionally, babies get one dose of Prevnar-13 at their 12-month appointment.

"Other provinces use three doses of Prevnar-13 at two, four and 12 months of age," said Dr. Nicholas Brousseau with the Comité sur l'immunisation du Québec (CIQ). "These two schedules offer good protection and show similar effectiveness."

However, according to CIQ Chair Dr. Caroline Quach Thanh, the number of children catching invasive pneumococcal diseases (IPD) jumped after the COVID-19 pandemic.

"An increase in respiratory syncytial virus (RSV) infection was a risk factor for IDP," she explained. "The addition of Prevnar-13 at 12 months of age seemed to control the transmission of disease."

WHO'S IN CHARGE?

For its part, Quebec's Health Ministry says it takes its directives from the CIQ.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

"The CIQ considers such a schedule to be safe in terms of reducing the burden of disease," the ministry tells CTV News. "The CIQ's advice may be revised according to the epidemiology of the disease and the availability of new vaccines."

The health care system is not federally dictated in Canada, so there are variations from province to province.

"There are several vaccines against meningitis (meningococcal vaccines) that are authorized in Canada, and they don't cover the same strains," explains Brousseau. "The main serogroup responsible for meningitis varies according to the province, so the specific vaccination strategy varies slightly by province."

It could be said that Quebec often marches to the beat of its own drummer -- though they usually "get it right," says Dr. Christos Karatzios, an assistant professor of pediatrics at the McGill University Health Centre (MUHC) division of infectious diseases.

"Whereas across many places in the world, pneumococcal vaccination was given at two, four, six and 12 months of age, Quebec, from the get-go omitted the six-month dose and got better antibody responses at the 12-month mark when they allowed more time to elapse between vaccine doses," he tells CTV News.

Karatzios notes other provinces have often taken note and followed suit.

"See what happened with the original Prevnar-13 being dropped at six months, the Gardasil vaccine series, and, of course, the COVID-19 vaccination schedules," he said.

Nevertheless, Karatzios says he chose -- and paid -- to have his children immunized with Prevnar-13 rather than Synflorix.

"We had good evidence for it working and was uncomfortable with Synflorix as it lacked three pneumococcal types that Prevnar-13 had," he said. "I am glad I did because, as you can see, the government brought back Prevnar-13 for the 12-month dose, didn't they?"

AN IMPERFECT SCIENCE

Now, two new pneumococcal vaccines have just been authorized in the country -- Vaxneuvance and Prevnar-20.

"The question of interest is whether or not they should replace Synflorix and Prevnar-13," Brousseau explains.

The Comité sur l'immunisation du Québec says it plans to publish recommendations regarding any potential changes to the province's pneumococcal vaccine schedule in the upcoming months.

"Whether or not children who already received their vaccination (Synflorix or Prevnar-13) will need an additional dose is one of the questions being evaluated," Brousseau explains.

For his part, Karatzios admits vaccine schedules aren't a perfect science.

"In Quebec, we used to give Prevnar-13, and then they stepped it back to Synflorix a few years back and then re-added Prevnar-13 at the one-year mark when it was realized that the strains not covered showed up again," he said. "So, here we are now. The rest of the world is on 13 and maybe 20 in the future, and I am uncertain what the next steps will be here."

Quebec has already implemented a Prevnar-20 program for children who are considered immunocompromised.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

Brousseau emphasizes that the most important thing parents can do is ensure their children get all their vaccines.

"There is a very small proportion of children who did not receive their pediatric vaccines -- about one per cent of children -- and it would be very beneficial for them to receive their primary vaccinations," he said.

Fuente: CTV News Montreal. Disponible en https://acortar.link/aiAZL2

A new Covid variant has become dominant amid slow uptake of the updated shots

Oct 27. A new Covid variant has become dominant in the U.S., but relatively few people have thus far gotten the new shots that could offer some protection against it.

The variant, called HV.1, replaced EG.5 as the country's most prevalent this week, according to data released Friday by the Centers for Disease Control and Prevention.

The two variants are genetically similar versions of omicron.

HV.1 makes up around 25% of Covid cases now, up from around 1% at the beginning of August. EG.5, meanwhile, represents nearly 22% of cases, down from 24% at the start of the month.

A woman receives her Covid vaccine at Kaiser Permanente Pasadena on Oct. 12, in Pasadena, Calif.Francine Orr / Los Angeles Times via Getty Images file

Both are descendants of the XBB variant. The updated Covid vaccines from Pfizer and Moderna, which became available last month, target a different XBB descendant, called XBB.1.5.

But disease experts say the new shots should offer cross-protection against the currently dominant strains. Dr. Scott Roberts, an infectious disease specialist at Yale Medicine, said that although the vaccine is not a "perfect match" for HV.1, "it's still a good match because it's still within the same family of variant."

However, just around 3.5 % of the U.S. population — approximately 12 million people — have received the new Covid shots since they became available in mid-September, a CDC spokesperson said. He cautioned that the number is a rough estimate because states are no longer required to report vaccination numbers.

"I hope uptick increases, but I'm pretty pessimistic," Roberts said. "I don't think we'll hit anywhere near the levels we had last year."

A few factors have hindered this season's vaccine rollout. On top of the issues of accessibility and hesitancy seen in past vaccination campaigns, this was the first time such vaccines were part of the commercial market instead of being ordered, distributed and funded by the federal government.

"The logistic complications certainly were not helpful, but I think that the low uptake is more than that. The low uptake reflects that most of the public is no longer concerned about Covid," said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

What to know about HV.1

Barouch said HV.1 could be slighter better than EG.5 at spreading among people or infecting those with prior immunity to Covid — but not enough to cause alarm among scientists.

"I would expect that it might be a slight increase in transmissibility or immune escape, which is why it appears to be dominating. Does it change any booster recommendations so far? Probably not," he said.

Since omicron took over in December 2021, all dominant variants have descended from it. Scientists expect the virus to continue to evolve in this way. For the most part, scientists aren't concerned about versions of omicron that look similar to those we've seen before.

While the CDC recommends updated shots for everyone ages 6 months and up, Barouch said he's particularly worried about low uptake among older adults and people who are immunosuppressed or have pre-existing medical issues.

"What concerns me is not the overall low number of people getting boosted. What concerns me is the low frequency of high-risk people getting boosted," he said.

Last fall's vaccine rollout got off to a stronger start: Six weeks after the bivalent booster came out in September 2022, more than 19 million people (5.5% of the population) had received the shot, according to CDC data.

About 17% of the U.S. population ultimately received that booster, which isn't available anymore because it targeted versions of omicron that no longer circulate widely.

Frustrations over the shaky vaccine rollout

In the current rollout, public and private insurers are responsible for the cost of the shot, and health care and pharmacy networks place their own orders.

That has given rise to new challenges, including insurance issues, shipment delays and appointment cancelations.

Though most insurers agreed to cover the new Covid vaccines in full, some didn't update their billing systems in time for people's appointments. As a result, people were told they needed to pay for their shots, prompting some to cancel their scheduled vaccinations. The Biden administration said at the end of September that the issues had largely been resolved.

Delayed vaccine shipments also forced some pharmacies to cancel appointments last month. And parents have reported difficulty finding appointments for young children, who require smaller doses. Roberts said some pediatricians' offices may not be equipped to provide cold storage for the shots or lack freezer space. Others may have underestimated demand or been unwilling to pay for large shipments.

Experts worry that people who hit roadblocks will stop attempting to get vaccinated.

"If people try and are unable to get their vaccine, then it's likely they'll never go back and try again," Barouch said.

Roberts said his children still haven't gotten their updated vaccines, despite his best efforts. He also ran into trouble getting his own shot, he said: His hospital was waiting on doses, and local pharmacies in New Haven, Connecticut, weren't offering appointments. He ended up traveling outside the region to get vaccinated.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

"I'm an infectious disease physician who works with Covid. I cannot imagine how difficult this is for the normal person out there in the community who wants to get vaccinated," Roberts said.

Though Covid transmission seems to be slowing right now, Roberts cautioned that the virus is still making people severely ill.

"We have patients today in our hospital admitted with this on mechanical ventilators," he said, adding: "We definitely need to push to get the high-risk people vaccinated because that's the strain on the health care system."

Fuente: NBC News. Disponible en https://acortar.link/A68UAQ

Pfizer and BioNTech report positive findings for COVID-flu mRNA combo vaccine

Oct 27. Moderna and BioNTech yesterday announced promising findings for their phase 1/2 trial of an mRNA vaccine that targets both COVID and flu.

Patrik Slezak / iStock

Scientists tested different combo vaccine candidates in healthy adults ages 18 to 64 against a licensed flu vaccine and the companies' earlier bivalent (two-strain) COVID vaccine, with both vaccines given at the same visit. Lead formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2, the virus that causes COVID-19.

The safety results for the combo vaccines were similar to the vaccine against COVID.

Based on the findings, the companies said they would advance the lead formulations to a phase 3 trial in the months ahead. The Food and Drug Administration (FDA) has given the company fast-track designation for the new vaccine.

Annaliesa Anderson, PhD, Pfizer's senior vice president and head of vaccine development, said in a statement that the companies are encouraged by the early trial results, which will appear in a peer-reviewed journal soon. "This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world," she said.

Earlier this month, Moderna reported promising findings from an early clinical trial of its mRNA combo vaccine against flu and COVID.

Fuente: CIDRAP University of Minnesota. Disponible en https://acortar.link/rKN6LE

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

México recibe casi tres millones de nuevas dosis de Abdala

29 oct. La Secretaria de Salud de México informó que recibió dos millones 851 mil dosis de la vacuna cubana antiCovid-19 Abdala, distribuidas en dos vuelos, que serán aplicadas durante la Campaña Nacional de Vacunación Invernal 2023-2024.

En un comunicado oficial, la entidad recuerda que el 29 de diciembre de 2021, la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) dictaminó procedente la autorización para uso de emergencia del mencionado inmunógeno cubano.

Esta se aprobó con la denominación distintiva: proteína recombinante del dominio de la unión al receptor del virus del SARS-CoV-2, cuyo desarrollo estuvo a cargo del Centro de Ingeniería Genética y Biotecnología del Ministerio de Salud Pública de Cuba.

La nota de la institución mexicana precisa que a las 19:50, hora local, del viernes 27 de octubre aterrizó en la Base Aérea Militar No. 1, en Santa Lucía, Estado de México, la primera aeronave, C-27J, de la Fuerza Aérea Mexicana; y en los primeros minutos de este sábado 28 de octubre, la segunda, C-295, procedentes de La Habana.

En el arribo, traslado y seguridad de las dosis participó personal de Laboratorios de Biológicos y Reactivos de México (Birmex), Centro Nacional para la Salud de la Infancia y la Adolescencia, y Cofepris, así como elementos del Ejército Mexicano y de la Guardia Nacional.

Birmex será la responsable de la distribución del fármaco a todas las entidades federativas.

Cabe mencionar, agrega el texto, que la Campaña Nacional de Vacunación contra influenza y Covid-19 para la temporada invernal 2023-2024 se realiza del 16 de octubre de este año al 31 de marzo del 2024, durante la cual se aplicarán 54,6 millones de dosis.

México cumple las recomendaciones de las organizaciones Mundial y Panamericana de la Salud (OMS/OPS) sobre incluir la vacunación contra Covid-19 a la campaña estacional.

Esta dependencia invita a que acuda a inmunizarse la población con más riesgo de presentar cuadros graves de la enfermedad, que incluye a personas mayores de 60 años, embarazadas, con comorbilidades, así como personal de atención médica. Para el caso de influenza estacional también se inmuniza a niños y niñas de entre seis y 59 meses.

Las personas con comorbilidades y, por lo tanto, candidatas a recibir las vacunas contra influenza estacional y Covid-19, son quienes viven con el virus de inmunodeficiencia humana (VIH), diabetes mellitus en descontrol, obesidad mórbida, cardiopatías agudas o crónicas, cáncer.

También quienes padecen insuficiencia renal, así como inmunosupresión desarrollada por enfermedad o por tratamiento médico, concluye el comunicado.

Fuente: TV Santiago. Disponible en https://acortar.link/6Njrs5

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Revista Vaccines publicó resultado en niños de vacuna cubana Soberana

30 oct. La revista médica Vaccines publicó un estudio con la evaluación de la respuesta celular en niños vacunados con el esquema heterólogo cubano Soberana 02 y Soberana Plus, comparándola con la respuesta a la infección natural.

La vicedirectora de Investigaciones y Desarrollo del Instituto Finlay de Vacunas (IFV), Dagmar García, escribió en la red social Facebook que se trata del primer reporte que caracteriza en profundidad la respuesta celular inducida por vacunas de proteínas en infantes menores de 12 años.

De acuerdo con los estudiosos, la vacuna cubana Soberana induce una respuesta coordinada de memoria humoral y celular contra la COVID-19 en la población pediátrica.

Esta respuesta es cualitativamente superior a la generada por la infección natural, subrayó la referida publicación científica revisada por pares.

Se trata de una excelente alternativa para la vacunación contra la COVID-19 en niños, agregó.

Más de 25 publicaciones científicas fueron realizadas entre 2020 y 2023 relacionadas con el desarrollo clínico de la vacuna Soberana diseñada y elaborada por especialistas del país caribeño.

Recientemente, el IFV anunció el inicio de un estudio clínico con Quimi-Vio, su candidato vacunal para la prevención de neumonías, meningitis, otitis y sepsis causadas por Streptococcus pneumoniae o neumococo, en población pediátrica con enfermedades crónicas.

Dicha vacuna conjugada heptavalente protege contra los serotipos de mayor prevalencia mundial de la bacteria.

La doctora Meybi Rodríguez, directora de Ensayos Clínicos del IFV, dijo a los medios cubanos que Quimi-Vio transitó por todas las fases de evaluación clínica, demostrando que es segura y eficaz en la prevención de la enfermedad neumocócica.

Apuntó que este producto fue desarrollado por los mismos investigadores de los inmunógenos Soberana 02 y Soberana Plus.

La enfermedad neumocócica afecta especialmente a los niños menores de cinco años.

Según la Organización Mundial de la Salud, la neumonía es la principal causa individual de mortalidad infantil en el mundo.

Fuente: Prensa Latina. Disponible en https://acortar.link/97NYXC

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Antibody Levels Remain High Long After Third MMR Vaccine Dose, But Immunity Does Wane



Oct 30. Measles and rubella neutralizing antibody levels increase and persist many years after receipt of three doses of measles-mumps-rubella (MMR) vaccine, but immunity can wane with time, according to data presented at IDWeek 2023, held in October in Boston.

"Adults in the U.S. can receive a third dose of MMR during measles and mumps outbreaks, but also in non-outbreak settings if they do not have acceptable evidence of immunity to measles, mumps or rubella," said presenting author Oluwakemi D. Alonge, MPH, an epidemiologist at the Marshfield Clinic Research Center, in Marshfield, Wis. "However, data on long-term immunity after a third MMR dose are limited."

The study looked at adults who received two MMR doses in childhood and a third dose as young adults during 2009 and 2010. They were then recalled at five and nine to 11 years after the receipt of their third vaccine dose.

At a median of five years after the third MMR dose, only 11% of participants were considered potentially susceptible to measles. At a median of 9.2 years following their third dose, only 10% of participants were potentially susceptible to measles.

For rubella, 0.3% of participants were considered potentially susceptible five years after their third vaccine dose. By the end of the last visit, 9.2 years following their third dose, no participants were considered potentially susceptible to rubella.

"Some three-dose vaccinated adults may become susceptible to measles infection over time, considering the waning of the antibody levels," Ms. Alonge noted.

Fuente: IDSE Infectious Disease Special Edition. Disponible en https://acortar.link/AmWF4R

GSK lidera mercado de vacuna VSR en Estados Unidos

Oct 30. GSK toma la delantera en la carrera de la vacuna VSR en EE.UU., superando a Pfizer, gracias a su asociación con CVS Health.

GSK (NYSE:GSK) ha tomado una ventaja temprana en la carrera por el dominio de la vacuna contra el virus sincitial respiratorio (VSR), superando a Pfizer Inc (NYSE:PFE), que anteriormente dominaba el mercado de la vacuna COVID-19.

La vacuna VSR de GSK ha ganado una tracción significativa en los Estados Unidos, con datos de IQVIA que revelan que representa casi dos tercios de las inyecciones de VSR administradas desde principios de septiembre.

Este éxito temprano se puede atribuir a la asociación estratégica de GSK con CVS Health Corp (NYSE:CVS), la cadena de farmacias más grande de los Estados Unidos y un actor clave en el mercado de vacunas minoristas.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

La disponibilidad exclusiva de la vacuna contra el VSR de GSK en CVS Health ha dado al fabricante de medicamentos británico una ventaja competitiva, señaló Reuters, citando a analistas y expertos de la industria.

Las consideraciones de precio también parecen desempeñar un papel, ya que la vacuna de GSK se lista con un ligero descuento en comparación con la oferta de Pfizer. El punto de precio puede estar influyendo en las decisiones de los farmacéuticos independientes a favor del producto de GSK.

A medida que ambas compañías buscan expandir sus ventas de vacunas, estas inyecciones representan una fuente potencial de ingresos para contrarrestar la próxima competencia genérica que enfrentan medicamentos más antiguos como Ibrance de Pfizer y Dovato de GSK.

Aunque la ventaja temprana de GSK es significativa, queda por ver cómo las decisiones futuras de las principales cadenas de farmacias como Walgreens Boots Alliance Inc (NASDAQ:WBA), Walmart Inc (NYSE:WMT), y Rite Aid Corp.(OTC: RADCQ) pueden influir en el panorama de la vacuna contra el VSR.

Movimiento de las acciones de GSK

Las acciones de GSK subieron un 2,24% a 35,34 dólares en la última revisión del lunes.

Descargo de responsabilidad: Este contenido fue producido parcialmente con la ayuda de herramientas de inteligencia artificial y fue revisado y publicado por editores de Benzinga.

Fuente: Benzinga. Disponible en https://acortar.link/zSQQiY

La EMA recomienda la aprobación de la vacuna Nuvaxovid, dirigida a la variante Ómicron XBB.1.5 del COVID-19



31 oct. Según las pautas de la EMA y el Centro Europeo para la Prevención y el Control de Enfermedades (ECDC), las personas que necesiten vacunarse recibirán una sola dosis.

El Comité de medicamentos de uso humano (CHMP) de la Agencia Europea del Medicamento (EMA) ha dado luz verde a la vacuna Nuvaxovid adaptada que se dirige específicamente a la subvariante Ómicron XBB.1.5 del coronavirus, recomendando su autorización. Esta vacuna, llamada Nuvaxovid XBB.1.5, se administrará a adultos y niños mayores de 12 años para protegerlos de la COVID-19.

Según las pautas de la EMA y el Centro Europeo para la Prevención y el Control de Enfermedades (ECDC), las personas que necesiten vacunarse recibirán una sola dosis, sin importar si ya han sido vacunadas frente a la COVID-19 anteriormente.

En su decisión de recomendar la autorización, el CHMP evaluó datos de laboratorio que muestran que la vacuna adaptada es capaz de desencadenar una respuesta inmunitaria adecuada contra XBB.1.5.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS CUBA

El Comité también consideró que se espera que Nuvaxovid XBB.1.5 desencadene una respuesta inmunitaria adecuada contra XBB.1.5. Los efectos secundarios más comunes de esta vacuna son dolor y sensibilidad en el lugar de la inyección, cansancio, dolor de cabeza, dolor muscular y malestar general.

La EMA ha enviado la recomendación del CHMP a la Comisión Europea para que adopte una decisión jurídicamente vinculante en toda la UE.

Apuntando a Ómicron XBB.1.5

Las vacunas contra la COVID-19 están adaptadas para que coincidan mejor con las variantes circulantes del virus SARS-CoV-2.

Esta vacuna se desarrolló para atacar a Ómicron XBB de acuerdo con las recomendaciones del grupo de trabajo de emergencia (ETF) de la EMA, así como de otros reguladores internacionales y la Organización Mundial de la Salud.

Como Ómicron XBB.1.5 está estrechamente relacionada con otras variantes que circulan actualmente, se espera que la vacuna ayude a mantener una protección óptima contra el COVID-19 causado por estas otras variantes, así como por Ómicron XBB.1.5.

Al igual que con otras vacunas contra la COVID-19, las autoridades nacionales de los Estados miembros de la UE determinarán cómo utilizar esta vacuna en las campañas nacionales de vacunación, teniendo en cuenta factores como las tasas de infección y hospitalización, el riesgo para las personas vulnerables y la disponibilidad de la vacuna.

Nuvaxovid se autorizó por primera vez en la UE en diciembre de 2021. Se desarrollaron versiones adaptadas de Nuvaxovid dirigidas a la variante Ómicron BA.5, pero no se presentaron para autorización de comercialización.

Fuente: EL GLOBAL. Disponible en https://acortar.link/AGCma9

VACCI MONITOR

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

EBSCO Information Services · Scopus · DOAJ Directory of Open Access Journals · SciELO · redalyc.org · FreeMedical Journals · HINARI Research in Health · latindex Sistema Regional de Información en Línea para Revistas Científicas de América Latina, el Caribe, España y Portugal · SeCiMed

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@VigilanciaCT

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/10/22 to 2023/10/31. “vaccine” (Title/Abstract) 497 records.

Primary brain tumours in adults.
van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM. Lancet. 2023 Oct 28;402(10412):1564-1579. doi: 10.1016/S0140-6736(23)01054-1. Epub 2023 Sep 19. PMID: 37738997

Causes and costs of global COVID-19 vaccine inequity.
Ferranna M. Semin Immunopathol. 2023 Oct 23. doi: 10.1007/s00281-023-00998-0. Online ahead of print. PMID: 37870569

mRNA Cancer Vaccines: Construction and Boosting Strategies.
Liu X, Huang P, Yang R, Deng H. ACS Nano. 2023 Oct 24;17(20):19550-19580. doi: 10.1021/acsnano.3c05635. Epub 2023 Oct 11. PMID: 37819640

Noble Nanomedicine: Celebrating Groundbreaking mRNA Vaccine Innovations.
Chan WCW, Artzi N, Chen C, Chen X, Ho D, Hu T, Kataoka K, Liz-Marzán LM, Oklu R, Parak WJ. ACS Nano. 2023 Oct 24;17(20):19476-19477. doi: 10.1021/acsnano.3c09781. Epub 2023 Oct 11. PMID: 37819863

Impact of the microbiome on mosquito-borne diseases.
Shi H, Yu X, Cheng G. Protein Cell. 2023 Oct 25;14(10):743-761. doi: 10.1093/procel/pwad021. PMID: 37186167

HV&I reviewer highlight.
Ellis R, Weiss A. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270862. doi: 10.1080/21645515.2023.2270862. Epub 2023 Oct 26. PMID: 37883655

Insights into the diagnosis, vaccines, and control of Taenia solium, a zoonotic, neglected parasite.
Hossain MS, Shabir S, Toye P, Thomas LF, Falcone FH. Parasit Vectors. 2023 Oct 24;16(1):380. doi: 10.1186/s13071-023-05989-6. PMID: 37876008

How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
Ozawa S, Schuh HB, Nakamura T, Yemeke TT, Lee YA, MacDonald NE. Vaccine. 2023 Oct 26;41(45):6710-6718. doi: 10.1016/j.vaccine.2023.09.027. Epub 2023 Oct 3. PMID: 37798209

Impact of a vaccine passport on first-dose SARS-CoV-2 vaccine coverage by age and area-level social determinants of health in the Canadian provinces of Quebec and Ontario: an interrupted time series analysis.
Anato JLF, Ma H, Hamilton MA, Xia Y, Harper S, Buckeridge D, Brisson M, Hillmer MP, Malikov K, Kerem A, Beall R, Wagner CE, Racine É, Baral S, Dubé È, Mishra S, Maheu-Giroux M. CMAJ Open. 2023 Oct 24;11(5):E995-E1005. doi: 10.9778/cmajo.20220242. Print 2023 Sep-Oct. PMID: 37875315

Ocular Inflammation Post-Vaccination.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Zou Y, Kamoi K, Zong Y, Zhang J, Yang M, Ohno-Matsui K. Vaccines (Basel). 2023 Oct 23;11(10):1626. doi: 10.3390/vaccines11101626. PMID: 37897028

Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S, Afroz S, Kang D, Noh J, Suh J, Kim JH, You HJ, Kang HG, Kim YJ, Kim JH. Mol Cells. 2023 Oct 31;46(10):579-588. doi: 10.14348/molcells.2023.0079. Epub 2023 Sep 22. PMID: 37853684

The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
Salloum M, Paviotti A, Bastiaens H, Van Geertruyden JP. Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.10.057. Online ahead of print. PMID: 37903681

Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
Febriani Y, Mansour T, Sadarangani M, Ulanova M, Amaral K, Halperin SA, De Serres G, Racine É, Brousseau N. Vaccine. 2023 Oct 26;41(45):6745-6753. doi: 10.1016/j.vaccine.2023.09.063. Epub 2023 Oct 8. PMID: 37816653

An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models.
Yuen CK, Wong WM, Mak LF, Lam JY, Cheung LY, Cheung DT, Ng YY, Lee AC, Zhong N, Yuen KY, Kok KH. Nat Commun. 2023 Oct 24;14(1):6762. doi: 10.1038/s41467-023-42349-5. PMID: 37875475

NK cells in COVID-19-from disease to vaccination.
Hammer Q, Cuapio A, Bister J, Björkström NK, Ljunggren HG. J Leukoc Biol. 2023 Oct 26;114(5):507-512. doi: 10.1093/jleuko/qiad031. PMID: 36976012

Global COVID-19 Vaccination in Infants and Children: Effectiveness, Safety, and Challenges.
Jantarabenjakul W, Chantasrisawad N, Nantanee R, Ganguli S, Puthanakit T. Asian Pac J Allergy Immunol. 2023 Oct 23. doi: 10.12932/AP-300423-1596. Online ahead of print. PMID: 37874316

Metacognition, public health compliance, and vaccination willingness.
Fischer H, Huff M, Anders G, Said N. Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2105425120. doi: 10.1073/pnas.2105425120. Epub 2023 Oct 18. PMID: 37851676

National governance and excess mortality due to COVID-19 in 213 countries: a retrospective analysis and perspectives on future pandemics.
da Silva RE, Novaes MRCG, de Oliveira C, Guilhem DB. Global Health. 2023 Oct 31;19(1):80. doi: 10.1186/s12992-023-00982-1. PMID: 37907968

Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19.
Wijkström J, Caldinelli A, Bruchfeld A, Nowak A, Artborg A, Stendahl M, Segelmark M, Lindholm B, Bellocco R, Rydell H, Evans M. Nephrol Dial Transplant. 2023 Oct 31;38(11):2607-2616. doi: 10.1093/ndt/gfad151. PMID: 37433606

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Neonatal varicella.
Longbottom K, Lyall H. Arch Dis Child. 2023 Oct 31:archdischild-2022-324820. doi: 10.1136/archdischild-2022-324820. Online ahead of print. PMID: 37907245

Vaccinated kidney transplant recipients are yet not sufficiently protected against COVID-19.
Messchendorp AL, Gansevoort RT. Nephrol Dial Transplant. 2023 Oct 31;38(11):2423-2425. doi: 10.1093/ndt/gfad127. PMID: 37370226

Latest developments in vaccine research: Selected papers from the 16th annual vaccine congress.
Beerens D, Poland GA. Vaccine. 2023 Oct 26;41(45):6761. doi: 10.1016/j.vaccine.2023.09.056. Epub 2023 Oct 3. PMID: 37798208

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens.
Zhang P, Luo S, Zou P, Deng Q, Wang C, Li J, Cai P, Zhang L, Li C, Li T. Microbiol Spectr. 2023 Oct 25:e0179423. doi: 10.1128/spectrum.01794-23. Online ahead of print. PMID: 37877750

[Expert consensus on pre-exposure rabies prophylaxis].
Rabies Prevention and Control Committee of the Chinese Preventive Medicine Association; Animal Injury Treatment Branch of China Association for Disaster and Emergency Rescue Medicine. Zhonghua Yi Xue Za Zhi. 2023 Oct 24;103(39):3103-3111. doi: 10.3760/cma.j.cn112137-20230411-00583. PMID: 37840181

Knowledge, beliefs and hesitancy among medical and non-medical university students toward COVID-19 vaccination in Punjab, Pakistan.
Nabeel M, Ali K, Bajwa A, Rehman HU, Rashid M, Rasool MF, Islam M, Saeed H. Biodemography Soc Biol. 2023 Oct 24:1-13. doi: 10.1080/19485565.2023.2272718. Online ahead of print. PMID: 37873818

Stabilizing the return to normal behavior in an epidemic.
Berry T, Ferrari M, Sauer T, Greybush SJ, Ebeigbe D, Whalen AJ, Schiff SJ. medRxiv. 2023 Oct 23:2023.03.13.23287222. doi: 10.1101/2023.03.13.23287222. Preprint. PMID: 36993470

Potential effects of biomaterials on macrophage function and their signalling pathways.
Zhu F, Wang S, Zhu X, Pang C, Cui P, Yang F, Li R, Zhan Q, Xin H. Biomater Sci. 2023 Oct 24;11(21):6977-7002. doi: 10.1039/d3bm01213a. PMID: 37695360

New-Onset Acute Interstitial Nephritis Post-SARS-CoV-2 Infection and COVID-19 Vaccination: A Panoramic Review.
Wang Y, Yang L, Xu G. J Epidemiol Glob Health. 2023 Oct 23. doi: 10.1007/s44197-023-00159-4. Online ahead of print. PMID: 37870719

Responsive Nucleic Acid-Based Organosilica Nanoparticles.
Picchetti P, Volpi S, Rossetti M, Dore MD, Trinh T, Biedermann F, Neri M, Bertucci A, Porchetta A, Corradini R, Sleiman H, De Cola L. J Am Chem Soc. 2023 Oct 25;145(42):22896-22902. doi: 10.1021/jacs.3c00393. Epub 2023 Sep 21. PMID: 37734737

Transient inhibition of lysosomal functions potentiates nucleic acid vaccines.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Wang C, Karlsson A, Oguin TH 3rd, Macintyre AN, Sempowski GD, McCarthy KR, Wang Y, Moody MA, Yuan F. Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2306465120. doi: 10.1073/pnas.2306465120. Epub 2023 Oct 23. PMID: 37871214

A new multi-epitope vaccine candidate based on S and M proteins is effective in inducing humoral and cellular immune responses against SARS-CoV-2 variants: an *in silico* design approach.
Samimi Hashjin A, Sardari S, Rostamian M, Ahmadi K, Madanchi H, Khalaj V. J Biomol Struct Dyn. 2023 Oct 24:1-18. doi: 10.1080/07391102.2023.2270699. Online ahead of print. PMID: 37874075

Willingness to vaccinate their daughters against human papillomavirus among parents of Ethiopian adolescent girls: a systematic review and meta-analysis.
Zewdie A, Kasahun AW, Adane HA, Mose A. J Pharm Policy Pract. 2023 Oct 24;16(1):126. doi: 10.1186/s40545-023-00639-9. PMID: 37875991

FusionNeoAntigen: a resource of fusion gene-specific neoantigens.
Kumar H, Luo R, Wen J, Yang C, Zhou X, Kim P. Nucleic Acids Res. 2023 Oct 23:gkad922. doi: 10.1093/nar/gkad922. Online ahead of print. PMID: 37870454

An investigation of the relationship between the general vaccination attitudes of pregnant women and their attitudes toward the COVID-19 vaccine.
Mamuk R, Akgün M, Turan Miral M, Göksu Ş. Women Health. 2023 Oct 23:1-10. doi: 10.1080/03630242.2023.2272199. Online ahead of print. PMID: 37867344

Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.
Chung YH, Ortega-Rivera OA, Volckaert BA, Jung E, Zhao Z, Steinmetz NF. Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2221859120. doi: 10.1073/pnas.2221859120. Epub 2023 Oct 16. PMID: 37844250

A Self-Immolative DNA Nanogel Vaccine toward Cancer Immunotherapy.
Hu Y, Gao S, Lu H, Tan S, Chen F, Ke Y, Ying JY. Nano Lett. 2023 Oct 25. doi: 10.1021/acs.nanolett.3c02449. Online ahead of print. PMID: 37877690

Manganese Mineralization of Pathogenic Viruses as a Universal Vaccine Platform.
Shi PD, Xu YP, Zhu Z, Zhou C, Wu M, He Y, Zhao H, Liu L, Zhao L, Li XF, Qin CF. Adv Sci (Weinh). 2023 Oct 22:e2303615. doi: 10.1002/advs.202303615. Online ahead of print. PMID: 37867242

Adenovirus-vectored PDCoV vaccines induce potent humoral and cellular immune responses in mice.
Miao X, Zhang L, Zhou P, Yu R, Zhang Z, Wang C, Guo H, Wang Y, Pan L, Liu X. Vaccine. 2023 Oct 26;41(45):6661-6671. doi: 10.1016/j.vaccine.2023.09.053. Epub 2023 Sep 29. PMID: 37777448

Expanding diversity of bunyaviruses identified in mosquitoes.
Orba Y, Abu YE, Chambaro HM, Lundu T, Muleya W, Eshita Y, Qiu Y, Harima H, Kajihara M, Mori-Kajihara A, Matsuno K, Sasaki M, Hall WW, Hang'ombe BM, Sawa H. Sci Rep. 2023 Oct 24;13(1):18165. doi: 10.1038/s41598-023-45443-2. PMID: 37875565

PreHevbrio: the first approved 3-antigen hepatitis B vaccine.
Vesikari T, Langley JM, Popovic V, Diaz-Mitoma F. Expert Rev Vaccines. 2023 Oct 25. doi: 10.1080/14760584.2023.2274482. Online ahead of print. PMID: 37877189

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Tumor vaccines: Toward multidimensional anti-tumor therapies.
Tan Y, Chen H, Gou X, Fan Q, Chen J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271334. doi: 10.1080/21645515.2023.2271334. Epub 2023 Oct 31. PMID: 37905395

Antibody Production after COVID-19 Vaccination in Patients with Inborn Errors of Immunity.
Nourizadeh M, Feizabadi E, Mirmoghtadaei M, Mohammadi A, Fazlollahi MR, Moradi L, Pourpak Z. Iran J Immunol. 2023 Oct 22;20(4). doi: 10.22034/iji.2023.97759.2525. Online ahead of print. PMID: 37865866

Assessing vaccine hesitancy and health literacy using a new Italian vaccine confidence index and a modified Italian medical term recognition test: A cross-sectional survey on Italian parents.
Arzilli G, Stacchini L, Casigliani V, Mazzilli S, Aquino F, Oradini-Alacreu A, Bruni B, Quattrone F, Papini F, Sironi D, Porretta AD, Privitera GP, Rizzo C, Tavoschi L, Lopalco PL. Hum Vaccin Immunother. 2023 Dec 15;19(3):2271765. doi: 10.1080/21645515.2023.2271765. Epub 2023 Oct 31. PMID: 37906161

Dendritic Cell-Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs.
Cao Y, Long J, Sun H, Miao Y, Sang Y, Lu H, Yu C, Zhang Z, Wang L, Yang J, Wang S. Adv Sci (Weinh). 2023 Oct 22:e2302423. doi: 10.1002/advs.202302423. Online ahead of print. PMID: 37867227

The humoral response to COVID-19 vaccinations can predict the booster effect on health care workers-toward personalized vaccinations?
Freund O, Harish A, Breslavsky A, Wand O, Zacks N, Bilenko N, Bar-Shai A. J Public Health (Oxf). 2023 Oct 23:fdad198. doi: 10.1093/pubmed/fdad198. Online ahead of print. PMID: 37872715

Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy.
Jorgensen SCJ, Drover SSM, Fell DB, Austin PC, D'Souza R, Guttmann A, Buchan SA, Wilson SE, Nasreen S, Schwartz KL, Tadrous M, Wilson K, Kwong JC. JAMA Pediatr. 2023 Oct 23:e234499. doi: 10.1001/jamapediatrics.2023.4499. Online ahead of print. PMID: 37870875

The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M, Mesher D, Panwar K, Anderson A, Beddows S, Soldan K. Vaccine. 2023 Oct 26;41(45):6734-6744. doi: 10.1016/j.vaccine.2023.10.002. Epub 2023 Oct 10. PMID: 37821315

Action to maximise childhood vaccination is urgently needed.
Bedford H, Skirrow H. BMJ. 2023 Oct 24;383:2426. doi: 10.1136/bmj.p2426. PMID: 37875295

Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists.
Khalaf JK, Bess LS, Walsh LM, Ward JM, Johnson CL, Livesay MT, Jackson KJ, Evans JT, Ryter KT, Bazin-Lee HG. J Med Chem. 2023 Oct 26;66(20):13900-13917. doi: 10.1021/acs.jmedchem.3c00724. Epub 2023 Oct 17. PMID: 37847244

Vaccine approaches for antigen capture by liposomes.
Zhou S, Luo Y, Lovell J. Expert Rev Vaccines. 2023 Oct 25. doi: 10.1080/14760584.2023.2274479. Online ahead of print. PMID: 37878481

Potentiating the Immune Responses of HBsAg-VLP Vaccine Using a Polyphosphoester-Based Cationic Polymer Adjuvant.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Liu X, Liu Y, Yang X, Lu X, Xu XN, Zhang J, Chen R. ACS Appl Mater Interfaces. 2023 Oct 25;15(42):48871-48881. doi: 10.1021/acsami.3c07491. Epub 2023 Oct 10. PMID: 37816068

The downstream bioprocess toolbox for therapeutic viral vectors.
Kilgore R, Minzoni A, Shastry S, Smith W, Barbieri E, Wu Y, LeBarre JP, Chu W, O'Brien J, Menegatti S. J Chromatogr A. 2023 Oct 25;1709:464337. doi: 10.1016/j.chroma.2023.464337. Epub 2023 Sep 9. PMID: 37722177

Immunomodulatory and Antiviral Therapy Improved Functional Cure Rate in CHB Patients with High HBsAg Level Experienced NA.
Jia H, Yu G, Yu J, Zhang X, Yang L, Wang B, Zhang J, Bai L, Zhang X, Wang K, Zhao P, Yang D, Zhao Y, Yu Y, Zhang Y, Gu J, Ye C, Cai H, Lu Y, Xiang D, Yu L, Lian J, Hu J, Zhang S, Jin C, Yang Y. J Clin Transl Hepatol. 2023 Oct 28;11(5):1003-1010. doi: 10.14218/JCTH.2022.00413. Epub 2023 Mar 10. PMID: 37577218

A Bionic Yeast Tumor Vaccine Using the Co-Loading Strategy to Prevent Post-Operative Tumor Recurrence.
Ma G, Li F, Wang X, Li Q, Hong Y, Wei Q, Gao F, Zhang W, Guo Y, Ma X, Hu Z. ACS Nano. 2023 Oct 23. doi: 10.1021/acsnano.3c06115. Online ahead of print. PMID: 37870500

A novel *Galleria mellonella* experimental model for zoonotic pathogen *Brucella*.
Wang S, Yin Y, Zai X, Gu Y, Guo F, Shao F, Zhang Y, Li Y, Li R, Zhang J, Xu J, Chen W. Virulence. 2023 Dec;14(1):2268496. doi: 10.1080/21505594.2023.2268496. Epub 2023 Oct 23. PMID: 37817444

Pregnancy and *SARS-CoV-2* infection with a focus on its vertical transmission, breastfeeding, cord blood banking, and vaccination during COVID-19 infection.
Ketabi K, Soleimanjahi H, Habibian A, Abroun S. J Immunoassay Immunochem. 2023 Nov 2;44(5-6):361-380. doi: 10.1080/15321819.2023.2259454. Epub 2023 Oct 31. PMID: 37794764

A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV.
Sulaiman SK, Musa MS, Tsiga-Ahmed FI, Sulaiman AK, Bako AT. Nat Hum Behav. 2023 Oct 30. doi: 10.1038/s41562-023-01733-3. Online ahead of print. PMID: 37904021

Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.
Messiah SE, Talebi Y, Swartz MD, Sabharwal R, Han H, Bergqvist E, Kohl HW 3rd, Valerio-Shewmaker M, DeSantis SM, Yaseen A, Kelder SH, Ross J, Padilla LN, Gonzalez MO, Wu L, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Pediatr Res. 2023 Oct 24. doi: 10.1038/s41390-023-02857-y. Online ahead of print. PMID: 37875728

Individual variation in vaccine immune response can produce bimodal distributions of protection.
Zachreson C, Tobin R, Szanyi J, Walker C, Cromer D, Shearer FM, Conway E, Ryan G, Cheng A, McCaw JM, Geard N. Vaccine. 2023 Oct 26;41(45):6630-6636. doi: 10.1016/j.vaccine.2023.09.025. Epub 2023 Oct 2. PMID: 37793975

Impact of Coronavirus Disease 2019 and Vaccination Attitudes on Alpha-1 Antitrypsin Deficiency.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Hay MA, Holm KE, McCathern J, Sandhaus RA, Strange C. Chronic Obstr Pulm Dis. 2023 Oct 26;10(4):335-342. doi: 10.15326/jcopdf.2023.0406. PMID: 37363861

Candida albicans chitinase 3 with potential as a vaccine antigen: production, purification, and characterisation.
Costa-Barbosa A, Ferreira D, Pacheco MI, Casal M, Duarte HO, Gomes C, Barbosa AM, Torrado E, Sampaio P, Collins T. Biotechnol J. 2023 Oct 24:e2300219. doi: 10.1002/biot.202300219. Online ahead of print. PMID: 37876300

Skin cancer prevention - Recent advances and unmet challenges.
Mortaja M, Demehri S. Cancer Lett. 2023 Oct 28;575:216406. doi: 10.1016/j.canlet.2023.216406. Epub 2023 Sep 19. PMID: 37734530

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
Chen JX, Huang WT, Zhang QY, Deng CE, Wei JL, Xie YL, Lin R, Feng GZ, Yang GL, Long J, Lu HY, Mo ZN. BMC Cancer. 2023 Oct 23;23(1):1018. doi: 10.1186/s12885-023-11523-9. PMID: 37872516

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B, Patel KS, Smith K, Walker R, Wang C, Greene AM, Smith G, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG). Vaccine. 2023 Oct 26;41(45):6762-6773. doi: 10.1016/j.vaccine.2023.07.040. Epub 2023 Sep 20. PMID: 37739888

Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.
Jucht A, Dumont S, Pooley C, Gonzalez Castro LN. Ther Adv Vaccines Immunother. 2023 Oct 24;11:25151355231206163. doi: 10.1177/25151355231206163. eCollection 2023. PMID: 37886714

Clinical decision support systems in community pharmacies: a scoping review.
Moon J, Chladek JS, Wilson P, Chui MA. J Am Med Inform Assoc. 2023 Oct 24:ocad208. doi: 10.1093/jamia/ocad208. Online ahead of print. PMID: 37875066

Retraction: COVID-19 vaccine acceptance and hesitancy among the general population of Pakistan: a population-based survey.
[No authors listed] BMJ Open. 2023 Oct 23;13(10):e064096.ret. doi: 10.1136/bmjopen-2022-064096.ret. PMID: 37875288

A broad-spectrum pneumococcal vaccine induces mucosal immunity and protects against lethal *Streptococcus pneumoniae* challenge.
Chiu FF, Tu LL, Chen W, Zhou H, Liu BS, Liu SJ, Leng CH. Emerg Microbes Infect. 2023 Dec;12(2):2272656. doi: 10.1080/22221751.2023.2272656. Epub 2023 Oct 26. PMID: 37855122

Effectiveness and Safety of COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National Population Study.
Gwak E, Kim T, Shin JY, Choi NK, Han S, Lee JY, Choe YJ, Choe SA. J Korean Med Sci. 2023 Oct 23;38(41):e314. doi: 10.3346/jkms.2023.38.e314. PMID: 37873626

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Exploring human papillomavirus vaccination decision making through mother and adolescent dyad interviews.
Cooper SC, Porter A, Edwards RG, Keegan J, Gallo J, McCaffery K, Skinner SR. Fam Syst Health. 2023 Oct 23. doi: 10.1037/fsh0000845. Online ahead of print. PMID: 37870807

Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria.
Bell GJ, Gyaase S, Goel V, Adu B, Mensah B, Essone P, Dosoo D, Osei M, Niare K, Wiru K, Brandt K, Emch M, Ghansah A, Asante KP, Mvalo T, Agnandji ST, Juliano JJ, Bailey JA. BMC Infect Dis. 2023 Oct 23;23(1):716. doi: 10.1186/s12879-023-08699-7. PMID: 37872492

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN, Qu P, Goodarzi N, Zheng YM, Carlin C, Saif LJ, Oltz EM, Xu K, Jones D, Gumina RJ, Liu SL. Emerg Microbes Infect. 2023 Dec;12(2):2270069. doi: 10.1080/22221751.2023.2270069. Epub 2023 Oct 26. PMID: 37819267

Kindergarten Vaccination Status in California After Changes to Medical Exemption Policy.
Delamater PL, Buttenheim AM, Salmon DA, Schwartz JL, Omer SB. JAMA. 2023 Oct 24;330(16):1585-1587. doi: 10.1001/jama.2023.16995. PMID: 37782512

Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Expert Rev Vaccines. 2023 Oct 23. doi: 10.1080/14760584.2023.2273892. Online ahead of print. PMID: 37872765

Protein-based vaccine candidate MecVax broadly protects against enterotoxigenic *Escherichia coli* intestinal colonization in a rabbit model.
Upadhyay I, Parvej SMD, Shen Y, Li S, Lauder KL, Zhang C, Zhang W. Infect Immun. 2023 Oct 24:e0027223. doi: 10.1128/iai.00272-23. Online ahead of print. PMID: 37874163

Nucleocapsid single point-mutation associated with drop-out on RT-PCR assay for SARS-CoV-2 detection.
de Mello Malta F, Amgarten D, Marra AR, Petroni RC, da Silva Nali LH, Siqueira RA, Neto MC, Oler SC, Pinho JRR. BMC Infect Dis. 2023 Oct 23;23(1):714. doi: 10.1186/s12879-023-08707-w. PMID: 37872472

Advances on the forefront of travelers' diarrhea.
Riddle MS, Ericsson CD, Steffen R. J Travel Med. 2023 Oct 23:taad123. doi: 10.1093/jtm/taad123. Online ahead of print. PMID: 37870499

Leveraging mHealth to Mitigate the Impact of COVID-19 in Black American Communities: Qualitative Analysis.
Harris KM, Mayo Gamble T, Yoo MG, Spell LA, Minor TN, Jones H, Lynch D. JMIR Hum Factors. 2023 Oct 23. doi: 10.2196/47294. Online ahead of print. PMID: 37874735

Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Jayaraman S, Montagne JM, Nirschl TR, Marcisak E, Johnson J, Huff A, Hsiao MH, Nauroth J, Heumann T, Zarif JC, Jaffee EM, Azad N, Fertig EJ, Zaidi N, Larman HB. Cell Rep Methods. 2023 Oct 23;3(10):100600. doi: 10.1016/j.crmeth.2023.100600. Epub 2023 Sep 29. PMID: 37776855

Occupational Health Providers' Perceptions of Employee Vaccine Hesitancy.
Dooley C, Saif NT, Hodorowicz MT, Doyle ML, Gucer PW, Edwards LA, Cloeren M. J Occup Environ Med. 2023 Oct 24. doi: 10.1097/JOM.0000000000003006. Online ahead of print. PMID: 37871581

Duration of SARS-CoV-2 Culturable Virus Shedding in Children.
Kumar N, Bendavid E, Sood N. JAMA Pediatr. 2023 Oct 23:e234511. doi: 10.1001/jamapediatrics.2023.4511. Online ahead of print. PMID: 37870828

Hepatitis A Vaccination Coverage Among People With Chronic Liver Disease in England (HEALD): Protocol for a Retrospective Cohort Study.
Meza-Torres B, Forbes A, Elson W, Kar D, Jamie G, Hinton W, Fan X, Byford R, Feher M, Whyte M, Joy M, de Lusignan S. JMIR Res Protoc. 2023 Oct 24;12:e51861. doi: 10.2196/51861. PMID: 37874614

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.
Gao R, Zheng C, Yang M, Dai L, Chen C, Yao J, Zhang Z, Tang L, Shi Y, Han X. Expert Rev Vaccines. 2023 Oct 25. doi: 10.1080/14760584.2023.2274484. Online ahead of print. PMID: 37878494

Cu^{2+} -Anchored Carbon Nano-Photocatalysts for Visible Water Splitting to Boost Hydrogen Cuproptosis.
Ding H, Ren F, Liu P, Feng Y, Ma X, Shen Z, Shi Q, Xu M, Li W, Chen H. Angew Chem Int Ed Engl. 2023 Oct 26;62(44):e202311549. doi: 10.1002/anie.202311549. Epub 2023 Sep 25. PMID: 37715322

Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8.
Zimmerman O, Zimmerman MI, Raju S, Nelson CA, Errico JM, Madden EA, Holmes AC, Hassan AO, VanBlargan LA, Kim AS, Adams LJ, Basore K, Whitener BM, Palakurty S, Davis-Adams HG, Sun C, Gilliland T Jr, Earnest JT, Ma H, Ebel GD, Zmasek C, Scheuermann RH, Klimstra WB, Fremont DH, Diamond MS. Cell. 2023 Oct 26;186(22):4818-4833.e25. doi: 10.1016/j.cell.2023.09.007. Epub 2023 Oct 6. PMID: 37804831

Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
Shen X, Hao Y, Wang S, Li D, Ren L, Zhu M, Wang S, Li J, Tang W, Fu Y, Chen R, Liu Y, Shao Y. Vaccine. 2023 Oct 26;41(45):6645-6653. doi: 10.1016/j.vaccine.2023.09.030. Epub 2023 Sep 26. PMID: 37770297

Barriers to and facilitators of human papillomavirus vaccination in an ethnically diverse group of migrant parents: A qualitative mixed methods study.
Khan A, Abonyi S, Neudorf C, Galea S, Ahmed S. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269721. doi: 10.1080/21645515.2023.2269721. Epub 2023 Oct 23. PMID: 37870066

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L, Ho DD. Cell Rep Med. 2023 Oct 24:101258. doi: 10.1016/j.xcrm.2023.101258. Online ahead of print. PMID: 37909042

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Bioengineered nanotechnology for nucleic acid delivery.
Zhang Y, Luo J, Gui X, Zheng Y, Schaar E, Liu G, Shi J. J Control Release. 2023 Oct 26;364:124-141. doi: 10.1016/j.jconrel.2023.10.034. Online ahead of print. PMID: 37879440

Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
Sana S, Merkelbach I, Magnée T, Kollmann J, Peeters RP, Kocken PL, Denktaş S. Vaccine. 2023 Oct 26;41(45):6754-6760. doi: 10.1016/j.vaccine.2023.08.074. Epub 2023 Sep 25. PMID: 37758568

Isolated thoracic aortitis following mRNA vaccination against SARS-CoV-2.
Noda S, Hanai S, Ito R, Kobayashi Y, Nakagomi D. QJM. 2023 Oct 23;116(10):875-876. doi: 10.1093/qjmed/hcad126. PMID: 37294845

Lessons Learned in Elective Surgeries After 6 Pandemic Waves of SARS-CoV-2. A Single European Center Experience.
García-Botella A, De la Serna Esteban S, López-Antoñanzas L, Avellana-Moreno R, Dziakova J, Cano Valderrama O, Martín-Antona E, Serrano-García I, Torres García AJ. World J Surg. 2023 Oct 24. doi: 10.1007/s00268-023-07222-y. Online ahead of print. PMID: 37875666

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets.
Dwivedi A, Dwivedi M. Curr Drug Targets. 2023 Oct 27. doi: 10.2174/0113894501265769231020031857. Online ahead of print. PMID: 37907492

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y, Zou J, Kurhade C, Deng X, Chang HC, Kim DK, Shi PY, Ren P, Xie X. Emerg Microbes Infect. 2023 Dec;12(2):2271089. doi: 10.1080/22221751.2023.2271089. Epub 2023 Oct 26. PMID: 37824708

Delivery of public health interventions by the ambulance sector: a scoping review.
Ablard S, Miller E, Poulton S, Cantrell A, Booth A, Lee A, Mason S, Bell F. BMC Public Health. 2023 Oct 24;23(1):2082. doi: 10.1186/s12889-023-16473-2. PMID: 37875881

Vaccination Attitudes Examination (VAX) Scale: a Bifactor-ESEM approach in a youth sample (15-24 years).
Jovanović V, Lazić M. BMC Psychol. 2023 Oct 23;11(1):351. doi: 10.1186/s40359-023-01388-9. PMID: 37872642

The role of the minor colonization factor CS14 in adherence to intestinal cell models by geographically diverse ETEC isolates.
Smith EM, Papadimas A, Gabor C, Cooney C, Wu T, Rasko D, Barry EM. mSphere. 2023 Oct 24;8(5):e0030223. doi: 10.1128/msphere.00302-23. Epub 2023 Oct 3. PMID: 37787523

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD. Nature. 2023 Oct 23. doi: 10.1038/s41586-023-06750-w. Online ahead of print. PMID: 37871613

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia.
Aljunid SM, Mad Tahir NS, Ismail A, Abdul Aziz AF, Azzeri A, Zafirah SA, Aizuddin AN. Sci Rep. 2023 Oct 31;13(1):18771. doi: 10.1038/s41598-023-46079-y. PMID: 37907537

A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan Africa.
Van Puyvelde S, de Block T, Sridhar S, Bawn M, Kingsley RA, Ingelbeen B, Beale MA, Barbé B, Jeon HJ, Mbuyi-Kalonji L, Phoba MF, Falay D, Martiny D, Vandenberg O, Affolabi D, Rutanga JP, Ceyssens PJ, Mattheus W, Cuypers WL, van der Sande MAB, Park SE, Kariuki S, Otieno K, Lusingu JPA, Mbwana JR, Adjei S, Sarfo A, Agyei SO, Asante KP, Otieno W, Otieno L, Tahita MC, Lompo P, Hoffman IF, Mvalo T, Msefula C, Hassan-Hanga F, Obaro S, Mackenzie G, Deborggraeve S, Feasey N, Marks F, MacLennan CA, Thomson NR, Jacobs J, Dougan G, Kariuki S, Lunguya O. Nat Commun. 2023 Oct 23;14(1):6392. doi: 10.1038/s41467-023-41152-6. PMID: 37872141

Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo.
Kayano T, Nishiura H. BMC Infect Dis. 2023 Oct 31;23(1):748. doi: 10.1186/s12879-023-08748-1. PMID: 37907865

The Planned Risk Information Seeking Model Applied to Vaccine Information Avoidance and the Role of Affect, Emotion and Perceived Benefits.
Link E, Kahlor LA. Health Commun. 2023 Oct 23:1-14. doi: 10.1080/10410236.2023.2268912. Online ahead of print. PMID: 37872691

Implementing the free HPV vaccination for adolescent girls aged below 14 in Shenzhen, Guangdong Province of China: experience, challenges, and lessons.
Wu D, Liu P, Song D, Wang H, Chen S, Tang W, Zhao X, Zhao F, Wang Y. Infect Dis Poverty. 2023 Oct 30;12(1):98. doi: 10.1186/s40249-023-01149-1. PMID: 37899444

Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity.
Connors J, Cusimano G, Mege N, Woloszczuk K, Konopka E, Bell M, Joyner D, Marcy J, Tardif V, Kutzler MA, Muir R, Haddad EK. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267295. doi: 10.1080/21645515.2023.2267295. Epub 2023 Oct 26. PMID: 37885158

Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.
Gutwein O, Herzog Tzarfati K, Apel A, Rahimi-Levene N, Ilana L, Tadmor T, Koren-Michowitz M. Cancer Med. 2023 Oct 25. doi: 10.1002/cam4.6397. Online ahead of print. PMID: 37877352

Implications of mosquito metabolism on vector competence.
Gao L, Yang W, Wang J. Insect Sci. 2023 Oct 31. doi: 10.1111/1744-7917.13288. Online ahead of print. PMID: 37907431

AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H, Yu W, Li Y, Bao X, Ni Y, Chen X, Sun Y, Chen A, Zhou W, Li J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269790. doi: 10.1080/21645515.2023.2269790. Epub 2023 Oct 25. PMID: 37877820

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Glycoconjugate vaccines against antimicrobial resistant pathogens.
Sorieul C, Dolce M, Romano MR, Codée J, Adamo R. Expert Rev Vaccines. 2023 Oct 30. doi: 10.1080/14760584.2023.2274955. Online ahead of print. PMID: 37902243

Human monkeypox: An updated appraisal on epidemiology, evolution, pathogenesis, clinical manifestations, and treatment strategies.
Ejaz M, Jabeen M, Sharif M, Syed MA, Shah PT, Faryal R. J Basic Microbiol. 2023 Oct 22. doi: 10.1002/jobm.202300455. Online ahead of print. PMID: 37867205

Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy.
Wang K, Zhang X, Ye H, Wang X, Fan Z, Lu Q, Li S, Zhao J, Zheng S, He Z, Ni Q, Chen X, Sun J. Nat Commun. 2023 Oct 24;14(1):6748. doi: 10.1038/s41467-023-42155-z. PMID: 37875481

Identification of *Streptococcus pneumoniae* genes associated with hypothiocyanous acid tolerance through genome-wide screening.
Shearer HL, Pace PE, Smith LM, Fineran PC, Matthews AJ, Camilli A, Dickerhof N, Hampton MB. J Bacteriol. 2023 Oct 26;205(10):e0020823. doi: 10.1128/jb.00208-23. Epub 2023 Oct 4. PMID: 37791755

Optimization of Plasmodium vivax infection of colonized Amazonian Anopheles darlingi.
Andrade AO, Santos NAC, Bastos AS, Pontual JDC, Araújo CS, Lima AS, Martinez LN, Ferreira AS, Aguiar ACC, Teles CBG, Guido RVC, Santana RA, Lopes SCP, Medeiros JF, Rizopoulos Z, Vinetz JM, Campo B, Lacerda MVG, Araújo MS. Sci Rep. 2023 Oct 24;13(1):18207. doi: 10.1038/s41598-023-44556-y. PMID: 37875508

Do alternative tobacco products induce less adverse respiratory risk than cigarettes?
Bhat TA, Kalathil SG, Leigh N, Hutson A, Goniewicz ML, Thanavala YM. Respir Res. 2023 Oct 31;24(1):261. doi: 10.1186/s12931-023-02568-2. PMID: 37907902

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.
Chen Y, Zhang X, Gong L, Liang Z, Hu X, Xing B, Liao Y, Yuan L, Chen G, Lv H. Expert Rev Vaccines. 2023 Oct 25. doi: 10.1080/14760584.2023.2274491. Online ahead of print. PMID: 37877219

The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
Cénat JM, Moshirian Farahi SMM, Broussard C, Dalexis RD. Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.10.048. Online ahead of print. PMID: 37891050

Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers' perspectives.
Cavit L, Charania NA. Vaccine. 2023 Oct 26;41(45):6690-6699. doi: 10.1016/j.vaccine.2023.09.055. Epub 2023 Oct 4. PMID: 37802749

AI-assisted structural consensus-proteome prediction of human monkeypox viruses isolated within a year after the 2022 multi-country outbreak.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Parigger L, Krassnigg A, Grabuschnig S, Gruber K, Steinkellner G, Gruber CC. Microbiol Spectr. 2023 Oct 24:e0231523. doi: 10.1128/spectrum.02315-23. Online ahead of print. PMID: 37874150

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan.
Liu Y, Chen T, Zhu Y, Furey A, Lowary TL, Chan J, Bournazos S, Ravetch JV, Achkar JM. JCI Insight. 2023 Oct 23;8(20):e167960. doi: 10.1172/jci.insight.167960. PMID: 37733444

Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy.
Sabharwal V, Taglauer E, Demos R, Snyder-Cappione J, Shaik-Dasthagirisaheb YB, Parker-Kelleher S, Hunnewell J, Boateng J, Clarke K, Yuen R, Barnett ED, Wachman EM, Yarrington CD. Am J Perinatol. 2023 Oct 31. doi: 10.1055/a-2183-9109. Online ahead of print. PMID: 37774748

[Preparation of *Mycobacterium tuberculosis* EsxV lipid nanoparticles subunit vaccine and its immunological characteristics].
Bai L, Lu Y, Ning H, Kang Y, Xie Y, Kang J, Li X, Cui R, Wei Y, Liu Y, Bai Y. Sheng Wu Gong Cheng Xue Bao. 2023 Oct 25;39(10):4085-4097. doi: 10.13345/j.cjb.230245. PMID: 37877392

A multicenter study on the epidemiology of complicated parapneumonic effusion in the era of currently available pneumococcal conjugate vaccines.
Papachristidou S, Lapea V, Charisi M, Kourkouni E, Kousi D, Xirogianni A, Dedousi O, Papaconstadopoulos I, Eleftheriou E, Krepis P, Pasparaki S, Pantalos G, Doudoulakakis A, Bozavoutoglou E, Daskalaki M, Kostaridou-Nikolopoulou S, Tzanakaki G, Spoulou V, Tsolia M. Vaccine. 2023 Oct 26;41(45):6727-6733. doi: 10.1016/j.vaccine.2023.10.004. Epub 2023 Oct 6. PMID: 37805358

Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs.
Shao G, Hua R, Song H, Chen Y, Zhu X, Hou W, Li S, Yang A, Yang G. PLoS Negl Trop Dis. 2023 Oct 23;17(10):e0011709. doi: 10.1371/journal.pntd.0011709. Online ahead of print. PMID: 37871121

Using Public Health Detailing to Increase Access and Confidence in COVID-19 Vaccines and Reinvest in Disproportionately Impacted NYC Communities.
Shabbat N, Dresser MG, Petrsoric LJ, Bhatnagar Ansari A, Morse ME. J Public Health Manag Pract. 2023 Oct 23. doi: 10.1097/PHH.0000000000001819. Online ahead of print. PMID: 37874972

Eastern Equine Encephalitis Virus: A Case Report and Brief Literature Review of Current Therapeutic and Preventative Strategies.
Ruiz C, Gibson G, Rojas S, Friend K. Vector Borne Zoonotic Dis. 2023 Oct 23. doi: 10.1089/vbz.2023.0011. Online ahead of print. PMID: 37870590

Co-administration of chicken IL-2 alleviates clinical signs and replication of the ILTV chicken embryo origin vaccine by pre-activating natural killer cells and cytotoxic T lymphocytes.
Hao X, Li J, Wang J, Zhou Z, Yuan X, Pan S, Zhu J, Zhang F, Yin S, Yang Y, Hu S, Shang S. J Virol. 2023 Oct 26:e0132223. doi: 10.1128/jvi.01322-23. Online ahead of print. PMID: 37882519

Akkermansia muciniphila induces slow extramedullary hematopoiesis via cooperative IL-1R/TLR signals.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Wang Y, Morishima T, Sezaki M, Sato R, Nakato G, Fukuda S, Kobiyama K, Ishii KJ, Li Y, Takizawa H. EMBO Rep. 2023 Oct 23:e57485. doi: 10.15252/embr.202357485. Online ahead of print. PMID: 37870318

Dengue fever in a 32-day-old patient. A rare case report.
Goldberg CG, López Alarcón AF, Salocha ML, Otero MF, Jiménez M, Medina A, de Sousa Serro R. Arch Argent Pediatr. 2023 Oct 26:e202310144. doi: 10.5546/aap.2023-10144.eng. Online ahead of print. PMID: 37871006

Wulfenioidins D-N, Structurally Diverse Diterpenoids with Anti-Zika Virus Activity Isolated from *Orthosiphon wulfenioides*.
Tu WC, Huang YX, Li B, Jiang YJ, Yang QY, Zeb MA, Yang PY, Wang HJ, Li XL, Xiao WL, Zheng CB, Liu MF. J Nat Prod. 2023 Oct 27;86(10):2348-2359. doi: 10.1021/acs.jnatprod.3c00543. Epub 2023 Sep 22. PMID: 37737089

Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
Harboe ZB, Hald A, Ekenberg C, Ete Wareham N, Fogt Lundbo L, Holler JG, Qvist T, Rask Hamm S, Bjerrum S, Rezahosseini O, Suno Krohn P, Gustafsson F, Perch M, Rasmussen A, Dam Nielsen S. Vaccine. 2023 Oct 26;41(45):6637-6644. doi: 10.1016/j.vaccine.2023.09.036. Epub 2023 Sep 28. PMID: 37775467

Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.
Aid M, Stephenson KE, Collier AY, Nkolola JP, Michael JV, McKenzie SE, Barouch DH. Nat Commun. 2023 Oct 23;14(1):6703. doi: 10.1038/s41467-023-42559-x. PMID: 37872311

Gallibacterium anatis infection in poultry: a comprehensive review.
Abd El-Ghany WA, Algammal AM, Hetta HF, Elbestawy AR. Trop Anim Health Prod. 2023 Oct 27;55(6):383. doi: 10.1007/s11250-023-03796-w. PMID: 37889324

STATs signaling pathways in dendritic cells: As potential therapeutic targets?
Sohrabi S, Masoumi J, Naseri B, Ghorbaninezhad F, Alipour S, Kazemi T, Ahmadian Heris J, Aghebati Maleki L, Basirjafar P, Zandvakili R, Doustvandi MA, Baradaran B. Int Rev Immunol. 2023 Oct 27:1-22. doi: 10.1080/08830185.2023.2274576. Online ahead of print. PMID: 37886903

Natural immunity to malaria preferentially targets the endothelial protein C receptor-binding regions of PfEMP1s.
Tewey MA, Coulibaly D, Lawton JG, Stucke EM, Zhou AE, Berry AA, Bailey JA, Pike A, Dara A, Ouattara A, Lyke KE, Ifeonu O, Laurens MB, Adams M, Takala-Harrison S, Niangaly A, Kouriba B, Koné AK, Rowe JA, Doumbo OK, Patel JJ, Tan JC, Felgner PL, Plowe CV, Thera MA, Travassos MA. mSphere. 2023 Oct 24;8(5):e0045123. doi: 10.1128/msphere.00451-23. Epub 2023 Oct 4. PMID: 37791774

Use of non-canonical amino acids in genetic code expansion-based therapeutics: Effects on mouse gut microbiota.
Liang M, Yang Y, Zhang J, Sun Y, Peng H, Yi H, Wang Q, Gao X. Microb Biotechnol. 2023 Oct 24. doi: 10.1111/1751-7915.14358. Online ahead of print. PMID: 37874686

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

[Pneumococcal Vaccination Coverage Rates (VCRs) Among Persons with Vaccine-Relevant Underlying Conditions and Persons Aged 60 Years and Older - An Analysis of Secondary Data from the Statutory Health Insurance (SHI) System].
Mihm S, Schelling J, Wölle R, Suck A, Häckl D, Weinke T, Böllinger T. Dtsch Med Wochenschr. 2023 Oct 24. doi: 10.1055/a-2178-8306. Online ahead of print. PMID: 37875123

Bioinspired and Biomimetic Gene Delivery Systems.
Tuyen Ho M, Barrett A, Wang Y, Hu Q. ACS Appl Bio Mater. 2023 Oct 31. doi: 10.1021/acsabm.3c00725. Online ahead of print. PMID: 37905498

Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study.
Spearman P, Jin H, Knopp K, Xiao P, Gingerich MC, Kidd J, Singh K, Tellier M, Radziewicz H, Wu S, McGregor M, Freda B, Wang Z, John SP, Villinger FJ, He B. Sci Adv. 2023 Oct 27;9(43):eadj7611. doi: 10.1126/sciadv.adj7611. Epub 2023 Oct 25. PMID: 37878713

Suppression of dengue virus replication by the French maritime pine extract Pycnogenol®.
Hossain KA, Akhter R, Rashid MHO, Akter L, Utsunomiya M, Kitab B, Ngwe Tun MM, Hishiki T, Kohara M, Morita K, Tsukiyama-Kohara K. Virus Res. 2023 Oct 25;339:199244. doi: 10.1016/j.virusres.2023.199244. Online ahead of print. PMID: 37832653

The advances of adjuvants in mRNA vaccines.
Xie C, Yao R, Xia X. NPJ Vaccines. 2023 Oct 26;8(1):162. doi: 10.1038/s41541-023-00760-5. PMID: 37884526

Effectiveness of COVID-19 vaccines against ICU admission during Omicron surge in Saudi Arabia: a nationwide retrospective cohort study.
Aldawish S, Abusaris R, Almohammadi E, Althobiti F, Albarrag A. BMC Infect Dis. 2023 Oct 31;23(1):746. doi: 10.1186/s12879-023-08686-y. PMID: 37907859

Community Cohesion, Social Support, and Mental Health among Black Individuals in Chicago: A Cross-Sectional Examination of the Effects on COVID-19 Vaccination.
Quinn KG, Hunt B, Jacobs J, Valencia J, Hirschtick J, Walsh JL. J Racial Ethn Health Disparities. 2023 Oct 23. doi: 10.1007/s40615-023-01837-6. Online ahead of print. PMID: 37872464

The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea.
Adamczyk-Popławska M, Golec P, Piekarowicz A, Kwiatek A. Crit Rev Microbiol. 2023 Oct 28:1-16. doi: 10.1080/1040841X.2023.2274849. Online ahead of print. PMID: 37897236

Awareness and acceptability of malaria vaccine among caregivers of under-5 children in Northern Nigeria.
Ajayi MY, Emeto DC. Malar J. 2023 Oct 31;22(1):329. doi: 10.1186/s12936-023-04768-z. PMID: 37907916

Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines.
Trkola A, Moore PL. Lancet Infect Dis. 2023 Oct 23:S1473-3099(23)00481-4. doi: 10.1016/S1473-3099(23)00481-4. Online ahead of print. PMID: 37883985

Computational exploration and design of a multi-epitopes vaccine construct against *Chlamydia psittaci*.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Alsubaiyel AM, Bukhari SI. J Biomol Struct Dyn. 2023 Oct 28:1-17. doi: 10.1080/07391102.2023.2268173. Online ahead of print. PMID: 37897717

Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment.
Huang Y, Nahar S, Alam MM, Hu S, McVicar DW, Yang D. ACS Nano. 2023 Oct 24;17(20):19740-19752. doi: 10.1021/acsnano.3c03195. Epub 2023 Oct 13. PMID: 37831945

Oral Self-Care, Pneumococcal Vaccination, and Pneumonia Among Japanese Older People, Assessed With Machine Learning.
Inoue Y, Cooray U, Ishimaru M, Saito K, Takeuchi K, Kondo K, Aida J. J Gerontol A Biol Sci Med Sci. 2023 Oct 28;78(11):2170-2175. doi: 10.1093/gerona/glad161. PMID: 37429575

High-precision rapid testing of omicron SARS-CoV-2 variants in clinical samples using AI-nanopore.
Murakami K, Kubota SI, Tanaka K, Tanaka H, Akabane K, Suzuki R, Shinohara Y, Takei H, Hashimoto S, Tanaka Y, Hojyo S, Sakamoto O, Naono N, Takaai T, Sato K, Kojima Y, Harada T, Hattori T, Fuke S, Yokota I, Konno S, Washio T, Fukuhara T, Teshima T, Taniguchi M, Murakami M. Lab Chip. 2023 Oct 25. doi: 10.1039/d3lc00572k. Online ahead of print. PMID: 37877206

Emergency department presentations for chest complaints after mRNA COVID-19 vaccinations in children and adolescents.
Parr M, Wilson CL, Jones B, Crawford NW, Ferguson S, Ramesh S, Eapen N, Craig S, Hearps S, Babl FE; Paediatric Research in Emergency Departments International Collaborative (PREDICT) Research Network. Emerg Med Australas. 2023 Oct 23. doi: 10.1111/1742-6723.14327. Online ahead of print. PMID: 37872323

"The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
Dionne M, Sauvageau C, Kiely M, Rathwell M, Bandara T, Neudorf C, Dubé È. Vaccine. 2023 Oct 26;41(45):6654-6660. doi: 10.1016/j.vaccine.2023.09.054. Epub 2023 Sep 28. PMID: 37777452

Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells.
Morgun E, Zhu J, Almunif S, Bobbala S, Aguilar MS, Wang J, Conner K, Cui Y, Cao L, Seshadri C, Scott EA, Wang CR. Elife. 2023 Oct 25;12:RP87431. doi: 10.7554/eLife.87431. PMID: 37877801

Safety and Benefits of COVID-19 Vaccination in Pregnancy-Implications for the Maternal Vaccination Platform.
Healy CM, Riley LE. JAMA Pediatr. 2023 Oct 23. doi: 10.1001/jamapediatrics.2023.4496. Online ahead of print. PMID: 37870867

Brequinar inhibits African swine fever virus replication in vitro by activating ferroptosis.
Chen Y, Guo Y, Chang H, Song Z, Wei Z, Huang Z, Zheng Z, Zhang G, Sun Y. Virol J. 2023 Oct 24;20(1):242. doi: 10.1186/s12985-023-02204-x. PMID: 37875895

Moral characteristics predicting COVID-19 vaccination.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Zher-Wen, Zhen S, Yu R. J Pers. 2023 Oct 29. doi: 10.1111/jopy.12892. Online ahead of print. PMID: 37899552

The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.
Norberg SM, Bai K, Sievers C, Robbins Y, Friedman J, Yang X, Kenyon M, Ward E, Schlom J, Gulley J, Lankford A, Semnani R, Sabzevari H, Brough DE, Allen CT. Sci Transl Med. 2023 Oct 25;15(719):eadj0740. doi: 10.1126/scitranslmed.adj0740. Epub 2023 Oct 25. PMID: 37878675

Impact of COVID-19 on sperm quality and the prostaglandin and polyamine systems in the seminal fluid.
Matzkin ME, Beguerie C, De Zuñiga I, Martinez G, Frungieri MB. Andrology. 2023 Oct 24. doi: 10.1111/andr.13548. Online ahead of print. PMID: 37873918

Awareness and Knowledge of HPV and HPV Vaccine among Asian American Adults by Origin Group: a 2014-2019 Population-Based Analysis.
Vu M, Zhu Y, Trinh DD, Hong YR, Suk R. J Gen Intern Med. 2023 Oct 26. doi: 10.1007/s11606-023-08485-w. Online ahead of print. PMID: 37884834

Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.
Munt JE, Henein S, Adams C, Young E, Hou YJ, Conrad H, Zhu D, Dong S, Kose N, Yount B, Meganck RM, Tse LPV, Kuan G, Balmaseda A, Ricciardi MJ, Watkins DI, Crowe JE Jr, Harris E, DeSilva AM, Baric RS. Cell Host Microbe. 2023 Oct 25:S1931-3128(23)00408-0. doi: 10.1016/j.chom.2023.10.004. Online ahead of print. PMID: 37909048

De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report.
Cho H, Lee HS, Kim SH, Shin J, Hwang JH. J Korean Med Sci. 2023 Oct 23;38(41):e341. doi: 10.3346/jkms.2023.38.e341. PMID: 37873632

Strong Protein Adhesives through Lanthanide-enhanced Structure Folding and Stack Density.
Chen J, Shi W, Ren Y, Zhao K, Liu Y, Jia B, Zhao L, Li M, Liu Y, Su J, Ma C, Wang F, Sun J, Tian Y, Li J, Zhang H, Liu K. Angew Chem Int Ed Engl. 2023 Oct 23;62(43):e202304483. doi: 10.1002/anie.202304483. Epub 2023 Sep 18. PMID: 37670725

VirulentPred 2.0: an improved method for prediction of virulent proteins in bacterial pathogens.
Sharma A, Garg A, Ramana J, Gupta D. Protein Sci. 2023 Oct 23:e4808. doi: 10.1002/pro.4808. Online ahead of print. PMID: 37872744

History of Veterinary Immunology in New Zealand.
Buddle BM. Immunol Cell Biol. 2023 Nov-Dec;101(10):902-905. doi: 10.1111/imcb.12705. Epub 2023 Oct 22. PMID: 37866824

Trial Launches of New HIV Vaccine Candidate With CMV Vector.
Harris E. JAMA. 2023 Oct 24;330(16):1515. doi: 10.1001/jama.2023.19203. PMID: 37792382 No abstract available.

COVID Vaccine Hesitancy and Long-term Traffic Risks.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Redelmeier DA, Wang J, Drover SSM. Am J Med. 2023 Oct 25:S0002-9343(23)00660-5. doi: 10.1016/j.amjmed.2023.10.020. Online ahead of print. PMID: 37890570

Stimuli-Responsive Hydrogel Microcapsules Harnessing the COVID-19 Immune Response for Cancer Therapeutics.
Fischer A, Ehrlich A, Plotkin Y, Ouyang Y, Asulin K, Konstantinos I, Fan C, Nahmias Y, Willner I. Angew Chem Int Ed Engl. 2023 Oct 23;62(43):e202311590. doi: 10.1002/anie.202311590. Epub 2023 Sep 19. PMID: 37675854

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.
Routhu NK, Stampfer SD, Lai L, Akhtar A, Tong X, Yuan D, Chicz TM, McNamara RP, Jakkala K, Davis-Gardner ME, St Pierre EL, Smith B, Green KM, Golden N, Picou B, Jean SM, Wood J, Cohen J, Moore IN, Patel N, Guebre-Xabier M, Smith G, Glenn G, Kozlowski PA, Alter G, Ahmed R, Suthar MS, Amara RR. Sci Immunol. 2023 Oct 27;8(88):eadg7015. doi: 10.1126/sciimmunol.adg7015. Epub 2023 Oct 27. PMID: 37191508

[mRNA vaccines for infectious diseases: research progress and applications].
Qin F, Ren N, Cheng W, Wei H. Sheng Wu Gong Cheng Xue Bao. 2023 Oct 25;39(10):3966-3984. doi: 10.13345/j.cjb.230273. PMID: 37877385

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
Kordus SL, Kroh HK, Rodríguez RC, Shrem RA, Peritore-Galve FC, Shupe JA, Wadzinski BE, Lacy DB, Spiller BW. PLoS Pathog. 2023 Oct 23;19(10):e1011496. doi: 10.1371/journal.ppat.1011496. Online ahead of print. PMID: 37871122

Trends in emerging vector-borne viral infections and their outcome in children over two decades.
Mukhopadhyay K, Sengupta M, Misra SC, Majee K. Pediatr Res. 2023 Oct 25. doi: 10.1038/s41390-023-02866-x. Online ahead of print. PMID: 37880334

Diverse regulatory pathways modulate bet hedging of competence induction in epigenetically-differentiated phase variants of Streptococcus pneumoniae.
Kwun MJ, Ion AV, Oggioni MR, Bentley SD, Croucher NJ. Nucleic Acids Res. 2023 Oct 27;51(19):10375-10394. doi: 10.1093/nar/gkad760. PMID: 37757859

Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation.
Pearson B, Pulley M, Diniz M, Baca N, Majlessipour F. Cancer Rep (Hoboken). 2023 Oct 22:e1907. doi: 10.1002/cnr2.1907. Online ahead of print. PMID: 37867406

Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity.
Lamoot A, Jangra S, Laghlali G, Warang P, Singh G, Chang LA, Park SC, Singh G, De Swarte K, Zhong Z, Louage B, De Lombaerde E, Ye T, Chen Y, Cuadrado-Castano S, Lienenklaus S, Sanders NN, Lambrecht BN, García-Sastre A, Schotsaert M, De Geest BG. Small. 2023 Oct 22:e2306892. doi: 10.1002/smll.202306892. Online ahead of print. PMID: 37867244

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Meeting the 2030 END TB goals in the wake of COVID-19: A modelling study of countries in the USAID TB portfolio.
Arinaminpathy N, Mukadi YD, Bloom A, Vincent C, Ahmedov S. PLOS Glob Public Health. 2023 Oct 23;3(10):e0001271. doi: 10.1371/journal.pgph.0001271. eCollection 2023. PMID: 37870997

The heme-responsive PrrH sRNA regulates *Pseudomonas aeruginosa* pyochelin gene expression.
Hoang T-M, Huang W, Gans J, Weiner J, Nowak E, Barbier M, Wilks A, Kane MA, Oglesby AG. mSphere. 2023 Oct 24;8(5):e0039223. doi: 10.1128/msphere.00392-23. Epub 2023 Oct 6. PMID: 37800921

Co-infection dynamics of COVID-19 and HIV/AIDS.
Batu TD, Obsu LL, Deressa CT. Sci Rep. 2023 Oct 27;13(1):18437. doi: 10.1038/s41598-023-45520-6. PMID: 37891225

Analysis of ethical considerations of COVID-19 vaccination: lessons for future.
Malekzadeh R, Abedi G, Ziapour A, Yıldırım M, Amirkhanlou A. BMC Med Ethics. 2023 Oct 27;24(1):91. doi: 10.1186/s12910-023-00969-y. PMID: 37891543

Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion.
Antonelli Incalzi R, Consoli A, Lopalco P, Maggi S, Sesti G, Veronese N, Volpe M. Intern Emerg Med. 2023 Oct 27. doi: 10.1007/s11739-023-03456-9. Online ahead of print. PMID: 37891453

Federated causal inference based on real-world observational data sources: application to a SARS-CoV-2 vaccine effectiveness assessment.
Meurisse M, Estupiñán-Romero F, González-Galindo J, Martínez-Lizaga N, Royo-Sierra S, Saldner S, Dolanski-Aghamanoukjan L, Degelsegger-Marquez A, Soiland-Reyes S, Van Goethem N, Bernal-Delgado E; BeYond-COVID project. BMC Med Res Methodol. 2023 Oct 23;23(1):248. doi: 10.1186/s12874-023-02068-3. PMID: 37872541

Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect.
Han L, Zhang B. Infect Agent Cancer. 2023 Oct 29;18(1):66. doi: 10.1186/s13027-023-00547-2. PMID: 37898754

Development of multi-epitope based subunit vaccine against *Mycobacterium Tuberculosis* using immunoinformatics approach.
Kumari R S, Sethi G, Krishna R. J Biomol Struct Dyn. 2023 Oct 25:1-20. doi: 10.1080/07391102.2023.2270065. Online ahead of print. PMID: 37880982

Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S, Chen F, Xu M, Liu B, Wang L. Thorac Cancer. 2023 Oct 31. doi: 10.1111/1759-7714.15126. Online ahead of print. PMID: 37905603

Immunoinformatic-guided designing and evaluating protein and mRNA-based vaccines against Cryptococcus neoformans for immunocompromised patients.
Elalouf A, Yaniv-Rosenfeld A. J Genet Eng Biotechnol. 2023 Oct 26;21(1):108. doi: 10.1186/s43141-023-00560-3. PMID: 37882985

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Volatile profiling distinguishes *Streptococcus pyogenes* from other respiratory streptococcal species.
Berna AZ, Merriman JA, Mellett L, Parchment DK, Caparon MG, Odom John AR. mSphere. 2023 Oct 24;8(5):e0019423. doi: 10.1128/msphere.00194-23. Epub 2023 Oct 4. PMID: 37791788

"Closed-Loop" O_2-Economizer Induced *In Situ* Therapeutic Vaccine against Hypoxic Tumors.
Zhao Y, Zhang M, Lv B, Xue G, Jiang H, Chen G, Ma Y, Sun Y, Cao J. ACS Nano. 2023 Oct 25. doi: 10.1021/acsnano.3c05034. Online ahead of print. PMID: 37877944

Spatial distribution and determinants of tetanus toxoid immunization among pregnant women in Ethiopia using data from Ethiopian demographic and health survey 2016.
Fentie B, Alemu TG, Techane MA, Wubneh CA, Assimamaw NT, Belay GM, Tamir TT, Muhye AB, Kassie DG, Wondim A, Terefe B, Tarekegn BT, Ali MS, Gonete AT, Tekeba B, Kassa SF, Desta BK, Ayele AD, Dessie MT, Atalell KA. BMC Pregnancy Childbirth. 2023 Oct 23;23(1):745. doi: 10.1186/s12884-023-05911-z. PMID: 37872486

COVID-19 vaccination of children with refugee backgrounds in Western Australia: a retrospective observational study.
Volkman T, Clarke R, Anstey J, Cherian S. Med J Aust. 2023 Oct 24. doi: 10.5694/mja2.52131. Online ahead of print. PMID: 37875281

FHL1 promotes chikungunya and o'nyong-nyong virus infection and pathogenesis with implications for alphavirus vaccine design.
Ng WH, Liu X, Ling ZL, Santos CNO, Magalhães LS, Kueh AJ, Herold MJ, Taylor A, Freitas JR, Koit S, Wang S, Lloyd AR, Teixeira MM, Merits A, Almeida RP, King NJC, Mahalingam S. Nat Commun. 2023 Oct 26;14(1):6605. doi: 10.1038/s41467-023-42330-2. PMID: 37884534

Alphavirus-based replicons demonstrate different interactions with host cells and can be optimized to increase protein expression.
Dominguez F, Palchevska O, Frolova EI, Frolov I. J Virol. 2023 Oct 25:e0122523. doi: 10.1128/jvi.01225-23. Online ahead of print. PMID: 37877718

Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction.
Maletzki C, Freiin Grote V, Kalle F, Kleitke T, Zimpfer A, Becker AS, Bergmann-Ewert W, Jonitz-Heincke A, Bader R, Vollmar B, Hackenberg S, Scherzad A, Mlynski R, Strüder D. Cell Death Discov. 2023 Oct 23;9(1):390. doi: 10.1038/s41420-023-01671-z. PMID: 37872173

Reply to comment to "axillary lymph nodes enlargement after Sars-CoV-2 vaccine in patients undergoing breast examination: a single-centre experience in 285 women".
Marcon M, Catanese C, Scarano AL, Del Grande F, Manganiello M, Palermo M, Rizzo S. Radiol Med. 2023 Oct 31. doi: 10.1007/s11547-023-01738-y. Online ahead of print. PMID: 37907674

Examining the effectiveness and duration of adjuvanted versus non-adjuvanted influenza vaccines in protecting older adults against symptomatic SARS-CoV-2 infection.
Lapi F, Domnich A, Marconi E, Rossi A, Grattagliano I, Cricelli C. Br J Clin Pharmacol. 2023 Oct 24. doi: 10.1111/bcp.15940. Online ahead of print. PMID: 37876110
Some evidence suggests "trained immunity" triggered by influenza vaccine might reduce the risk of

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope.
Mopuri R, Welbourn S, Charles T, Ralli-Jain P, Rosales D, Burton S, Aftab A, Karunakaran K, Pellegrini K, Kilembe W, Karita E, Gnanakaran S, Upadhyay AA, Bosinger SE, Derdeyn CA. PLoS Pathog. 2023 Oct 25;19(10):e1011717. doi: 10.1371/journal.ppat.1011717. Online ahead of print. PMID: 37878666

Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
López-Zambrano MA, Pita CC, Escribano MF, Galán Meléndez IM, Cebrián MG, Arroyo JJG, Huerta C, Cuadrado LM, Ruiperez CM, Núñez C, Zapata AP, de la Pinta MLR, Uriz MAS, Conejo IS, Gomila CM, Carbajo MDL, Gómez AS. Vaccine. 2023 Oct 26;41(45):6719-6726. doi: 10.1016/j.vaccine.2023.09.047. Epub 2023 Oct 6. PMID: 37806803

Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy.
Dong Q, Xue T, Yan H, Liu F, Liu R, Zhang K, Chong Y, Du J, Zhang H. J Nanobiotechnology. 2023 Oct 30;21(1):395. doi: 10.1186/s12951-023-02152-2. PMID: 37899463

The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Dzau V, Swaminathan S, Baker C, Bright RA, Castillo J, Chuan TC, Draghia-Akli R, Eardley-Patel R, Gao GF, Ishii K, Tebeje YK, Lambe T, Machingaidze S, Røttingen JA, Shaligram U, Simão M, Swarup R, Toussaint JF, Wairagkar NS. Lancet. 2023 Oct 28;402(10412):1507-1510. doi: 10.1016/S0140-6736(23)01775-0. Epub 2023 Sep 6. PMID: 37683681

What are the research priorities for strengthening public health emergency preparedness and response in Africa?
Onwujekwe O, Mbachu C, Okeibunor J, Ezema GU, Ejiofor N, Braka F, Thiam A, Koua EL, Chamla D, Gueye AS. Health Res Policy Syst. 2023 Oct 23;21(1):107. doi: 10.1186/s12961-023-01059-6. PMID: 37872548

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Suryawanshi RK, Taha TY, McCavitt-Malvido M, Silva I, Khalid MM, Syed AM, Chen IP, Saldhi P, Sreekumar B, Montano M, Foresythe K, Tabata T, Kumar GR, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Kojima N, Arellanor T, Bussanich A, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Wang Y, Ghazarian S, Davis G, Rodriguez D, Doudna J, Spraggon L, Chiu CY, Ott M. Emerg Microbes Infect. 2023 Dec;12(2):2270071. doi: 10.1080/22221751.2023.2270071. Epub 2023 Oct 31. PMID: 37869789

Cooperative Assembly of Self-Adjusting α-Helical Coiled Coils along the Length of an mRNA Chain to Form a Thermodynamically Stable Nanotube Carrier.
Jung YJ, Choi JS, Ryu JY, Zhang Z, Lim YB. J Am Chem Soc. 2023 Oct 25;145(42):23048-23056. doi: 10.1021/jacs.3c05638. Epub 2023 Sep 21. PMID: 37735109

Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
Gubernot D, Menis M, Whitaker B. Vaccine. 2023 Oct 25:S0264-410X(23)01208-2. doi: 10.1016/j.vaccine.2023.10.025. Online ahead of print. PMID: 37891051

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
Okoli GN, Righolt CH, Zhang G, Alessi-Severini S, Van Caeseele P, Kuo IF, Mahmud SM. Vaccine. 2023 Oct 26;41(45):6679-6689. doi: 10.1016/j.vaccine.2023.09.050. Epub 2023 Sep 29. PMID: 37778900

Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
Okoli GN, Righolt CH, Zhang G, Alessi-Severini S, Van Caeseele P, Kuo IF, Mahmud SM. Vaccine. 2023 Oct 26;41(45):6679-6689. doi: 10.1016/j.vaccine.2023.09.050. Epub 2023 Sep 29. PMID: 37778900

Newer COVID-19 vaccines: Still lights and shadows?
Angeli F, Zappa M, Verdecchia P. Eur J Intern Med. 2023 Oct 25:S0953-6205(23)00380-1. doi: 10.1016/j.ejim.2023.10.025. Online ahead of print. PMID: 37891024

A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.
Dower WJ, Park AI, Bakker AV, Cwirla SE, Pongtornpipat P, Williams BM, Joshi P, Baxter BA, Needels MC, Barrett RW. PLoS One. 2023 Oct 24;18(10):e0286834. doi: 10.1371/journal.pone.0286834. eCollection 2023. PMID: 37874823

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lüke F, Kutsch N, Müller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, Kühlcke K, Preußner L, Rengstl B, Türeci Ö, Şahin U. Nat Med. 2023 Oct 23. doi: 10.1038/s41591-023-02612-0. Online ahead of print. PMID: 37872225

Lyotropic liquid crystalline phases: drug delivery and biomedical applications.
Chavda VP, Dyawnapelly S, Dawre S, Ferreira-Faria I, Bezbaruah R, Rani Gogoi N, Kolimi P, Dave DJ, Cláudia Santos A, Vora LK. Int J Pharm. 2023 Oct 24:123546. doi: 10.1016/j.ijpharm.2023.123546. Online ahead of print. PMID: 37884213

Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
Edgar JE, Trezise S, Anthony RM, Krammer F, Palese P, Ravetch JV, Bournazos S. Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2314905120. doi: 10.1073/pnas.2314905120. Epub 2023 Oct 23. PMID: 37871218

A Bacterial mRNA-Lysis-Mediated Cargo Release Vaccine System for Regulated Cytosolic Surveillance and Optimized Antigen Delivery.
Li YA, Sun Y, Zhang Y, Li Q, Wang S, Curtiss R 3rd, Shi H. Adv Sci (Weinh). 2023 Oct 22:e2303568. doi: 10.1002/advs.202303568. Online ahead of print. PMID: 37867213

Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Nyambayo PPM, Gold MS, Mehta UC, Clarke S, Manyevere R, Chirinda L, Zifamba EN, Nyamandi T. Vaccine. 2023 Oct 26;41(45):6700-6709. doi: 10.1016/j.vaccine.2023.09.037. Epub 2023 Oct 5. PMID: 37805357

[Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines].
Zaragoza Vargas G, Cacho Calvo J, Martínez-Arce R, Molina Arana D, Ramos Blázquez B, Pérez Abeledo M, Sanz Moreno JC. Rev Esp Quimioter. 2023 Oct 24:zaragoza24oct2023. doi: 10.37201/req/034.2023. Online ahead of print. PMID: 37873744

Routine Vaccination Coverage - Worldwide, 2022.
Kaur G, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, Francis L, Grevendonk J, Sodha SV, Sugerman C, Wallace A. MMWR Morb Mortal Wkly Rep. 2023 Oct 27;72(43):1155-1161. doi: 10.15585/mmwr.mm7243a1. PMID: 37883326

The impact of rotavirus vaccination on acute diarrhea in Thai children under 5 years of age in the first year of universal implementation of rotavirus vaccines in the National Immunization Program (NIP) in Thailand: a 6-year analysis.
Charoenwat B, Suwannaying K, Paibool W, Laoaroon N, Sutra S, Thepsuthammarat K, Sirirattanakul S. BMC Public Health. 2023 Oct 27;23(1):2109. doi: 10.1186/s12889-023-16958-0. PMID: 37891542 Free

Should HIV Vaccines Be Made Available at No or Subsidized Cost? A Qualitative Inquiry of HIV Vaccine Trial Stakeholders in Tanzania.
Pancras G, Ezekiel M, Mbugi E, Merz JF. AJOB Empir Bioeth. 2023 Oct 27:1-8. doi: 10.1080/23294515.2023.2274599. Online ahead of print. PMID: 37889211

Rational design of multi-epitope-based vaccine by exploring all dengue virus serotypes proteome: an immunoinformatic approach.
Alsaiari AA, Hakami MA, Alotaibi BS, Alkhalil SS, Hazazi A, Alkhorayef N, Jalal K, Yasmin F. Immunol Res. 2023 Oct 25. doi: 10.1007/s12026-023-09429-6. Online ahead of print. PMID: 37880483

Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC, Hanif N, Hermawan A. Daru. 2023 Oct 31. doi: 10.1007/s40199-023-00484-w. Online ahead of print. PMID: 37907683

No increased risk of intussusception after pentavalent rotavirus vaccination in China: a retrospective birth cohort using electronic health records of Ningbo city.
Liu Z, Li N, Liu G, Xu L, Dong Y, Meng R, Yang Y, Zhan S. Emerg Microbes Infect. 2023 Dec;12(2):2270062. doi: 10.1080/22221751.2023.2270062. Epub 2023 Oct 26. PMID: 37815175

Assessing the use of minimally invasive self-sampling at home for long-term monitoring of the microbiota within UK families.
Nikolaou E, German EL, Howard A, Nabwera HM, Matope A, Robinson R, Shiham F, Liatsikos K, McNamara C, Kattera S, Carter K, Parry CM, Read JM, Allen SJ, Urban BC, Hawcutt DB, Hill H, Collins AM, Ferreira DM. Sci Rep. 2023 Oct 24;13(1):18201. doi: 10.1038/s41598-023-45574-6. PMID: 37875557

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Construction of an indicator framework for vaccine inclusion in public health programs: A Delphi-entropy method study.
Wang Q, Dai P, Jia M, Jiang M, Li J, Yang W, Feng L. Hum Vaccin Immunother. 2023 Dec 15;19(3):2272539. doi: 10.1080/21645515.2023.2272539. Epub 2023 Oct 31. PMID: 37905961

Preclinical support for tumor protein D52 as a cancer vaccine antigen.
Bright RK. Hum Vaccin Immunother. 2023 Dec 15;19(3):2273699. doi: 10.1080/21645515.2023.2273699. Epub 2023 Oct 30. PMID: 37904517

The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination.
Favaro R, Formai A, Pavia G, Gargiulo L, Avagliano J, Valenti M, Facheris P, Salsano B, Latorre RV, Bellinato F, Gisondi P, Narcisi A, Costanzo A. Br J Dermatol. 2023 Oct 25;189(5):635-637. doi: 10.1093/bjd/ljad242. PMID: 37463513

Wild and partially synanthropic bird yeast diversity, in vitro virulence, and antifungal susceptibility of Candida parapsilosis and Candida tropicalis strains isolated from feces.
Glushakova A, Kachalkin A. Int Microbiol. 2023 Oct 24. doi: 10.1007/s10123-023-00437-y. Online ahead of print. PMID: 37874524

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season.
Moss S, Jurkowicz M, Nemet I, Atari N, Kliker L, Abd-Elkader B, Gonen T, Martin ET, Lustig Y, Regev-Yochay G, Mandelboim M. Vaccines (Basel). 2023 Oct 22;11(10):1624. doi: 10.3390/vaccines11101624. PMID: 37897026

Host immunity associated with spontaneous suppression of viremia in therapy-naïve young rhesus macaques following neonatal SHIV infection.
Evangelous TD, Berry M, Venkatayogi S, LeMaster C, Geanes ES, De Naeyer N, DeMarco T, Shen X, Li H, Hora B, Solomonis N, Misamore J, Lewis MG, Denny TN, Montefiori D, Shaw GM, Wiehe K, Bradley T, Williams WB. J Virol. 2023 Oct 24:e0109423. doi: 10.1128/jvi.01094-23. Online ahead of print. PMID: 37874153

Awareness and knowledge about HPV and primary HPV screening among women in Great Britain: An online population-based survey.
Waller J, Waite F, Marlow L. J Med Screen. 2023 Oct 24:9691413231205965. doi: 10.1177/09691413231205965. Online ahead of print. PMID: 37875156

PF4 activates the c-Mpl-Jak2 pathway in platelets.
Buka RJ, Montague SJ, Moran LA, Martin EM, Slater A, Watson SP, Nicolson PLR. Blood. 2023 Oct 26:blood.2023020872. doi: 10.1182/blood.2023020872. Online ahead of print. PMID: 37883794

Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
Kitikoon P, Knetter SM, Mogler MA, Morgan CL, Hoehn A, Puttamreddy S, Strait EL, Segers RPAM. Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.10.005. Online ahead of print. PMID: 37884412

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Assessment of immunization session practices in primary health care centers in Al-Najaf province.
Ali Qanbar M, Jasim AK, Mahmood AA. J Public Health Afr. 2023 Oct 24;14(9):2754. doi: 10.4081/jphia.2023.2754. eCollection 2023 Oct 1. PMID: 37881728

Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
Kanevsky I, Surendran N, McElwee K, Lei L, Watson W, Pride M, Scully I, Karauzum H, Anderson A, Young M. Vaccine. 2023 Oct 26;41(45):6625-6629. doi: 10.1016/j.vaccine.2023.09.043. Epub 2023 Oct 3. PMID: 37793976

Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
Tani N, Ikematsu H, Goto T, Kondo S, Gondo K, Fujiyoshi N, Minami J, Harada Y, Nagano S, Horiuchi T, Kuwano H, Akashi K, Shimono N, Chong Y. Vaccine. 2023 Oct 26;41(45):6672-6678. doi: 10.1016/j.vaccine.2023.09.051. Epub 2023 Sep 27. PMID: 37775465

Guidance for health care providers on the newest COVID-19 vaccine.
Wood SK, Maki DG, Glickman M, Hennekens CH, Ferris AH. Am J Med. 2023 Oct 23:S0002-9343(23)00670-8. doi: 10.1016/j.amjmed.2023.10.011. Online ahead of print. PMID: 37879591

Gonococcal PorB: a multifaceted modulator of host immune responses.
Jones RA, Jerse AE, Tang CM. Trends Microbiol. 2023 Oct 25:S0966-842X(23)00291-3. doi: 10.1016/j.tim.2023.10.002. Online ahead of print. PMID: 37891023

Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection.
Tang Z, You X, Xiao Y, Chen W, Li Y, Huang X, Liu H, Xiao F, Liu C, Koo S, Kong N, Tao W. Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2304966120. doi: 10.1073/pnas.2304966120. Epub 2023 Oct 25. PMID: 37878720

Study of self-assembling properties of HBc-VLP derivatives aided by molecular dynamic simulations from a thermodynamic perspective.
Luo H, Ma Y, Ren Y, Li Z, Sheng Y, Wang Y, Su Z, Bi J, Zhang S. J Biomol Struct Dyn. 2023 Oct 31:1-14. doi: 10.1080/07391102.2023.2273438. Online ahead of print. PMID: 37908124

Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial.
Kildegaard H, Lund LC, Pottegård A, Stensballe LG. Lancet Child Adolesc Health. 2023 Oct 25:S2352-4642(23)00225-0. doi: 10.1016/S2352-4642(23)00225-0. Online ahead of print. PMID: 37898144

ORF3c is expressed in SARS-CoV-2-infected cells and inhibits innate sensing by targeting MAVS.
Müller M, Herrmann A, Fujita S, Uriu K, Kruth C, Strange A, Kolberg JE, Schneider M, Ito J, Müller MA, Drosten C, Ensser A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K, Sauter D. EMBO Rep. 2023 Oct 23:e57137. doi: 10.15252/embr.202357137. Online ahead of print. PMID: 37870297

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Dual RNA-seq to catalogue host and parasite gene expression changes associated with virulence of T. annulata-transformed bovine leukocytes: towards identification of attenuation biomarkers.
Elati K, Tajeri S, Obara I, Mhadhbi M, Zweygarth E, Darghouth MA, Nijhof AM. Sci Rep. 2023 Oct 24;13(1):18202. doi: 10.1038/s41598-023-45458-9. PMID: 37875584

Behavioral Changes Associated With COVID-19 Vaccination: Cross-National Online Survey.
De Gaetano A, Bajardi P, Gozzi N, Perra N, Perrotta D, Paolotti D. J Med Internet Res. 2023 Oct 31;25:e47563. doi: 10.2196/47563. PMID: 37906219

A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques.
Bian T, Hao M, Zhao X, Zhao C, Luo G, Zhang Z, Fu G, Yang L, Chen Y, Wang Y, Yu C, Yang Y, Li J, Chen W. NPJ Vaccines. 2023 Oct 27;8(1):164. doi: 10.1038/s41541-023-00763-2. PMID: 37891181

Knowledge-map analysis of bladder cancer immunotherapy.
Lv Z, Hou J, Wang Y, Wang X, Wang Y, Wang K. Hum Vaccin Immunother. 2023 Dec 15;19(3):2267301. doi: 10.1080/21645515.2023.2267301. Epub 2023 Oct 30. PMID: 37903500

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C, Thomsen MK, Andersen JB, Jensen JMB, Bayarri-Olmos R, Garred P, Hermansen MF, Johannsen AD, Larsen ML, Mistegaard CE, Mikkelsen S, Nielsen L, Olesen R, Pérez-Alós L, Vils SR, Szabados F, Søgaard OS, Tolstrup M, Erikstrup C, Hauge EM, Troldborg A. Clin Exp Rheumatol. 2023 Oct 23. doi: 10.55563/clinexprheumatol/orpp04. Online ahead of print. PMID: 37877429

Preventive antibody products are immunizations.
Hughes RH, Choudhury S. Vaccine. 2023 Oct 24:S0264-410X(23)01244-6. doi: 10.1016/j.vaccine.2023.10.046. Online ahead of print. PMID: 37884414

Supporting the Manufacturing of Medical Supplies in Africa: Collaboration Between Africa CDC, Partners, and Member States.
Mohammed A, Idris-Dantata H, Okwor T, Tanui P, Paintsil E, Kabwe PC, Alimi Y, Tajudeen R, Mankoula W, Ilesanmi OS, Balogun MS, Ihekweazu C, Hornsey E, Ogbuagu O. Glob Health Sci Pract. 2023 Oct 30;11(5):e2300121. doi: 10.9745/GHSP-D-23-00121. Print 2023 Oct 30. PMID: 37903581

Exploring COVID-19 conspiracy theories: education, religiosity, trust in scientists, and political orientation in 26 European countries.
Jabkowski P, Domaradzki J, Baranowski M. Sci Rep. 2023 Oct 23;13(1):18116. doi: 10.1038/s41598-023-44752-w. PMID: 37872233

First malaria vaccine slashes childhood deaths.
Wadman M. Science. 2023 Oct 27;382(6669):357. doi: 10.1126/science.adl5521. Epub 2023 Oct 26. PMID: 37883572

Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.
Singal AG, Kanwal F, Llovet JM. Nat Rev Clin Oncol. 2023 Oct 26. doi: 10.1038/s41571-023-00825-3. Online ahead of print. PMID: 37884736

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Ascorbate deficiency increases progression of shigellosis in guinea pigs and mice infection models.
Skerniskyte J, Mulet C, André AC, Anderson MC, Injarabian L, Buck A, Prade VM, Sansonetti PJ, Reibel-Foisset S, Walch AK, Lebel M, Lykkesfeldt J, Marteyn BS. Gut Microbes. 2023 Dec;15(2):2271597. doi: 10.1080/19490976.2023.2271597. Epub 2023 Oct 24. PMID: 37876025

Anti-Influenza Virus Activity of *Citrullus lanatus* var. *citroides* as a Functional Food: A Review.
Morimoto R, Isegawa Y. Foods. 2023 Oct 22;12(20):3866. doi: 10.3390/foods12203866. PMID: 37893759

Relationship of maternal cytomegalovirus-specific antibody responses and viral load to vertical transmission risk following primary maternal infection in a rhesus macaque model.
Otero CE, Barfield R, Scheef E, Nelson CS, Rodgers N, Wang HY, Moström MJ, Manuel TD, Sass J, Schmidt K, Taher H, Papen C, Sprehe L, Kendall S, Davalos A, Barry PA, Früh K, Pollara J, Malouli D, Chan C, Kaur A, Permar SR. PLoS Pathog. 2023 Oct 23;19(10):e1011378. doi: 10.1371/journal.ppat.1011378. Online ahead of print. PMID: 37871009

Characterization of a highly virulent Avibacterium paragallinarum isolate.
Mei C, Zhi Y, Xu J, Liang Z, Zhang X, Hu G, Wang H. J Anim Sci. 2023 Oct 26:skad365. doi: 10.1093/jas/skad365. Online ahead of print. PMID: 37882211

Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases.
Lv M, Ding Y, Zhang Y, Liu S. Rev Med Virol. 2023 Oct 31:e2487. doi: 10.1002/rmv.2487. Online ahead of print. PMID: 37905912

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.
Albelda SM. Nat Rev Clin Oncol. 2023 Oct 30. doi: 10.1038/s41571-023-00832-4. Online ahead of print. PMID: 37904019

Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
Flor N, García MI, Molineri A, Bottasso O, Diez C, Veaute C. Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.10.038. Online ahead of print. PMID: 37884413

Diagnostic performance of host protein signatures as a triage test for active pulmonary TB.
Koeppel L, Denkinger CM, Wyss R, Broger T, Chegou NN, Dunty JM, Scott K, Cáceres T, Dutoit E, Ugarte-Gil C, Nicol M, Gotuzzo E, Corstjens PLAM, Geluk A, Sutherland J, Sigal GB, Moreau E, Albertini A, Mantsoki A, Ongarello S, Walzl G, Fernandez Suarez M. J Clin Microbiol. 2023 Oct 24;61(10):e0026423. doi: 10.1128/jcm.00264-23. Epub 2023 Sep 19. PMID: 37724874

Identification of a novel transcriptional regulator, CorR, for copper stress response in *Edwardsiella piscicida*.
Xia F, Xu P, Zhang B, Zhang Y, Liu X, Ma Y, Zhang Y, Wang Q, Shao S. Appl Environ Microbiol. 2023 Oct 31;89(10):e0089923. doi: 10.1128/aem.00899-23. Epub 2023 Sep 21. PMID: 37732742

Bibliometric analysis of monoclonal antibodies for atherosclerosis.
Ma J, Zhao K, Zhu Y, Xu W, Huang J, Wei X, Zhao Z. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266926. doi: 10.1080/21645515.2023.2266926. Epub 2023 Oct 31. PMID: 37905896

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.
Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, Saginur R, Booth R, Little J, McGuinty M, Buchan CA, Crawley A, Langlois MA, Cooper C. BMJ Open. 2023 Oct 31;13(10):e077714. doi: 10.1136/bmjopen-2023-077714. PMID: 37907304

A Multidimensional Approach to Modulating Ionizable Lipids for High-Performing and Organ-Selective mRNA Delivery.
He Z, Le Z, Shi Y, Liu L, Liu Z, Chen Y. Angew Chem Int Ed Engl. 2023 Oct 23;62(43):e202310401. doi: 10.1002/anie.202310401. Epub 2023 Sep 15. PMID: 37661193

Did COVID-19 or COVID-19 Vaccines Influence the Patterns of Dengue in 2021? An Exploratory Analysis of Two Observational Studies from North India.
Kaur U, Jethwani P, Mishra S, Dehade A, Yadav AK, Chakrabarti S, Sankha SC. Am J Trop Med Hyg. 2023 Oct 30:tpmd230418. doi: 10.4269/ajtmh.23-0418. Online ahead of print. PMID: 37903443

Naturally acquired functional antibody responses to group A *Streptococcus* differ between major strain types.
McGregor R, Paterson A, Sharma P, Chen T, Lovell JR, Carlton LH, Steer AC, Osowicki J, Loh JMS, Moreland NJ. mSphere. 2023 Oct 24;8(5):e0017923. doi: 10.1128/msphere.00179-23. Epub 2023 Sep 20. PMID: 37729548

Comparison of O-specific polysaccharide responses in patients following infection with *Vibrio cholerae* O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh.
Kaisar MH, Kelly M, Kamruzzaman M, Bhuiyan TR, Chowdhury F, Khan AI, LaRocque RC, Calderwood SB, Harris JB, Charles RC, Čížová A, Mečárová J, Korcová J, Bystrický S, Kováč P, Xu P, Qadri F, Ryan ET. mSphere. 2023 Oct 24;8(5):e0025523. doi: 10.1128/msphere.00255-23. Epub 2023 Aug 30. PMID: 37646517

Assessing the Anxiety and Knowledge about Monkeypox Virus: A Cross-Sectional Cohort Study.
Alqthami OA, Alaseeri RH, Alzahrani AA, Al-Otaibi AA, Alghoraibi YA, Abdel-Moneim AS, A Mohamed IA, S Alzahrani AH, Al-Ghamdi AN. Cureus. 2023 Oct 27;15(10):e47806. doi: 10.7759/cureus.47806. eCollection 2023 Oct. PMID: 37899897

Refractory drug-induced systemic small-vessel vasculitis with two varied extracutaneous manifestations: a case report and review of the literature.
Jovanovic M, Sabovic M. J Med Case Rep. 2023 Oct 27;17(1):470. doi: 10.1186/s13256-023-04174-8. PMID: 37885023

A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
Ramsay JA, Jones M, Vande More AM, Hunt SL, Williams PCM, Messer M, Wood N, Macartney K, Lee FJ, Britton WJ, Snelling TL, Caterson ID. Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.10.050. Online ahead of print. PMID: 37903680

Mental Health and Contraceptive Knowledge in High Schoolers: Comparing Remote and In-Person Learning during COVID-19.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Hinoveanu D, Anastasiu DM, Citu C, Crisan DC, Popa ZL, Nicolae N, Dumitru C, Neda-Stepan O, Fericean RM, Stelea L. Medicina (Kaunas). 2023 Oct 22;59(10):1876. doi: 10.3390/medicina59101876. PMID: 37893594

Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence.
Gulati S, Mattsson AH, Schussek S, Zheng B, DeOliveira RB, Shaughnessy J, Lewis LA, Rice PA, Comstedt P, Ram S. mBio. 2023 Oct 31:e0250023. doi: 10.1128/mbio.02500-23. Online ahead of print. PMID: 37905891

Acceptance of influenza vaccination and associated factors among teachers in China: A cross-sectional study based on health belief model.
Gu W, Liu Y, Chen Q, Wang J, Che X, Du J, Zhang X, Xu Y, Zhang X, Jiang W, Wang J, Xie Q, Lu Z, Yang Y, Gu L, Chen J. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270325. doi: 10.1080/21645515.2023.2270325. Epub 2023 Oct 31. PMID: 37905951

Description of mpox reinfection by whole genome sequencing.
Martínez-Sanz J, Ponce M, Martínez-García L, de la Cueva V, Olavarrieta L, Montero L, Pérez-Elías MJ, Galán JC. Int J Infect Dis. 2023 Oct 24:S1201-9712(23)00754-3. doi: 10.1016/j.ijid.2023.10.017. Online ahead of print. PMID: 37884258

Providing Pneumococcal Vaccines Reduces the Risk of Serious Infections From Pneumococcal Pneumonia. We Should Consider a Simplified Immunization Schedule.
Almasry M, Caldera F. Crohns Colitis 360. 2023 Oct 27;5(4):otad056. doi: 10.1093/crocol/otad056. eCollection 2023 Oct. PMID: 37901190

Insights and expectations of healthcare professionals on the implementation of the updated pediatric regional immunization Calendar in Calabria, Italy.
Giuffrida S, Seta G, Gurnari A, Fiasca F, Marchetti F. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275475. doi: 10.1080/21645515.2023.2275475. Epub 2023 Oct 30. PMID: 37904511

Human papillomavirus vaccine uptake and associated factors among adolescent girls in high schools of Nekemte city, Western Ethiopia, 2020.
Hailu G, Wirtu D, Tesfaye T, Getachew M. BMC Womens Health. 2023 Oct 28;23(1):560. doi: 10.1186/s12905-023-02702-8. PMID: 37898731

Characteristics and economic burden of hospitalized patients with herpes zoster in China, before vaccination.
Chen P, Chen Z, Xiao Y, Chen X, Li J, Tang Y, Shen M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2268990. doi: 10.1080/21645515.2023.2268990. Epub 2023 Oct 30. PMID: 37899682

Allan William Cripps: a mucosal immunologist and mentor from beginning to end.
Gleeson M, West NP. Immunol Cell Biol. 2023 Nov-Dec;101(10):916-920. doi: 10.1111/imcb.12706. Epub 2023 Oct 27. PMID: 37885423

Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Gong W, Du J. J Korean Med Sci. 2023 Oct 30;38(42):e343. doi: 10.3346/jkms.2023.38.e343. PMID: 37904656

Antrodia cinnamomea May Interfere with the Interaction Between ACE2 and SARS-CoV-2 Spike Protein in vitro and Reduces Lung Inflammation in a Hamster Model of COVID-19.
Li LH, Chiu HW, Wong WT, Huang KC, Lin TW, Chen ST, Hua KF. J Inflamm Res. 2023 Oct 26;16:4867-4884. doi: 10.2147/JIR.S431222. eCollection 2023. PMID: 37908202

Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity.
Hoving D, Marques AHC, Huisman W, Nosoh BA, de Kroon AC, van Hengel ORJ, Wu BR, Steenbergen RAM, van Helden PM, Urban BC, Dhar N, Ferreira DM, Kwatra G, Hokke CH, Jochems SP. Commun Biol. 2023 Oct 28;6(1):1095. doi: 10.1038/s42003-023-05444-3. PMID: 37898698

Leveling the Research Playing Field: Decolonizing Global Health Research Through Web-Based Platforms.
Seth R, Dhaliwal BK, Miller E, Best T, Sullivan A, Thankachen B, Qaiyum Y, Shet A. J Med Internet Res. 2023 Oct 31;25:e46897. doi: 10.2196/46897. PMID: 37906225

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.
Hejazi NS, Shen X, Carpp LN, Benkeser D, Follmann D, Janes HE, Baden LR, El Sahly HM, Deng W, Zhou H, Leav B, Montefiori DC, Gilbert PB. Int J Infect Dis. 2023 Oct 25;137:28-39. doi: 10.1016/j.ijid.2023.09.012. Online ahead of print. PMID: 37820782

From disease- to people-centred pandemic management: organized communities, community-oriented primary care and health information systems.
Leyns C, Willems S, Powell RA, Camacho V, Fabrega R, De Maeseneer J, Rawaf S, Mangtani P, El-Osta A. Int J Equity Health. 2023 Oct 23;22(1):225. doi: 10.1186/s12939-023-02032-z. PMID: 37872591

Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service.
Radhakrishnan N, Liu M, Idowu B, Bansari A, Rathi K, Magar S, Mundhra L, Sarmiento J, Ghaffar U, Kattan J, Jones R, George J, Yang Y, Southwick F. BMC Infect Dis. 2023 Oct 31;23(1):747. doi: 10.1186/s12879-023-08714-x. PMID: 37907849

Graves' disease after COVID mRNA vaccination for the first time diagnosed in adolescence-case report. Cause and effect relationship or simple coincidence?
Mainieri F, Chiarelli F, Betterle C, Bernasconi S. J Pediatr Endocrinol Metab. 2023 Aug 24;36(10):993-997. doi: 10.1515/jpem-2023-0181. Print 2023 Oct 26. PMID: 37608729

"Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
Walliar T, Khan B, Newstead S, Al-Assadi G, Salter SM, Seubert L, Carlson SJ, Attwell K. Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.10.045. Online ahead of print. PMID: 37891049

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Assessment of Equine Influenza Virus Status in the Republic of Korea from 2020 to 2022.
Lim SI, Kim MJ, Kim MJ, Lee SK, Yang HS, Kwon M, Lim EH, Ouh IO, Kim EJ, Hyun BH, Lee YH. Viruses. 2023 Oct 23;15(10):2135. doi: 10.3390/v15102135. PMID: 37896912

Explaining the challenges of resources management and its underlying factors in COVID-19 era in Iran: a qualitative study.
Vatandoost V, Tabatabaee SS, Okhovati M, Barooni M. BMC Public Health. 2023 Oct 27;23(1):2118. doi: 10.1186/s12889-023-17045-0. PMID: 37891547

Role of human papillomavirus (HPV) in cancers.
Khan A. S Afr Med J. 2023 Oct 23;113(10):10. doi: 10.7196/SAMJ.2023.v113i10.1318. PMID: 37881906

Billions boost next-generation weapons against SARS-CoV-2.
Cohen J. Science. 2023 Oct 27;382(6669):359-360. doi: 10.1126/science.adl5523. Epub 2023 Oct 26. PMID: 37883560

APR-246 increases tumor antigenicity independent of p53.
Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao ZK, Ouerfelli O, Liu H, Stockwell BR, Campesato LF, Zamarin D, Zappasodi R, Wolchok JD, Merghoub T. Life Sci Alliance. 2023 Oct 27;7(1):e202301999. doi: 10.26508/lsa.202301999. Print 2024 Jan. PMID: 37891002

Chitosan-Alginate Polymeric Nanocomposites as a Potential Oral Vaccine Carrier Against Influenza Virus Infection.
Kang HJ, Li J, Razzak MA, Eom GD, Yoon KW, Mao J, Chu KB, Jin H, Choi SS, Quan FS. ACS Appl Mater Interfaces. 2023 Oct 30. doi: 10.1021/acsami.3c11756. Online ahead of print. PMID: 37903218

Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
Sharif H, Ghani H, Ahmad L, Bagol S, Wong J, Tan CW, Zhu F, Wang LF, Naing L, Cunningham AC. Vaccine. 2023 Oct 23:S0264-410X(23)01227-6. doi: 10.1016/j.vaccine.2023.10.044. Online ahead of print. PMID: 37880070

Identification of key residues of B cell epitopes in hemagglutinin of H6 influenza A virus.
Wan Z, Gong J, Sang J, Jiang W, Zhao Z, Tang T, Li Y, Zhao Y, Kan Q, Xie Q, Li T, Shao H, Gao W, Qin A, Ye J. Microbiol Spectr. 2023 Oct 26:e0205923. doi: 10.1128/spectrum.02059-23. Online ahead of print. PMID: 37882566

Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.
Hyun H, Jang AY, Suh JW, Bae IG, Choi WS, Seo YB, Lee J, Yoon JG, Noh JY, Cheong HJ, Kim WJ, Kim MJ, Song JY. J Korean Med Sci. 2023 Oct 30;38(42):e330. doi: 10.3346/jkms.2023.38.e330. PMID: 37904655

Understanding the Health Effects of Caregiving Stress: New Directions in Molecular Aging.
Christian LM, Wilson SJ, Madison AA, Prakash RS, Burd CE, Rosko AE, Kiecolt-Glaser JK. Ageing Res Rev. 2023 Oct 26:102096. doi: 10.1016/j.arr.2023.102096. Online ahead of print. PMID: 37898293

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series.
Diab R, Rakhshan A, Salarinejad S, Pourani MR, Ansar P, Abdollahimajd F. J Cosmet Dermatol. 2023 Oct 29. doi: 10.1111/jocd.16042. Online ahead of print. PMID: 37899662

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.
Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C, Basu P. BMJ Open. 2023 Oct 24;13(10):e069616. doi: 10.1136/bmjopen-2022-069616. PMID: 37879679

Human Papillomavirus (HPV) Infections Among Participants Undergoing Chlamydia trachomatis Testing in Reunion Island (RUN-SurV-HPV Study): Protocol for a Prevalence Study.
Gandelin M, Tran PL, Chirpaz E, Jaffar-Bandjee MC, Traversier N, Machalek D, Bertolotti A. JMIR Res Protoc. 2023 Oct 31;12:e47379. doi: 10.2196/47379. PMID: 37906221

Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
Anastassopoulou C, Boufidou F, Hatziantoniou S, Vasileiou K, Spanakis N, Tsakris A. Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.10.030. Online ahead of print. PMID: 37891048

Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile.
Jara A, Cuadrado C, Undurraga EA, García C, Nájera M, Bertoglia MP, Vergara V, Fernández J, García-Escorza H, Araos R. Nat Commun. 2023 Oct 27;14(1):6836. doi: 10.1038/s41467-023-41942-y. PMID: 37884492

Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Duri K, Munjoma PT, Mataramvura H, Mazhandu AJ, Chandiwana P, Marere T, Gumbo FZ, Mazengera LR. BMC Infect Dis. 2023 Oct 27;23(1):736. doi: 10.1186/s12879-023-08523-2. PMID: 37891471

Comparison of Post-Vaccination Response between mRNA and Vector Vaccines against SARS-CoV-2 in Terms of Humoral Response after Six Months of Observation.
Slomka S, Zieba P, Rosiak O, Piekarska A. Vaccines (Basel). 2023 Oct 23;11(10):1625. doi: 10.3390/vaccines11101625. PMID: 37897027

Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.
Burnett E, Riaz A, Anwari P, Myat TW, Chavers TP, Talat N, Safi N, Aung NNT, Cortese MM, Sultana S, Samsor A, Thu HM, Saddal NS, Safi S, Lin H, Qazi SH, Safi H, Ali A, Parashar UD, Tate JE. Vaccine. 2023 Oct 24:S0264-410X(23)01225-2. doi: 10.1016/j.vaccine.2023.10.042. Online ahead of print. PMID: 37884416

Cost of the COVID-19 pandemic versus the cost-effectiveness of mitigation strategies in EU/UK/OECD: a systematic review.
Vardavas C, Zisis K, Nikitara K, Lagou I, Marou V, Aslanoglou K, Athanasakis K, Phalkey R, Leonardi-Bee J, Fernandez E, Condell O, Lamb F, Sandmann F, Pharris A, Deogan C, Suk JE. BMJ Open. 2023 Oct 31;13(10):e077602. doi: 10.1136/bmjopen-2023-077602. PMID: 37907290

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure.
Schönborn L, Esteban O, Wesche J, Dobosz P, Broto M, Rovira Puig S, Fuhrmann J, Torres R, Serra J, Llevadot R, Palicio M PhD, Wang JJ Dr, Gordon TP Professor, Lindhoff-Last E, Hoffmann T, Alberio L, Langer F, Boehme C, Biguzzi E, Grosse L, Endres M, Liman TG, Thiele T, Warkentin TE, Greinacher A. Blood. 2023 Oct 26:blood.2023022136. doi: 10.1182/blood.2023022136. Online ahead of print. PMID: 37883798

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
Liu Y, Sánchez-Ovando S, Carolan L, Dowson L, Khvorov A, Jessica Hadiprodjo A, Tseng YY, Delahunty C, Khatami A, Macnish M, Dougherty S, Hagenauer M, Riley KE, Jadhav A, Harvey J, Kaiser M, Mathew S, Hodgson D, Leung V, Subbarao K, Cheng AC, Macartney K, Koirala A, Marshall H, Clark J, Blyth CC, Wark P, Kucharski AJ, Sullivan SG, Fox A. Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.10.034. Online ahead of print. PMID: 37903679

Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
Skowronski DM, Kaweski SE, Irvine MA, Chuang ESY, Kim S, Sabaiduc S, Reyes RC, Henry B, Sekirov I, Smolina K. CMAJ. 2023 Oct 30;195(42):E1427-E1439. doi: 10.1503/cmaj.230721. PMID: 37903524

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, Xie F, Takhar H, Ogun OA, Simmons S, Zamparo JM, Valluri SR, Jodar L, McLaughlin JM. Lancet Respir Med. 2023 Oct 25:S2213-2600(23)00306-5. doi: 10.1016/S2213-2600(23)00306-5. Online ahead of print. PMID: 37898148

Estimating counterfactual placebo HIV incidence in HIV prevention trials without placebo arms based on markers of HIV exposure.
Zhu Y, Gao F, Glidden DV, Donnell D, Janes H. Clin Trials. 2023 Oct 25:17407745231203327. doi: 10.1177/17407745231203327. Online ahead of print. PMID: 37877356

Using a time-varying LCAR-based strategy to investigate the spatiotemporal pattern of association between short-term exposure to particulate matter and COVID-19 incidence: a case study in the continental USA.
Liu S, Luo J, Dai X, Ji S, Lu D. Environ Sci Pollut Res Int. 2023 Oct 28. doi: 10.1007/s11356-023-30621-6. Online ahead of print. PMID: 37897578

Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study.
Kuijpers Y, Picavet HSJ, de Rond L, de Zeeuw-Brouwer ML, Rutkens R, Gijsbers E, Slits I, Engelfriet P, Buisman AM, Verschuren WMM. Immun Ageing. 2023 Oct 25;20(1):57. doi: 10.1186/s12979-023-00382-4. PMID: 37880758

Immune response to COVID-19 vaccines among people living with human T-cell lymphotropic virus type 1 infection: a retrospective cohort study from Iran.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Jafarzadeh Esfehani R, Vahidi Z, Shariati M, Mosavat A, Shafaei A, Shahi M, Rafatpanah H, Bidkhori HR, Boostani R, Hedayati-Moghaddam MR. J Neurovirol. 2023 Oct 23. doi: 10.1007/s13365-023-01176-6. Online ahead of print. PMID: 37870718

Mutations in Coding and Non-Coding Regions in Varicella-Zoster Virus Causing Fatal Hemorrhagic Fever Without Rash in an Immunocompetent Patient: Case Report.
Camacho J, Negredo A, Carrilero B, Segovia M, Moreno A, Pozo F, Echevarría JE, Echevarría JM, Sánchez-Seco MP, Tarragó D. Infect Dis Ther. 2023 Oct 23. doi: 10.1007/s40121-023-00884-0. Online ahead of print. PMID: 37870692

The full health, economic, and social benefits of prospective Strep A vaccination.
Cadarette D, Ferranna M, Cannon JW, Abbas K, Giannini F, Zucker L, Bloom DE. NPJ Vaccines. 2023 Oct 30;8(1):166. doi: 10.1038/s41541-023-00758-z. PMID: 37903813

Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
Chen HC, Wang CW, Toh WH, Lee HE, Chung WH, Chen CB. Clin Rev Allergy Immunol. 2023 Oct 28. doi: 10.1007/s12016-023-08973-1. Online ahead of print. PMID: 37897588

Understanding covid-19 outcomes among people with intellectual disabilities in England.
Sosenko F, Mackay D, Pell JP, Hatton C, Jani BD, Cairns D, Ward L, Henderson A, Fleming M, Nijhof D, Melville C; CVD-COVID-UK/COVID-IMPACT Consortium. BMC Public Health. 2023 Oct 25;23(1):2099. doi: 10.1186/s12889-023-16993-x. PMID: 37880687

IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination.
Muñoz-Gómez MJ, Martin-Vicente M, Vigil-Vazquez S, Carrasco I, Lobo AH, Mas V, Vázquez M, Manzanares A, Cano O, Zamora C, Alonso R, Sepulveda-Crespo D, Tarancon-Diez L, Muñoz-Fernández MÁ, Muñoz-Chapuli M, Resino S, Navarro ML, Martinez I. Infection. 2023 Oct 28. doi: 10.1007/s15010-023-02111-x. Online ahead of print. PMID: 37898587

COVID-19 vaccination and infection status: a cross-sectional survey of patients with rheumatic diseases in China.
Chen C, Huang S, Geng L, Lai P, Dou H, Zhang H, Chen H, Liang J, Sun L. Rheumatol Int. 2023 Oct 28. doi: 10.1007/s00296-023-05438-8. Online ahead of print. PMID: 37897662

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention.
Lee SB, Pan J, Xiong D, Palen K, Johnson B, Lubet RA, Shoemaker RH, Green JE, Fernando RI, Sei S, You M, Wang Y. NPJ Precis Oncol. 2023 Oct 25;7(1):108. doi: 10.1038/s41698-023-00461-1. PMID: 37880313

A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses.
Han X, Gao Z, Cheng Y, Wu S, Chen J, Zhang W. Int J Mol Sci. 2023 Oct 23;24(20):15469. doi: 10.3390/ijms242015469. PMID: 37895145

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Omicron breakthrough infections in vaccinated or previously infected hamsters.
Zhou J, Sukhova K, Peacock TP, McKay PF, Brown JC, Frise R, Baillon L, Moshe M, Kugathasan R, Shattock RJ, Barclay WS. Proc Natl Acad Sci U S A. 2023 Nov 7;120(45):e2308655120. doi: 10.1073/pnas.2308655120. Epub 2023 Oct 30. PMID: 37903249

Knowledge, Attitudes, and Practices Related to Cervical Cancer Prevention and Screening among Female Pharmacy Students at a Public University in a Southern Region of Saudi Arabia.
Easwaran V, Shorog EM, Alshahrani AA, Mohammad AAS, Sadiq MMJ, Alavudeen SS, Khan NA, Akhtar MS, Almeleebia TM, Alshahrani SM. Healthcare (Basel). 2023 Oct 22;11(20):2798. doi: 10.3390/healthcare11202798. PMID: 37893872

Effect of the COVID-19 Pandemic on Injuries Related to Individual and Team Sports: An Analysis of the NEISS Database Between 2017 and 2021.
Leipman J, Shahriar R. Orthop J Sports Med. 2023 Oct 26;11(10):23259671231205317. doi: 10.1177/23259671231205317. eCollection 2023 Oct. PMID: 37900862

Complete genome reconstruction of the global and European regional dispersal history of the lumpy skin disease virus.
Van Borm S, Dellicour S, Martin DP, Lemey P, Agianniotaki EI, Chondrokouki ED, Vidanovic D, Vaskovic N, Petrović T, Lazić S, Koleci X, Vodica A, Djadjovski I, Krstevski K, Vandenbussche F, Haegeman A, De Clercq K, Mathijs E. J Virol. 2023 Oct 31:e0139423. doi: 10.1128/jvi.01394-23. Online ahead of print. PMID: 37905838

Echocardiographic function evaluation in adolescents following BNT162b2 Pfizer-BioNTech mRNA vaccination: a preliminary prospective study.
Hsu WF, Hsu CH, Jeng MJ. J Chin Med Assoc. 2023 Oct 26. doi: 10.1097/JCMA.0000000000001013. Online ahead of print. PMID: 37882061

Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis.
Niu J, Jiang W, Fan D, Li X, Zhou W, Zhang H. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269794. doi: 10.1080/21645515.2023.2269794. Epub 2023 Oct 26. PMID: 37885280

Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
Lau JJ, Cheng SMS, Leung K, Lee CK, Hachim A, Tsang LCH, Yam KWH, Chaothai S, Kwan KKH, Chai ZYH, Lo THK, Mori M, Wu C, Valkenburg SA, Amarasinghe GK, Lau EHY, Hui DSC, Leung GM, Peiris M, Wu JT. Nat Med. 2023 Oct 24. doi: 10.1038/s41591-023-02648-2. Online ahead of print. PMID: 37875568

Molecular imaging of bacterial outer membrane vesicles based on bacterial surface display.
Szöllősi D, Hajdrik P, Tordai H, Horváth I, Veres DS, Gillich B, Shailaja KD, Smeller L, Bergmann R, Bachmann M, Mihály J, Gaál A, Jezsó B, Barátki B, Kövesdi D, Bősze S, Szabó I, Felföldi T, Oszwald E, Padmanabhan P, Gulyás BZ, Hamdani N, Máthé D, Varga Z, Szigeti K. Sci Rep. 2023 Oct 31;13(1):18752. doi: 10.1038/s41598-023-45628-9. PMID: 37907509

Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Mendes SG, Combo SI, Allain T, Domingues S, Buret AG, Da Silva GJ. Eur J Clin Microbiol Infect Dis. 2023 Oct 28. doi: 10.1007/s10096-023-04677-8. Online ahead of print. PMID: 37897520

Organ Dysfunction in Children With Blood Culture-Proven Sepsis: Comparative Performance of Four Scores in a National Cohort Study.
Schlapbach LJ, Goertz S, Hagenbuch N, Aubert B, Papis S, Giannoni E, Posfay-Barbe KM, Stocker M, Heininger U, Bernhard-Stirnemann S, Niederer-Loher A, Kahlert CR, Natalucci G, Relly C, Riedel T, Aebi C, Berger C, Agyeman PKA; Swiss Pediatric Sepsis Study Group. Pediatr Crit Care Med. 2023 Oct 25. doi: 10.1097/PCC.0000000000003388. Online ahead of print. PMID: 37878412

3-[[(3S)-1,2,3,4-Tetrahydroisoquinoline-3-Carbonyl]Amino]Propanoic Acid (THICAPA) Is Protective Against Aβ42-Induced Toxicity In Vitro and in an Alzheimer's Disease Drosophila.
Tan FHP, Ting ACJ, Najimudin N, Watanabe N, Shamsuddin S, Zainuddin A, Osada H, Azzam G. J Gerontol A Biol Sci Med Sci. 2023 Oct 28;78(11):1944-1952. doi: 10.1093/gerona/glad169. PMID: 37453137

Gynaecological cancer resources for Aboriginal and Torres Strait Islander women: A resource audit.
Kinghorn M, Garvey G, Butler TL. Health Promot J Austr. 2023 Oct 26. doi: 10.1002/hpja.822. Online ahead of print. PMID: 37883991

Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
Barnwal A, Gaur V, Sengupta A, Tyagi W, Das S, Bhattacharyya J. ACS Biomater Sci Eng. 2023 Oct 23. doi: 10.1021/acsbiomaterials.3c00469. Online ahead of print. PMID: 37870457

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Bartsch YC, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, van Heesbeen R, Sadoff J, Comeaux CA, Heijnen E, Callendret B, Alter G, Bastian AR. J Virol. 2023 Oct 30:e0077123. doi: 10.1128/jvi.00771-23. Online ahead of print. PMID: 37902399

Typology of ICU-Healthcare Providers Who Delayed or Declined COVID-19 Vaccination.
Azoulay E, Pochard F, Dumas G, Kentish-Barnes N; FAMIREA Study Group. Crit Care Med. 2023 Oct 30. doi: 10.1097/CCM.0000000000006090. Online ahead of print. PMID: 37902430

[Progress on mRNA vaccine for the prevention of major infectious diseases in humans and animals].
Gao JQ, Zhao XJ, Hua JL. Sheng Li Xue Bao. 2023 Oct 25;75(5):647-658. PMID: 37909136

Identifying reasons for non-acceptance of influenza vaccine in healthcare workers: an observational study using declination form data.
Challenger A, Sumner P, Powell E, Bott L. BMC Health Serv Res. 2023 Oct 27;23(1):1167. doi: 10.1186/s12913-023-10141-2. PMID: 37891521

Burden, clinical features, and outcomes of post-tuberculosis chronic obstructive lung diseases.
Sehgal IS, Dhooria S, Muthu V, Salzer HJF, Agarwal R. Curr Opin Pulm Med. 2023 Oct 31. doi: 10.1097/MCP.0000000000001026. Online ahead of print. PMID: 37902135

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Structural and biological insights into outer membrane protein lipotoxin F of Pseudomonas aeruginosa: Implications for vaccine application.
Cheng X, Chen Z, Gao C, Zhang Y, Yang L, Wan J, Wei Y, Zeng S, Zhang Y, Zhang Y, Li Y, Zhang W, Zou Q, Lu G, Gu J. Int J Biol Macromol. 2023 Oct 24:127634. doi: 10.1016/j.ijbiomac.2023.127634. Online ahead of print. PMID: 37884248

The first case of SARS-CoV-2 induced eosinophilic fasciitis.
Boussaa H, Kamoun M, Miladi S, Makhlouf Y, Abdelghani KB, Fazaa A, Laatar A. Mod Rheumatol Case Rep. 2023 Oct 30:rxad063. doi: 10.1093/mrcr/rxad063. Online ahead of print. PMID: 37902576

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.
Doss-Gollin S, Thomas S, Brook B, Abedi K, Lebas C, Auderset F, Lugo-Rodriguez Y, Sanchez-Schmitz G, Dowling DJ, Levy O, van Haren SD. NPJ Vaccines. 2023 Oct 26;8(1):163. doi: 10.1038/s41541-023-00759-y. PMID: 37884538

Synthesis of methylphosphorylated oligomannosides structurally related to lipopolysaccharide O-antigens of *Klebsiella pneumoniae* serotype O3 and their application for detection of specific antibodies in rabbit and human sera.
Solovev AS, Denisova EM, Kurbatova EA, Kutsevalova OY, Boronina LG, Ageevets VA, Sidorenko SV, Krylov VB, Nifantiev NE. Org Biomol Chem. 2023 Oct 25;21(41):8306-8319. doi: 10.1039/d3ob01203d. PMID: 37794804

Using the AS04C-adjuvanted hepatitis B vaccine in patients classified as non-responders.
Fernández Sánchez-Escalonilla S, Gonzalez-Rubio J, Najera A, Cantero Escribano JM, Molina Cabrero FJ, García Guerrero J. Trans R Soc Trop Med Hyg. 2023 Oct 28:trad078. doi: 10.1093/trstmh/trad078. Online ahead of print. PMID: 37897239

Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.
Mittal N, Kumar S, Rajmani RS, Singh R, Lemoine C, Jakob V, Bj S, Jagannath N, Bhat M, Chakraborty D, Pandey S, Jory A, Sa SS, Kleanthous H, Dubois P, Ringe RP, Varadarajan R. NPJ Vaccines. 2023 Oct 25;8(1):161. doi: 10.1038/s41541-023-00755-2. PMID: 37880298

Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-16 to 2020-21 seasons: from the VENUS study.
Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H. J Antimicrob Chemother. 2023 Oct 28:dkad340. doi: 10.1093/jac/dkad340. Online ahead of print. PMID: 37897719

What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Ravlić S, Kurtović T, Cvetko Krajinović L, Hećimović A, Miloš M, Mateljak Lukačević S, Markotić A, Halassy B. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270310. doi: 10.1080/21645515.2023.2270310. Epub 2023 Oct 31. PMID: 37905722

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

An atlas of continuous adaptive evolution in endemic human viruses.
Kistler KE, Bedford T. Cell Host Microbe. 2023 Oct 23:S1931-3128(23)00380-3. doi: 10.1016/j.chom.2023.09.012. Online ahead of print. PMID: 37883977

African swine fever virus B175L inhibits the type I interferon pathway by targeting STING and 2'3'-cGAMP.
Ranathunga L, Dodantenna N, Cha J-W, Chathuranga K, Chathuranga WAG, Weerawardhana A, Subasinghe A, Haluwana DK, Gamage N, Lee J-S. J Virol. 2023 Oct 30:e0079523. doi: 10.1128/jvi.00795-23. Online ahead of print. PMID: 37902401

HPV Vaccine Completion by 13: a Quality Improvement Initiative in a Large Primary Care Network.
Huang E, Filograna K, Lockwood KK, Crossette J, Jenssen BP. Acad Pediatr. 2023 Oct 29:S1876-2859(23)00399-6. doi: 10.1016/j.acap.2023.10.008. Online ahead of print. PMID: 37907128

Characterization of hypermetabolic lymph nodes after SARS-CoV-2 vaccination using PET-CT derived node-RADS, in patients with melanoma.
Gennari AG, Rossi A, Sartoretti T, Maurer A, Skawran S, Treyer V, Sartoretti E, Curioni-Fontecedro A, Schwyzer M, Waelti S, Huellner MW, Messerli M. Sci Rep. 2023 Oct 26;13(1):18357. doi: 10.1038/s41598-023-44215-2. PMID: 37884535

Estimated number of reported vaccine-preventable disease cases averted following the introduction of routine vaccination programs in Sweden, 1910-2019.
Martin LJ, Galanis I, Lepp T, Lindstrand A. Eur J Public Health. 2023 Oct 26:ckad169. doi: 10.1093/eurpub/ckad169. Online ahead of print. PMID: 37883058

Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir.
Kumar MR, Fray EJ, Bender AM, Zitzmann C, Ribeiro RM, Perelson AS, Barouch DH, Siliciano JD, Siliciano RF. Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2313209120. doi: 10.1073/pnas.2313209120. Epub 2023 Oct 16. PMID: 37844236

Health status, healthcare use and child MMR vaccination coverage in Travellers according to their environmental and living conditions in Nouvelle-Aquitaine, France, 2019-2022.
Mondeilh A, Brabant G, Haidar S, Saboni L, Ruello M, Lesieur S, Castor C, Autes-Treand E, Le Strat Y, Vandentorren S. Eur J Public Health. 2023 Oct 27:ckad175. doi: 10.1093/eurpub/ckad175. Online ahead of print. PMID: 37889591

Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population.
Zou P, Wang Q, Zhang P, Luo S, Wang C, Zhang E, Zhang L, Li C, Li T. Viral Immunol. 2023 Oct 30. doi: 10.1089/vim.2023.0023. Online ahead of print. PMID: 37903228

Assessing the Level of Knowledge and Experience Regarding Cervical Cancer Prevention and Screening among Roma Women in Romania.
Voidăzan S, Budianu AM, Francisc RF, Kovacs Z, Uzun CC, Apostol BE, Bodea R. Medicina (Kaunas). 2023 Oct 23;59(10):1885. doi: 10.3390/medicina59101885. PMID: 37893602

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

T Cell Antigen Recognition and Discrimination by Electrochemiluminescence Imaging.
Yan Y, Zhou P, Ding L, Hu W, Chen W, Su B. Angew Chem Int Ed Engl. 2023 Oct 30:e202314588. doi: 10.1002/anie.202314588. Online ahead of print. PMID: 37903724

Treatment-prognostication-adjustment a new therapeutic idea by analyzing T cell immune checkpoint in tumor microenvironment by algorithm: A bibliometric analysis.
Ma S, Wu X, Wu Z, Zhao Q. Hum Vaccin Immunother. 2023 Dec 15;19(3):2269788. doi: 10.1080/21645515.2023.2269788. Epub 2023 Oct 31. PMID: 37905399

Healthcare resource use and costs of varicella and its complications: A systematic literature review.
Williame I, George M, Shah HA, Homer N, Alderson D, Jamet N. Hum Vaccin Immunother. 2023 Dec 15;19(3):2266225. doi: 10.1080/21645515.2023.2266225. Epub 2023 Oct 27. PMID: 37885425

Bibliometric analysis of scientific papers on adverse reactions to COVID-19 vaccines published between 2019 and 2023.
Yang X, Chen M, Cao L, Zhao M. Hum Vaccin Immunother. 2023 Dec 15;19(3):2270194. doi: 10.1080/21645515.2023.2270194. Epub 2023 Oct 27. PMID: 37885372

Changes in Sexual Behaviors Due to Mpox: a Cross-Sectional Study of Sexual and Gender Minority Individuals in Illinois.
Phillips G 2nd, Curtis MG, Felt D, Davoudpour S, Rodriguez-Ortiz AE, Cortez A, French AL, Hosek SG, Serrano PA. Prev Sci. 2023 Oct 31. doi: 10.1007/s11121-023-01604-3. Online ahead of print. PMID: 37906357

Measuring unequal distribution of pandemic severity across census years, variants of concern and interventions.
Nguyen QD, Chang SL, Jamerlan CM, Prokopenko M. Popul Health Metr. 2023 Oct 29;21(1):17. doi: 10.1186/s12963-023-00318-6. PMID: 37899455

Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study.
Coulongeat M, Marlet J, Aidoud A, Donati F, Jamard S, Van Der Werf S, Debacq C, Leroy V, Lemaignen A, Munier S, Fougère B. Clin Exp Med. 2023 Oct 31. doi: 10.1007/s10238-023-01203-0. Online ahead of print. PMID: 37906387

mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice.
Kim JY, Jeon K, Park SI, Bang YJ, Park HJ, Kwak HW, Kim DH, Lee SY, Choi EJ, Cho NH, Nam JH. NPJ Vaccines. 2023 Oct 31;8(1):167. doi: 10.1038/s41541-023-00771-2. PMID: 37907507

Hierarchical shift of the Aedes albopictus microbiota caused by anti-microbiota vaccine increases fecundity and egg hatching rate in female mosquitoes.
Mateos-Hernández L, Maitre A, Abuin-Denis L, Obregon D, Martin E, Luis P, Maye J, Wu-Chuang A, Moro CV, Cabezas-Cruz A. FEMS Microbiol Ecol. 2023 Oct 28:fiad140. doi: 10.1093/femsec/fiad140. Online ahead of print. PMID: 37898556

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Jin Z, Wu J, Wang Y, Huang T, Zhao K, Liu J, Wang H, Zhu T, Gou J, Huang H, Wu X, Yin H, Song J, Li R, Zhang J, Li L, Chen J, Li X, Zhang M, Li J, Hou M, Song Y, Wang B, Gao Q, Wu L, Kong Y, Dong R. J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.10.012. Online ahead of print. PMID: 37898410

Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections.
Yoon SW, Widyasari K, Jang J, Lee S, Kang T, Kim S. BMC Infect Dis. 2023 Oct 27;23(1):732. doi: 10.1186/s12879-023-08728-5. PMID: 37891503

Differences in the characteristics of people who purchase pesticides from shops for self-harm versus those who use pesticides available in the domestic environment in Sri Lanka.
Weerasinghe M, Jobe L, Konradsen F, Eddleston M, Pearson M, Jayamanne S, Hawton K, Gunnell D, Agampodi S. Trop Med Int Health. 2023 Oct 23. doi: 10.1111/tmi.13941. Online ahead of print. PMID: 37871998

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
Tricou V, Winkle PJ, Tharenos LM, Rauscher M, Escudero I, Hoffman E, LeFevre I, Borkowski A, Wallace D. Vaccine. 2023 Oct 24:S0264-410X(23)01132-5. doi: 10.1016/j.vaccine.2023.09.049. Online ahead of print. PMID: 37884415

Post-Vaccine SARS-CoV-2 Reinfection and Associated Factors Among Health Care Providers: Comment.
Kleebayoon A, Wiwanitkit V. Health Serv Res Manag Epidemiol. 2023 Oct 23;10:23333928231208248. doi: 10.1177/23333928231208248. eCollection 2023 Jan-Dec. PMID: 37881480

Prevalence and factors associated with immunization coverage among children under five years in Mohamed Mooge health center, Hargeisa, Somaliland: a cross-sectional study.
Abdilahi MM, Mohamed AI, Jonah KM, Ismail AS. BMC Pediatr. 2023 Oct 30;23(1):545. doi: 10.1186/s12887-023-04371-w. PMID: 37904092

Helper T cell bias following tuberculosis chemotherapy identifies opportunities for therapeutic vaccination to prevent relapse.
Martinez-Martinez YB, Huante MB, Chauhan S, Naqvi KF, Bharaj P, Endsley JJ. NPJ Vaccines. 2023 Oct 28;8(1):165. doi: 10.1038/s41541-023-00761-4. PMID: 37898618

Cost-effectiveness of One Health interventions for rabies elimination: a systematic review.
Nujum ZT, Asaria M, Kurup KK, Mini M, Mazumdar S, Daptardar M, Tiwari H. Trans R Soc Trop Med Hyg. 2023 Oct 30:trad074. doi: 10.1093/trstmh/trad074. Online ahead of print. PMID: 37903657

A structural foundation for studying chlamydial polymorphic membrane proteins.
Debrine AM, Karplus PA, Rockey DD. Microbiol Spectr. 2023 Oct 26:e0324223. doi: 10.1128/spectrum.03242-23. Online ahead of print. PMID: 37882824

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination.
Luthria G, Baratto L, Adams L, Morakote W, Daldrup-Link HE. J Nucl Med. 2023 Oct 26:jnumed.123.266271. doi: 10.2967/jnumed.123.266271. Online ahead of print. PMID: 37884331

Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein.
den Hartog G, Andeweg SP, Hoeve CE, Smits G, Voordouw B, Eggink D, Knol MJ, van Binnendijk RS. Sci Rep. 2023 Oct 26;13(1):18394. doi: 10.1038/s41598-023-45718-8. PMID: 37884642

Inadvertent inoculation of *Apophysomyces* following tetanus immunisation- a case report.
Darlington C, Cunningham S, Asomah F, Norton R. Oxf Med Case Reports. 2023 Oct 23;2023(10):omad106. doi: 10.1093/omcr/omad106. eCollection 2023 Oct. PMID: 37881259

Deep proteome coverage advances knowledge of Treponema pallidum protein expression profiles during infection.
Houston S, Gomez A, Geppert A, Eshghi A, Smith DS, Waugh S, Hardie DB, Goodlett DR, Cameron CE. Sci Rep. 2023 Oct 25;13(1):18259. doi: 10.1038/s41598-023-45219-8. PMID: 37880309

Engineered CpG-Loaded Nanorobots Drive Autophagy-Mediated Immunity for TLR9-Positive Cancer Therapy.
Wang Y, Qiao SL, Wang J, Yu MZ, Wang NN, Mamuti M, An HW, Lin YX, Wang H. Adv Mater. 2023 Oct 28:e2306248. doi: 10.1002/adma.202306248. Online ahead of print. PMID: 37897408

RTS, S/AS02A malaria vaccine-induced IgG responses equally recognize native-like fucosylated and non-fucosylated Plasmodium falciparum circumsporozoite proteins.
Jairoce C, Macià D, Torres-Yaguana JP, Mayer L, Vidal M, Santano R, Hurtado-Guerrero R, Reiter K, Narum DL, Lopez-Gutierrez B, Hamerly T, Sacarlal J, Aguilar R, Dinglasan RR, Moncunill G, Izquierdo L, Dobaño C. J Infect Dis. 2023 Oct 27:jiad471. doi: 10.1093/infdis/jiad471. Online ahead of print. PMID: 37889513

[Production and antigenicity analysis of a recombinant insulinoma associated protein-2 in HEK293 cells].
Qian J, Wang P, Zhang Y, Liu Q. Sheng Wu Gong Cheng Xue Bao. 2023 Oct 25;39(10):4246-4257. doi: 10.13345/j.cjb.230087. PMID: 37877403

How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines.
Bai I, Doshi P, Herder M. BMJ Evid Based Med. 2023 Oct 28:bmjebm-2023-112475. doi: 10.1136/bmjebm-2023-112475. Online ahead of print. PMID: 37898504

Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
Jordan SC, Joung SY, Wang M, Tran TA, Bravo M, Masoom H, Chang C, Mendez M, Sun N, Patel J, Kittleson M, Frias E, Prostko JC, Ebinger JE, Cheng S, Sobhani K. Transpl Infect Dis. 2023 Oct 27:e14182. doi: 10.1111/tid.14182. Online ahead of print. PMID: 37885435

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Embedding of exogenous B cell epitopes on the surface of UreB structure generates a broadly reactive antibody response against Helicobacter pylori.
Ji Q, Ma J, Wang S, Liu Q. Immunology. 2023 Oct 29. doi: 10.1111/imm.13703. Online ahead of print. PMID: 37899627

Predictors of COVID-19 Vaccine Hesitancy Among Parents of Children Aged 5-11 Years in Korea.
Kim JH, Yoon D, Noh Y, Jung J, Choe YJ, Shin JY. J Korean Med Sci. 2023 Oct 30;38(42):e315. doi: 10.3346/jkms.2023.38.e315. PMID: 37904653

[Expert recommendations for the prevention and control of pediatric respiratory syncytial virus infections in China (2023 edition)].
Subspecialty Group of Respiratory Diseases, the Society of Pediatrics, Chinese Medical Association; Child Health Special Committee, Chongqing Maternal and Child Health Association; Vaccine and Health Branch of China Health Culture Association. Zhonghua Yi Xue Za Zhi. 2023 Oct 31;103(40):3155-3159. doi: 10.3760/cma.j.cn112137-20230712-01213. PMID: 37879868

Factors associated with COVID-19 vaccination among pregnant women in Rio De Janeiro City, Brazil.
Borges MASB, Florentino PTV, Cerqueira-Silva T, de Carvalho LF, de Araújo Oliveira V, Aguilar GMO, Prado RS, Soranz D, Werneck GL, Pescarini JM, da Costa PSS, Barreto ML, de Oliveira Garcia MH, Penna GO, Barral-Netto M, Paixão ES. Sci Rep. 2023 Oct 25;13(1):18235. doi: 10.1038/s41598-023-44370-6. PMID: 37880238

AMPK activation induces immunogenic cell death in AML.
Mondesir J, Ghisi M, Poillet L, Bossong RA, Kepp O, Kroemer G, Sarry JE, Tamburini J, Lane AA. Blood Adv. 2023 Oct 30:bloodadvances.2022009444. doi: 10.1182/bloodadvances.2022009444. Online ahead of print. PMID: 37903311

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Mitsi E, Diniz MO, Reiné J, Collins AM, Robinson RE, Hyder-Wright A, Farrar M, Liatsikos K, Hamilton J, Onyema O, Urban BC, Solórzano C, Belij-Rammerstorfer S, Sheehan E, Lambe T, Draper SJ, Weiskopf D, Sette A, Maini MK, Ferreira DM. Nat Commun. 2023 Oct 26;14(1):6815. doi: 10.1038/s41467-023-42433-w. PMID: 37884506

Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice.
Ali MT, Johnson M, Irwin T, Henry S, Sugeng L, Kansal S, Allison TG, Bremer ML, Jones VR, Martineau MD, Wong C, Marecki G, Stebbins J, Michelena HI, McCully RB, Svatikova A, Padang R, Scott CG, Kanuga MJ, Arsanjani R, Pellikka PA, Kane GC, Thaden JJ. J Am Soc Echocardiogr. 2023 Oct 23:S0894-7317(23)00555-2. doi: 10.1016/j.echo.2023.10.010. Online ahead of print. PMID: 37879379

VarEPS-Influ:an risk evaluation system of occurred and virtual variations of influenza virus genomes.
Shu C, Sun Q, Fan G, Peng K, Yu Z, Luo Y, Gao S, Ma J, Deng T, Hu S, Wu L. Nucleic Acids Res. 2023 Oct 27:gkad912. doi: 10.1093/nar/gkad912. Online ahead of print. PMID: 37889020

Computational analysis of control of hepatitis B virus disease through vaccination and treatment strategies.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Butt AIK, Imran M, Aslam J, Batool S, Batool S. PLoS One. 2023 Oct 26;18(10):e0288024. doi: 10.1371/journal.pone.0288024. eCollection 2023. PMID: 37883381

Cutaneous Tuberculosis and its possible association with COVID-19.
Saraswat N, Tripathy DM, Mishra A, Kumar S, Goel S. J Eur Acad Dermatol Venereol. 2023 Oct 31. doi: 10.1111/jdv.19592. Online ahead of print. PMID: 37907287

Whole genome sequencing characteristics of Chlamydia psittaci caprine AMK-16 strain, a promising killed whole cell veterinary vaccine candidate against chlamydia infection.
Feodorova VA, Zaitsev SS, Lyapina AM, Kichemazova NV, Saltykov YV, Khizhnyakova MA, Evstifeev VV, Larionova OS. PLoS One. 2023 Oct 30;18(10):e0293612. doi: 10.1371/journal.pone.0293612. eCollection 2023. PMID: 37903115

Task-Shifting Immunization Activities to Community Health Workers: A Mixed-Method Cross-Sectional Study in Sahel Region, Burkina Faso.
Ouédraogo HS, Kabore YLB, Sawadogo AG, Bakouan M, Sawadogo N, Mano M, Zongo A, Sanou S, Kaboré L. Glob Health Sci Pract. 2023 Oct 30;11(5):e2300044. doi: 10.9745/GHSP-D-23-00044. Print 2023 Oct 30. PMID: 37903579

Factors Associated with Symptom Persistence in PANS: Part II-Presenting Features, Medical Comorbidities, and IVIG Treatment History.
Calaprice-Whitty D, Tang A, Tona J. J Child Adolesc Psychopharmacol. 2023 Oct 30. doi: 10.1089/cap.2023.0023. Online ahead of print. PMID: 37902971

Public opinion on COVID-19 pandemic in Bangladesh: Disruption to public lives and trust in government's immunisation performance.
Biswas RK, Afiaz A, Huq S, Farzana M, Kabir E. Int J Health Plann Manage. 2023 Oct 29. doi: 10.1002/hpm.3721. Online ahead of print. PMID: 37898969

Impact of cervical screening by human papillomavirus genotype: Population-based estimations.
Wang J, Elfström KM, Lagheden C, Eklund C, Sundström K, Sparén P, Dillner J. PLoS Med. 2023 Oct 27;20(10):e1004304. doi: 10.1371/journal.pmed.1004304. Online ahead of print. PMID: 37889928

Identification of antigens in the Trichinella spiralis extracellular vesicles for serological detection of early stage infection in swine.
Li C, Li C, Xu F, Wang H, Jin X, Zhang Y, Liu X, Wang R, You X, Liu M, Bai X, Yang Y. Parasit Vectors. 2023 Oct 26;16(1):387. doi: 10.1186/s13071-023-06013-7. PMID: 37884927

Evolutionary History and Genetic Variation of Zika Virus: Connection Between Thailand Zika Viruses and Global Outbreaks Strains.
Bahoussi AN, Shah PT, Liu Y, Guo YY, Bu H, Wu C, Xing L. Vector Borne Zoonotic Dis. 2023 Oct 27. doi: 10.1089/vbz.2023.0037. Online ahead of print. PMID: 37890113

mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Zhao GX, Bu GL, Liu GF, Kong XW, Sun C, Li ZQ, Dai DL, Sun HX, Kang YF, Feng GK, Zhong Q, Zeng MS. Adv Sci (Weinh). 2023 Oct 27:e2302116. doi: 10.1002/advs.202302116. Online ahead of print. PMID: 37890462

Identifying Predominant Causes of Death Among Hospitalized COVID-19 Patients During Poland's Second and Third Waves.
Niecwietajewa I, Frączek M, Mroczkowska M, Frączek M. Med Sci Monit. 2023 Oct 26;29:e941455. doi: 10.12659/MSM.941455. PMID: 37880930

Impact of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
Yii YC, Shih HM, Chen CL, Lai ZL, Hsu YL, Lai CH, Hsueh PR, Cho DY. Int J Antimicrob Agents. 2023 Oct 26:107020. doi: 10.1016/j.ijantimicag.2023.107020. Online ahead of print. PMID: 37898365

Preclinical screen for protection efficacy of chlamydial antigens that are immunogenic in humans.
Lu C, Wang J, Zhong G. Infect Immun. 2023 Oct 27:e0034923. doi: 10.1128/iai.00349-23. Online ahead of print. PMID: 37889004

Recent advances in hepatitis A virus (HAV) research and clinical practice guidelines for HAV infection in Japan.
Kanda T, Sasaki-Tanaka R, Ishii K, Suzuki R, Inoue J, Tsuchiya A, Nakamoto S, Abe R, Fujiwara K, Yokosuka O, Li TC, Kunita S, Yotsuyanagi H, Okamoto H; AMED HAV and HEV Study Group. Hepatol Res. 2023 Oct 31. doi: 10.1111/hepr.13983. Online ahead of print. PMID: 37906585

Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge.
Eckhardt E, Schinköthe J, Gischke M, Sehl-Ewert J, Corleis B, Dorhoi A, Teifke J, Albrecht D, Geluk A, Gilleron M, Bastian M. Sci Rep. 2023 Oct 30;13(1):18613. doi: 10.1038/s41598-023-45898-3. PMID: 37903877

Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy.
Poola S, Kratzer M, Sewell K, Tillmann HL. Dig Dis Sci. 2023 Oct 27. doi: 10.1007/s10620-023-08141-7. Online ahead of print. PMID: 37891440

The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors.
Wang G, Cao J, Gui M, Huang P, Zhang L, Qi R, Chen R, Lin L, Han Q, Lin Y, Chen T, He P, Ma J, Fu R, Hong J, Wu Q, Yu H, Chen J, Huang C, Zhang T, Yuan Q, Zhang J, Chen Y, Xia N. J Exp Clin Cancer Res. 2023 Oct 27;42(1):284. doi: 10.1186/s13046-023-02848-1. PMID: 37891570

Wife-Mother Role Conflict at the Critical Child-Rearing Stage: A Machine-Learning Approach to Identify What and How Matters in Maternal Depression Symptoms in China.
Hong L, Yang A, Liang Q, He Y, Wang Y, Tao S, Chen L. Prev Sci. 2023 Oct 28. doi: 10.1007/s11121-023-01610-5. Online ahead of print. PMID: 37897552

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Park JJ, Kim H, Kim YK, Lee SS, Jung E, Lee JS, Lee J. J Korean Med Sci. 2023 Oct 30;38(42):e347. doi: 10.3346/jkms.2023.38.e347. PMID: 37904658

Monkeypox: an Italian, multicenter study of 104 cases.
Maronese CA, Ramoni S, Avallone G, Giacalone S, Quattri E, Gaspari V, Rapparini L, Robuffo S, Delmonte S, Merli M, Tutone M, Facci G, Carugno A, Parietti M, Latini A, Giuliani E, Sena P, Ribero S, Quaglino P, Piraccini BM, Marzano AV. J Eur Acad Dermatol Venereol. 2023 Oct 27. doi: 10.1111/jdv.19587. Online ahead of print. PMID: 37888494

Tumor-Infiltrating Lymphocytes and Adoptive Cell Therapy: State of the Art in Colorectal, Breast and Lung Cancer.
Zemanek T, Nova Z, Nicodemou A. Physiol Res. 2023 Oct 27;72(S3):S209-S224. PMID: 37888965

Rethinking Coagulation: From enzymatic and cell-based reactions to a convergent model involving innate immune activation.
Yong J, Toh CH. Blood. 2023 Oct 27:blood.2023021166. doi: 10.1182/blood.2023021166. Online ahead of print. PMID: 37890148

Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients.
De Novellis D, Folliero V, Giudice V, Pezzullo L, Sanna G, Fontana R, Guariglia R, Zannella C, Mettivier L, Ferrara I, Boccia G, Buonanno MT, Martorelli MC, Luponio S, Crudele A, Pagliano P, Sessa AM, Velino F, Langella M, Manzin A, Galdiero M, Selleri C, Franci G, Serio B. Clin Exp Med. 2023 Oct 28. doi: 10.1007/s10238-023-01223-w. Online ahead of print. PMID: 37898572

Human papillomavirus vaccination: a quantitative cross-sectional study of perceived barriers, influential advisors, and acculturation among Chinese college students aged 18-26 in the USA.
Tung WC, Chen Y, Yang X, Lam C. Psychol Health Med. 2023 Oct 31:1-12. doi: 10.1080/13548506.2023.2277152. Online ahead of print. PMID: 37906530

Inference of transmission dynamics and retrospective forecast of invasive meningococcal disease.
Cascante-Vega J, Galanti M, Schley K, Pei S, Shaman J. PLoS Comput Biol. 2023 Oct 27;19(10):e1011564. doi: 10.1371/journal.pcbi.1011564. Online ahead of print. PMID: 37889910

Vaccination against COVID-19 reduced the mortality risk of COVID-positive hip fracture patients to baseline levels: the nationwide data-linked IMPACT Protect study.
Hall AJ, Clement ND, MacLullich AMJ, White TO, Duckworth AD. Osteoporos Int. 2023 Oct 28. doi: 10.1007/s00198-023-06954-w. Online ahead of print. PMID: 37897507

The unseen toll: excess mortality during covid-19 lockdowns.
Ege F, Mellace G, Menon S. Sci Rep. 2023 Oct 31;13(1):18745. doi: 10.1038/s41598-023-45934-2. PMID: 37907531

Recombinant outer membrane vesicles delivering eukaryotic expression plasmid of cytokines act as enhanced adjuvants against *Helicobacter pylori* infection in mice.
Liu Q, Li B, Lu J, Zhang Y, Shang Y, Li Y, Gong T, Zhang C. Infect Immun. 2023 Oct 27:e0031323. doi: 10.1128/iai.00313-23. Online ahead of print. PMID: 37889003

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Direct and indirect impact of the COVID-19 pandemic on the survival of kidney transplant recipients: a national observational study in France.
Leye E, Delory T, El Karoui K, Espagnacq M, Khlat M, Le Coeur S, Lapidus N, Hejblum G; COVID-HOSP working group. Am J Transplant. 2023 Oct 26:S1600-6135(23)00819-5. doi: 10.1016/j.ajt.2023.10.017. Online ahead of print. PMID: 37898317

COV2Var, a function annotation database of SARS-CoV-2 genetic variation.
Feng Y, Yi J, Yang L, Wang Y, Wen J, Zhao W, Kim P, Zhou X. Nucleic Acids Res. 2023 Oct 28:gkad958. doi: 10.1093/nar/gkad958. Online ahead of print. PMID: 37897356

Spatio-temporal analysis of sheep and goat pox outbreaks in Uganda during 2011-2022.
Nizeyimana G, Vudriko P, Erume J, Mubiru F, Eneku W, Biryomumaisho S, Mwebe R, Arinaitwe E, Ademun R, Atim S, Ayebazibwe C, Muhanguzi D, Tweyongyere R. BMC Vet Res. 2023 Oct 28;19(1):224. doi: 10.1186/s12917-023-03788-w. PMID: 37891597

First evidence of tick-borne encephalitis (TBE) outside of Hokkaido Island in Japan.
Ohira M, Yoshii K, Aso Y, Nakajima H, Yamashita T, Takahashi-Iwata I, Maeda N, Shindo K, Suenaga T, Matsuura T, Sugie K, Hamano T, Arai A, Furutani R, Suzuki Y, Kaneko C, Kobayashi Y, Campos-Alberto E, Harper LR, Edwards J, Bender C, Pilz A, Ito S, Angulo FJ, Erber W, Madhava H, Moïsi J, Jodar L, Mizusawa H, Takao M. Emerg Microbes Infect. 2023 Oct 31:2278898. doi: 10.1080/22221751.2023.2278898. Online ahead of print. PMID: 37906509

Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
Choe YJ, Ahn YH, Gwak E, Jo E, Kim J, Choe SA. Pediatr Nephrol. 2023 Oct 25. doi: 10.1007/s00467-023-06195-3. Online ahead of print. PMID: 37880380

Biophysical evolution of the receptor binding domains of SARS-CoVs.
Upadhyay V, Panja S, Lucas A, Patrick C, Mallela KMG. Biophys J. 2023 Oct 27:S0006-3495(23)00662-8. doi: 10.1016/j.bpj.2023.10.026. Online ahead of print. PMID: 37897042

High-Stakes Treatment Negotiations Gone Awry: The Importance of Interactions for Understanding Treatment Advocacy and Patient Resistance.
Tate A, Spencer KL. J Health Soc Behav. 2023 Oct 31:221465231204354. doi: 10.1177/00221465231204354. Online ahead of print. PMID: 37905523

Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
Stefanizzi P, Di Lorenzo A, Martinelli A, Moscara L, Stella P, Ancona D, Tafuri S. Vaccine. 2023 Oct 26:S0264-410X(23)01158-1. doi: 10.1016/j.vaccine.2023.09.061. Online ahead of print. PMID: 37891052

The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
Slingerland P, van Hunsel FPAM, Lieber T, van Balveren L, Duijster JW. Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356-7. Online ahead of print. PMID: 37882905

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Continually recruited naïve T cells contribute to the follicular helper and regulatory T cell pools in germinal centers.
Merkenschlager J, Berz RM, Ramos V, Uhlig M, MacLean AJ, Nowosad CR, Oliveira TY, Nussenzweig MC. Nat Commun. 2023 Oct 31;14(1):6944. doi: 10.1038/s41467-023-41880-9. PMID: 37907454

Understanding the Impact of Mpox on Sexual Health Clinical Services: A National Knowledge, Attitudes, and Practices Survey - United States, 2022.
Schubert SL, Miele K, Quilter L, Agnew-Brune C, Coor A, Kachur R, Lewis F, Ard KL, Wendel K, Anderson T, Nagendra G, Tromble E; National Network of STD Clinical Prevention Training Center Co-Authors. Sex Transm Dis. 2023 Oct 23. doi: 10.1097/OLQ.0000000000001882. Online ahead of print. PMID: 37889929

Physiological Temperature and Osmotic Changes Drive Dynamic Proteome Alterations in the Leptospiral Outer Membrane and Enhance Protein Export Systems.
Phukan H, Sarma A, Rex DAB, Christie SAD, Sabu SK, Hariharan S, Prasad TSK, Madanan MG. J Proteome Res. 2023 Oct 25. doi: 10.1021/acs.jproteome.3c00295. Online ahead of print. PMID: 37877620

Bordetella spp. block eosinophil recruitment to suppress the generation of early mucosal protection.
First NJ, Parrish KM, Martínez-Pérez A, González-Fernández Á, Bharrhan S, Woolard M, McLachlan JB, Scott RS, Wang J, Gestal MC. Cell Rep. 2023 Oct 25;42(11):113294. doi: 10.1016/j.celrep.2023.113294. Online ahead of print. PMID: 37883230

Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study.
Hill EL, Mehta HB, Sharma S, Mane K, Singh SK, Xie C, Cathey E, Loomba J, Russell S, Spratt H, DeWitt PE, Ammar N, Madlock-Brown C, Brown D, McMurry JA, Chute CG, Haendel MA, Moffitt R, Pfaff ER, Bennett TD; N3C Consortium; RECOVER Consortium. BMC Public Health. 2023 Oct 25;23(1):2103. doi: 10.1186/s12889-023-16916-w. PMID: 37880596

Willingness to receive Herpes Zoster vaccination among adults and older people: A cross sectional study in Italy.
Di Giuseppe G, Pelullo CP, Napoli A, Napolitano F. Vaccine. 2023 Oct 23:S0264-410X(23)01247-1. doi: 10.1016/j.vaccine.2023.10.049. Online ahead of print. PMID: 37880069

Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study.
Mink S, Saely CH, Leiherer A, Frick M, Plattner T, Drexel H, Fraunberger P. Sci Rep. 2023 Oct 26;13(1):18326. doi: 10.1038/s41598-023-45700-4. PMID: 37884649

Dynamics in a behavioral-epidemiological model for individual adherence to a nonpharmaceutical intervention.
Saad-Roy CM, Traulsen A. Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2311584120. doi: 10.1073/pnas.2311584120. Epub 2023 Oct 27. PMID: 37889930

To boost or not to boost: navigating post-pandemic COVID-19 vaccination.
Goldberg Y, Huppert A. Lancet Respir Med. 2023 Oct 25:S2213-2600(23)00350-8. doi: 10.1016/S2213-2600(23)00350-8. Online ahead of print. PMID: 37898149

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Correction: A spatial vaccination strategy to reduce the risk of vaccine-resistant variants.
Zhang X, Lobinska G, Feldman M, Dekel E, Nowak MA, Pilpel Y, Pauzner Y, Barzel B, Pauzner A. PLoS Comput Biol. 2023 Oct 30;19(10):e1011608. doi: 10.1371/journal.pcbi.1011608. eCollection 2023 Oct. PMID: 37903105

A robust pipeline for high-content, high-throughput immunophenotyping reveals age- and genetics-dependent changes in blood leukocytes.
Liechti T, Van Gassen S, Beddall M, Ballard R, Iftikhar Y, Du R, Venkataraman T, Novak D, Mangino M, Perfetto S, Larman HB, Spector T, Saeys Y, Roederer M. Cell Rep Methods. 2023 Oct 23;3(10):100619. doi: 10.1016/j.crmeth.2023.100619. PMID: 37883924

Relative age and persistence of ADHD diagnosis in young children.
Wong ICK. Lancet Psychiatry. 2023 Oct 25:S2215-0366(23)00334-6. doi: 10.1016/S2215-0366(23)00334-6. Online ahead of print. PMID: 37898141

Epidemiology and Risk Factors for Diarrheagenic Escherichia coli Carriage among Children in Northern Ibadan, Nigeria.
Akinlabi OC, Nwoko EQ, Dada RA, Ekpo S, Omotuyi A, Nwimo CC, Adepoju A, Popoola O, Dougan G, Thomson NR, Okeke IN. Am J Trop Med Hyg. 2023 Oct 30:tpmd220618. doi: 10.4269/ajtmh.22-0618. Online ahead of print. PMID: 37903436

Characterizing HIV status documentation among cancer patients at regional cancer centers in Malawi, Zimbabwe, and South Africa.
Montaño MA, Mtisi T, Ndlovu N, Borok M, Bula A, Joffe M, Bender Ignacio R, Chagomerana MB. Infect Agent Cancer. 2023 Oct 26;18(1):65. doi: 10.1186/s13027-023-00548-1. PMID: 37884958

Readiness of public schools before reopening during COVID-19 pandemic: School-based cross-sectional survey in southern Ethiopia.
Endriyas M, Woldemariam B, Shibru E, Hussen M, Bedru B, Moges M, Melka M, Lemango F, Mate M, Lejiso T, Gebremedhin B, Tolcha A, Shiferaw B, Wondimu G, Terefe T, Ayele S, Misganaw T, Samuel T, Kelaye T, Gebru A, Assefa A, Getachew W, Yalew B, Geleta D. PLoS One. 2023 Oct 31;18(10):e0293722. doi: 10.1371/journal.pone.0293722. eCollection 2023. PMID: 37906545

Deciphering Interactions between Potential Inhibitors and the *Plasmodium falciparum* DHODH Enzyme: A Computational Perspective.
Lima Costa AH, Bezerra KS, de Lima Neto JX, Oliveira JIN, Galvão DS, Fulco UL. J Phys Chem B. 2023 Oct 28. doi: 10.1021/acs.jpcb.3c05738. Online ahead of print. PMID: 37897437

Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, Macdonald P, Milan G, Palanee-Phillips T, Reddy K, Tahuringana E, Muhlanga F, Nakabiito C, Bekker LG, Siziba B, Hillier SL, Baeten JM, Garcia M, Johnson S, McClure T, Levy L, Livant E, Jacobson C, Soto-Torres L, van der Straten A, Hosek S, Rooney JF, Steytler J, Bunge K, Parikh U, Hendrix C, Anderson P, Ngure K; REACH Protocol Team. Lancet HIV. 2023 Oct 25:S2352-3018(23)00227-8. doi: 10.1016/S2352-3018(23)00227-8. Online ahead of print. PMID: 37898146

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Underimmunization of very low birth weight infants at discharge from the neonatal intensive care unit.
Quiett V, Thompson E, Raman SR, DeMeo SD, Hornik CP, Clark R, Zimmerman KO, Smith PB, Greenberg RG. J Perinatol. 2023 Oct 25. doi: 10.1038/s41372-023-01806-1. Online ahead of print. PMID: 37880407

[Cognitive Impairment as a Sequela of COVID-19: Pathophysiology and Prospects for Treatment].
Shimohata T. Rinsho Shinkeigaku. 2023 Oct 25. doi: 10.5692/clinicalneurol.cn-001902. Online ahead of print. PMID: 37880112

Development of a double-antigen sandwich ELISA for African swine fever virus antibody detection based on K205R protein.
Feng L, Shi Z, Luo J, Zhang X, Wei J, Zhou J, Liao H, Wang W, Tian H, Zheng H. Int J Biol Macromol. 2023 Oct 26:127724. doi: 10.1016/j.ijbiomac.2023.127724. Online ahead of print. PMID: 37898252

Recovery of Complete Genome Sequences of Crimean-Congo Haemorrhagic Fever Virus (CCHFV) Directly from Clinical Samples: A Comparative Study Between Targeted Enrichment and Metagenomic Approaches.
D'Addiego J, Wand N, Afrough B, Fletcher T, Kurosaki Y, Leblebicioglu H, Hewson R. J Virol Methods. 2023 Oct 23:114833. doi: 10.1016/j.jviromet.2023.114833. Online ahead of print. PMID: 37879367

Letter to the Editor: Immunogenicity After the Third Dose of COVID-19 Vaccine in Cardiac Transplantation.
Rahman A, Golombeck D, Malhame K, Rossi D, Wallach F, Avila M, Maybaum S. Transplantation. 2023 Oct 30. doi: 10.1097/TP.0000000000004843. Online ahead of print. PMID: 37899474

[Rac1 promotes the formation of heterotypic cell-in-cell structure].
Hu T, Feng P, Li H, Zhou L, Niu Z, Huang Y, Wang X, Wang C, Liu H, Wu C. Sheng Wu Gong Cheng Xue Bao. 2023 Oct 25;39(10):4123-4134. doi: 10.13345/j.cjb.230091. PMID: 37877395

Continental concerted efforts to control the seventh outbreak of Ebola Virus disease in Uganda: The first 90 days of the response.
Aceng JR, Bosa HK, Kamara N, Atwine D, Mwebesa H, Nyika H, Maureen K, Olaro C, Kagirita A, Larmode M, Riek LP, Temfack E, Salyer S, Aliddeki D, Machingaidze S, Mazuguni F, Kirenga B, Muttamba W, Wayengera M, Bbuye M, Kasambula A, Eurien D, Grace A, Ampaire I, Herbert I, Tut M, Bangure D, Mankoula W, Sonko I, Kokou AN, Magodi S, Mhiraf A, Bulwadda D, Kyabayinze D, Kabami Z, Muruta A, Bahatungire R, George U, Nabadda S, Birungi G, Richard K, Aragaw M, Ouma AO. J Public Health Afr. 2023 Oct 24;14(9):2735. doi: 10.4081/jphia.2023.2735. eCollection 2023 Oct 1. PMID: 37881727

Long-term impact of the COVID-19 pandemic on self-management of chronic conditions among high-risk adults in the USA: protocol for the C3 observational cohort study.
Lovett R, Filec S, Bonham M, Yoshino Benavente J, O'Conor R, Russell A, Zheng P, Wismer G, Yoon E, Weiner-Light S, Vogeley A, Morrissey Kwasny M, Lowe S, Curtis LM, Federman A, Bailey SC, Wolf M. BMJ Open. 2023 Oct 29;13(10):e077911. doi: 10.1136/bmjopen-2023-077911. PMID: 37899164

Modifications to Sexual Behaviors Associated with Mpox (Monkeypox) Virus Transmission Among Persons Presenting for Mpox Vaccination, Washington, D.C., August-October, 2022.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Copen CE, Delaney KP, Agnew-Brune C, Berry I, Griffin I, Hassan R, Oakley LP, Wondmeneh S, Rhodes T, Gillani S, Lee M, Ashley P, Willut C, Mangla A, Waltenburg MA, Jackson DA; DC Mpox Response Project Team*. Sex Transm Dis. 2023 Oct 26. doi: 10.1097/OLQ.0000000000001889. Online ahead of print. PMID: 37889944

COVID-19 vaccination is not associated with reduced SGA or low Apgar score.
El-Qushayri AE. Pediatr Res. 2023 Oct 31. doi: 10.1038/s41390-023-02875-w. Online ahead of print. PMID: 37903938

Trends and long-term variation explaining nutritional determinants of child linear growth: analysis of Bangladesh Demographic and Health Surveys 1996-2018.
Ahmed KT, Karimuzzaman M, Afroz S, Hossain MM, Huq SS, Abdulla F, Rahman A. Public Health Nutr. 2023 Oct 27:1-30. doi: 10.1017/S1368980023002288. Online ahead of print. PMID: 37886806

A shared vaccination ambulatory for patients with cancer in Udine, Italy.
Valent F, Degani G, Gri M, Donato R, Varadi G, Cardellino GG, Fasola G. Tumori. 2023 Oct 30:3008916231208622. doi: 10.1177/03008916231208622. Online ahead of print. PMID: 37904307

Evaluation of SARS-CoV-2 identification methods through surveillance of companion animals in SARS-CoV-2-positive homes in North Carolina, March to December 2020.
Gin TE, Petzold EA, Uthappa DM, Neighbors CE, Borough AR, Gin C, Lashnits E, Sempowski GD, Denny T, Bienzle D, Weese JS, Callahan BJ, Woods CW. PeerJ. 2023 Oct 24;11:e16310. doi: 10.7717/peerj.16310. eCollection 2023. PMID: 37901455

Immunized mice naturally process in silico-derived peptides from the nucleocapsid of SARS-CoV-2.
Campos-Ruíz MA, Illades-Aguiar B, Del Moral-Hernández O, Romo-Castillo M, Salazar-García M, Espinoza-Rojo M, Vences-Velázquez A, Cortés-Sarabia K, Luna-Pineda VM. BMC Microbiol. 2023 Oct 28;23(1):319. doi: 10.1186/s12866-023-03076-5. PMID: 37898784

SARS-CoV-2 genome incidence on the inanimate surface of the material used in the flow of biological samples from the collection point to the testing unit.
Moura CRF, Garcia BCC, de Oliveira Ottone V, Brito PL, Silva TJ, Cantuária VL, de Oliveira DB, Rocha-Vieira E. Ir J Med Sci. 2023 Oct 26. doi: 10.1007/s11845-023-03554-9. Online ahead of print. PMID: 37882949

Correspondence Regarding: McShane H. Improving TB vaccine trial efficiency: A tough nut to crack. J Infect Dis. 2023.
Hill PC, Cobelens F, Martinez L, Garcia-Basteiro A, Behr M, Rangaka MX, Churchyard G, Evans T, Hanekom W, White R. J Infect Dis. 2023 Oct 28:jiad466. doi: 10.1093/infdis/jiad466. Online ahead of print. PMID: 37897697

Biographical Feature: In memoriam Reinhard Glück (1950-2021)-Swiss by birth, Sicilian by choice.
Douradinha B. J Virol. 2023 Oct 25:e0149523. doi: 10.1128/jvi.01495-23. Online ahead of print. PMID: 37877720

Longitudinal Study of Subclinical Mastitis in Sheep in Greece: An Investigation into Incidence Risk, Associations with Milk Quality and Risk Factors of the Infection.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Michael CK, Lianou DT, Vasileiou NGC, Mavrogianni VS, Petinaki E, Fthenakis GC. Animals (Basel). 2023 Oct 22;13(20):3295. doi: 10.3390/ani13203295. PMID: 37894019

Substantial antiviral potential of deoxyribozymes fixed on anatase nanoparticles against influenza A viruses in vitro and in vivo.
Levina AS, Repkova MN, Netesova NA, Ternovoi VA, Mazurkov OY, Filippova EI, Mazurkova NA, Zarytova VF. J Pharm Sci. 2023 Oct 23:S0022-3549(23)00436-7. doi: 10.1016/j.xphs.2023.10.028. Online ahead of print. PMID: 37879408

Considerations for Subgroup Analyses in Cluster-Randomized Trials Based on Aggregated Individual-Level Predictors.
Williamson BD, Coley RY, Hsu C, McCracken CE, Cook AJ. Prev Sci. 2023 Oct 28. doi: 10.1007/s11121-023-01606-1. Online ahead of print. PMID: 37897553

Identifying target areas for risk-based surveillance and control of transboundary animal diseases: a seasonal analysis of slaughter and live-trade cattle movements in Uganda.
González-Gordon L, Porphyre T, Muwonge A, Nantima N, Ademun R, Ochwo S, Mwiine NF, Boden L, Muhanguzi D, Bronsvoort BMC. Sci Rep. 2023 Oct 30;13(1):18619. doi: 10.1038/s41598-023-44518-4. PMID: 37903814

Proteomic profile of naturally released extracellular vesicles secreted from Leptospira interrogans serovar Pomona in response to temperature and osmotic stresses.
Techawiwattanaboon T, Phanchamnan E, Iadsee N, Makjaroen J, Pisitkun T, Patarakul K. Sci Rep. 2023 Oct 30;13(1):18601. doi: 10.1038/s41598-023-45863-0. PMID: 37903905

Stimuli-Responsive Nanoadjuvant Rejuvenates Robust Immune Responses to Sensitize Cancer Immunotherapy.
Huang R, Zhou P, Chen B, Zhu Y, Chen X, Min Y. ACS Nano. 2023 Oct 28. doi: 10.1021/acsnano.3c06233. Online ahead of print. PMID: 37897704

Enhanced transformation efficiency in Treponema denticola enabled by SyngenicDNA-based plasmids lacking restriction-modification target motifs.
Johnston CD, Goetting-Minesky MP, Kennedy K, Godovikova V, Zayed SM, Roberts RJ, Fenno JC. Mol Oral Microbiol. 2023 Oct 25. doi: 10.1111/omi.12441. Online ahead of print. PMID: 37880921

Time to death and its determinant factors of visceral leishmaniasis with HIV co-infected patients during treatment period admitted at Metema hospital, Metema, Ethiopia: a hospital-based cross-sectional study design.
Alemu C, Wudu H, Dessie G, Gashu C. Trop Dis Travel Med Vaccines. 2023 Oct 29;9(1):18. doi: 10.1186/s40794-023-00203-y. PMID: 37898767

PGAM5 degrades PDCoV N protein and activates type I interferon to antagonize viral replication.
Yang X, Kong N, Qin W, Zhai X, Song Y, Tong W, Li L, Liu C, Zheng H, Yu H, Zhang W, Tong G, Shan T. J Virol. 2023 Oct 26:e0147023. doi: 10.1128/jvi.01470-23. Online ahead of print. PMID: 37882521

Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8$^+$ T cells.

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Calzada-Fraile D, Iborra S, Ramírez-Huesca M, Jorge I, Dotta E, Hernández-García E, Martín-Cófreces N, Nistal-Villán E, Veiga E, Vázquez J, Pasqual G, Sánchez-Madrid F. Nat Commun. 2023 Oct 25;14(1):6772. doi: 10.1038/s41467-023-42480-3. PMID: 37880206

Development and Validation of a Highly Specific In-house Chemiluminescent-based Serological Assay for the Detection of Antibodies Directed against the Human Monkeypox Virus.
Therrien C, Prévost J, Blais AC, Turcotte S, Gendron-Lepage G, Finzi A, Fafard J. J Virol Methods. 2023 Oct 25:114836. doi: 10.1016/j.jviromet.2023.114836. Online ahead of print. PMID: 37890729

Association between rare earth elements and depression: Evidence from pilot mice model of chronic unpredictable mild stress-induced depression and human studies of major depressive disorder.
Cao B, Wang R, Kwan ATH, McIntyre RS, Yan L. Chemosphere. 2023 Oct 23;345:140525. doi: 10.1016/j.chemosphere.2023.140525. Online ahead of print. PMID: 37879378

Characterizing Epstein-Barr virus infection of the central nervous system in Zambian adults living with HIV.
Musukuma-Chifulo K, Ghebremichael M, Chilyabanyama ON, Bates M, Munsaka S, Simuyandi M, Chisenga C, Tembo J, Sinkala E, Koralnik IJ, Dang X, Chilengi R, Siddiqi OK. J Neurovirol. 2023 Oct 30. doi: 10.1007/s13365-023-01178-4. Online ahead of print. PMID: 37902948

Optimized bilosome-based nanoparticles enhance cytotoxic and pro-apoptotic activity of costunolide in LS174T colon cancer cells.
Alamoudi AJ, Badr-Eldin SM, Ahmed OAA, Fahmy UA, Elbehairi SEI, Alfaifi MY, Asfour HZ, Mohamed GA, Ibrahim SRM, Abdel-Naim AB, Abdallah HM. Biomed Pharmacother. 2023 Oct 26;168:115757. doi: 10.1016/j.biopha.2023.115757. Online ahead of print. PMID: 37897972

Nutritional analysis and characterization of carbapenemase producing-Klebsiella pneumoniae resistant genes associated with bovine mastitis infected cow's milk.
Mr Saddam, Khan M, Jamal M, Rahman SU, Qadeer A, Khan I, Mahmoud MH, Batiha GE, Shah SH. PLoS One. 2023 Oct 27;18(10):e0293477. doi: 10.1371/journal.pone.0293477. eCollection 2023. PMID: 37889925

Hepatitis B antibody levels after different doses of hepatitis B vaccination: a retrospective study based on hospitalized children.
Chai Y, Tang J, Su Y, Xuan K, Xu L, Hao J, Lu Z, Wang B, Chen X, Luo X, He J, Zhu L. Epidemiol Infect. 2023 Oct 26:1-13. doi: 10.1017/S0950268823001747. Online ahead of print. PMID: 37881897

Boron Compound-Based Treatments Against Multidrug-Resistant Bacterial Infections in Lung Cancer In Vitro Model.
Celebı D, Celebı O, Aydin E, Baser S, Güler MC, Yildirim S, Taghizadehghalehjoughi A. Biol Trace Elem Res. 2023 Oct 26. doi: 10.1007/s12011-023-03912-9. Online ahead of print. PMID: 37884681

Human Cutaneous Leishmaniasis in North Africa and Its Threats to Public Health: A Statistical Study Focused on Djelfa (Algeria).
Messaoudene F, Boukraa S, Boubidi SC, Guerzou A, Ouahabi A. Microorganisms. 2023 Oct 22;11(10):2608. doi: 10.3390/microorganisms11102608. PMID: 37894266

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents.
Islam MA, Marzan AA, Arman MS, Shahi S, Sakif TI, Hossain M, Islam T, Hoque MN. Sci Rep. 2023 Oct 30;13(1):18644. doi: 10.1038/s41598-023-45517-1. PMID: 37903828

Freeze-Induced Phase Transition and Local Pressure in a Phospholipid/Water System: Novel Insights Were Obtained from a Time/Temperature Resolved Synchrotron X-ray Diffraction Study.
Rodrigues MA, Matsarskaia O, Rego P, Geraldes V, Connor LE, Oswald IDH, Sztucki M, Shalaev E. Mol Pharm. 2023 Oct 27. doi: 10.1021/acs.molpharmaceut.3c00657. Online ahead of print. PMID: 37889088

Ventricular arrhythmia burden in ICD patients during the second wave of the COVID-19 pandemic.
Rath B, Doldi F, Willy K, Ellermann C, Köbe J, Güner F, Reinke F, Lange PS, Frommeyer G, Eckardt L. Clin Res Cardiol. 2023 Oct 30. doi: 10.1007/s00392-023-02320-2. Online ahead of print. PMID: 37902845

Feeding and reproductive parameters of adult female Ixodes scapularis (Acari: Ixodidae) and Amblyomma americanum parasitizing white-tailed deer (Odocoileus virginianus).
Baker AS, Persinger KA, Olafson PU, Mulenga AO, Johnson TL. J Med Entomol. 2023 Oct 28:tjad144. doi: 10.1093/jme/tjad144. Online ahead of print. PMID: 37897421

Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor.
Hamada S, Tsukahara T, Watanabe Y, Murata K, Mizue Y, Kubo T, Kanaseki T, Hirohashi Y, Emori M, Nakatsugawa M, Teramoto A, Yamashita T, Torigoe T. Cancer Sci. 2023 Oct 25. doi: 10.1111/cas.15967. Online ahead of print. PMID: 37879364

Identification of CCZ1 as an essential lysosomal trafficking regulator in Marburg and Ebola virus infections.
Monteil V, Kwon H, John L, Salata C, Jonsson G, Vorrink SU, Appelberg S, Youhanna S, Dyczynski M, Leopoldi A, Leeb N, Volz J, Hagelkruys A, Kellner MJ, Devignot S, Michlits G, Foong-Sobis M, Weber F, Lauschke VM, Horn M, Feldmann H, Elling U, Penninger JM, Mirazimi A. Nat Commun. 2023 Oct 25;14(1):6785. doi: 10.1038/s41467-023-42526-6. PMID: 37880247

Underrecognition and Suboptimal Quality of Care for Nonalcoholic Fatty Liver Disease Cirrhosis in Primary Care Patients with Diabetes Mellitus.
Chu JN, Goldman ML, Brandman D, Sohn JH, Islam K, Ross L, Fox RK. Am J Med. 2023 Oct 25:S0002-9343(23)00652-6. doi: 10.1016/j.amjmed.2023.10.002. Online ahead of print. PMID: 37890572

The sociodemographic patterning of sick leave and determinants of longer sick leave after mild and severe COVID-19: a nationwide register-based study in Sweden.
Spetz M, Natt Och Dag Y, Li H, Nwaru C, Santosa A, Nyberg F, Rosvall M. Eur J Public Health. 2023 Oct 27:ckad191. doi: 10.1093/eurpub/ckad191. Online ahead of print. PMID: 37889580

Prevalence of permethrin-resistant kdr mutation in head lice (*Pediculus humanus capitis*) from elementary school students in Jeddah, Saudi Arabia.
Alsaady IM, Altwaim S, Gattan HS, Alghanmi M, Zawawi A, Ahmedah H, Wakid MH, Azhar EI. PeerJ. 2023 Oct 25;11:e16273. doi: 10.7717/peerj.16273. eCollection 2023. PMID: 37901472

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Flavivirus genome recoding by codon optimisation confers genetically stable in vivo attenuation in both mice and mosquitoes.
Chin WX, Kong HY, Zhu IXY, Teo ZY, Faruk R, Lee RCH, Ho SX, Aw ZQ, Yi B, Hou XJ, Tan AKY, Yogarajah T, Huber RG, Cai Y, Wan Y, Chu JJH. PLoS Pathog. 2023 Oct 26;19(10):e1011753. doi: 10.1371/journal.ppat.1011753. Online ahead of print. PMID: 37883598

Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study.
Otiende M, Nyaguara A, Bottomley C, Walumbe D, Mochamah G, Amadi D, Nyundo C, Kagucia EW, Etyang AO, Adetifa IMO, Brand SPC, Maitha E, Chondo E, Nzomo E, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Barasa E, Tsofa B, Mwangangi J, Bejon P, Agweyu A, Williams TN, Scott JAG. Nat Commun. 2023 Oct 28;14(1):6879. doi: 10.1038/s41467-023-42615-6. PMID: 37898630

Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.
Liu Z, Ulrich vonBargen R, Kendricks AL, Wheeler K, Leão AC, Sankaranarayanan K, Dean DA, Kane SS, Hossain E, Pollet J, Bottazzi ME, Hotez PJ, Jones KM, McCall LI. Nat Commun. 2023 Oct 25;14(1):6769. doi: 10.1038/s41467-023-42247-w. PMID: 37880260

Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
Gong IY, Prica A, Ante Z, Calzavara A, Krzyzanowska MK, Singh S, Suleman A, Cheung MC, Crump M. Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166. Online ahead of print. PMID: 37886835

Targeted randomization dose optimization trials enable fractional dosing of scarce drugs.
Boonstra PS, Tabarrok A, Strohbehn GW. PLoS One. 2023 Oct 30;18(10):e0287511. doi: 10.1371/journal.pone.0287511. eCollection 2023. PMID: 37903093

Diagnostic value of rapid test for malaria among febrile neonates in a tertiary hospital in North-East Nigeria: a prospective cross-sectional study.
Adeniji YR, Jalo I, Okonkwo I, Poksireni MR, Manga M, Wariri O, Alhassan HA, Warnow EI. Arch Dis Child. 2023 Oct 25:archdischild-2023-325906. doi: 10.1136/archdischild-2023-325906. Online ahead of print. PMID: 37879855

Advancing diagnostic efficacy using a computer vision-assisted lateral flow assay for influenza and SARS-CoV-2 detection.
Lee S, Yoo YK, Han SI, Lee D, Cho SY, Park C, Lee D, Yoon DS, Lee JH. Analyst. 2023 Oct 26. doi: 10.1039/d3an01189e. Online ahead of print. PMID: 37882491

Trend of the Tuberculous Pleurisy Notification Rate in Eastern China During 2017-2021: Spatiotemporal Analysis.
Zhou Y, Luo D, Liu K, Chen B, Chen S, Pan J, Liu Z, Jiang J. JMIR Public Health Surveill. 2023 Oct 30;9:e49859. doi: 10.2196/49859. PMID: 37902822

Cost and Utilization of Healthcare Services for Persons with Diabetes.
Reynolds EL, Mizokami-Stout K, Putnam NM, Banerjee M, Albright D, Ang L, Lee J, Pop-Busui R, Feldman EL, Callaghan BC. Diabetes Res Clin Pract. 2023 Oct 25:110983. doi: 10.1016/j.diabres.2023.110983. Online ahead of print. PMID: 37890702

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, Solis S, Ciampricotti M, Yeaton AH, Ivanova E, Wohlhieter CA, Buus TB, Hayashi M, Karadal-Ferrena B, Pass HI, Poirier JT, Rudin CM, Wong KK, Moreira AL, Khanna KM, Tsirigos A, Papagiannakopoulos T, Koralov SB. Cell Rep. 2023 Oct 25;42(11):113295. doi: 10.1016/j.celrep.2023.113295. Online ahead of print. PMID: 37889752

TMPRSS2 is a functional receptor for human coronavirus HKU1.
Saunders N, Fernandez I, Planchais C, Michel V, Rajah MM, Baquero Salazar E, Postal J, Porrot F, Guivel-Benhassine F, Blanc C, Chauveau-Le Friec G, Martin A, Grzelak L, Oktavia RM, Meola A, Ahouzi O, Hoover-Watson H, Prot M, Delaune D, Cornelissen M, Deijs M, Meriaux V, Mouquet H, Simon-Lorière E, van der Hoek L, Lafaye P, Rey F, Buchrieser J, Schwartz O. Nature. 2023 Oct 25. doi: 10.1038/s41586-023-06761-7. Online ahead of print. PMID: 37879362

Sequence Analysis of the Malaysian Low Pathogenic Avian Influenza Virus Strain H5N2 from Duck.
Rizal FA, Ho KL, Omar AR, Tan WS, Mariatulqabtiah AR, Iqbal M. Genes (Basel). 2023 Oct 22;14(10):1973. doi: 10.3390/genes14101973. PMID: 37895321

Clinical diagnosis of SARS-CoV-2 infection: An observational study of respiratory tract infection in primary care in the early phase of the pandemic.
van der Velden AW, Shanyinde M, Bongard E, Böhmer F, Chlabicz S, Colliers A, García-Sangenís A, Malania L, Pauer J, Tomacinschii A, Yu LM, Loens K, Ieven M, Verheij TJ, Goossens H, Vellinga A, Butler CC. Eur J Gen Pract. 2023 Dec;29(1):2270707. doi: 10.1080/13814788.2023.2270707. Epub 2023 Oct 23. PMID: 37870070

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses.
Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Cancer Commun (Lond). 2023 Oct 26. doi: 10.1002/cac2.12498. Online ahead of print. PMID: 37882647 No abstract available.

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20231022:20231031 as the publication date 48 records*

1.WO/2023/202711MRNA VACCINE BASED ON NOVEL CORONAVIRUS
WO - 26.10.2023

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clasificación Internacional C12N 15/50 Nº de solicitud PCT/CN2023/089871 Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD. Inventor/a CEN, Shan
The present disclosure relates to an mRNA vaccine based on a novel coronavirus, in particular to a mRNA vaccine for preventing or treating coronavirus infection, a synthesis method for the mRNA vaccine, and an RNA composition. In particular, the present disclosure relates to an mRNA vaccine for preventing coronavirus infection by inducing an effective coronavirus antigen-specific immune response. The present disclosure further describes a method for preparing the vaccine and immunological evaluation of the vaccine.

2.20230338512CORONAVIRUS VACCINE
US - 26.10.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18071499 Solicitante BioNTech SE Inventor/a Alexander Muik
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

3.20230338497METHOD FOR PREPARING A VACCINE COMPOSITION FROM LYOPHILIZED ANTIGENS
US - 26.10.2023
Clasificación Internacional A61K 39/108 Nº de solicitud 18004980 Solicitante VAXINANO Inventor/a Didier Betbeder
The field of extemporaneous preparation of vaccine compositions from lyophilized antigens. More specifically, the present disclosure relates to the use of cationic nanoparticles to render the lyophilized antigens more soluble without adding a lyophilization aid, with a view to extemporaneous use for administering a vaccine composition. In a particular embodiment, the present disclosure allows a vaccine formulation to be prepared or one or more valencies to be added to a previously formulated vaccine composition.

4.20230338510NOVEL CORONAVIRUS TANDEM EPITOPE POLYPEPTIDE VACCINE AND USE THEREOF
US - 26.10.2023
Clasificación Internacional A61P 31/14 Nº de solicitud 18010522 Solicitante SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Inventor/a Likun GONG
Provided are a tandem epitope polypeptide vaccine for novel coronavirus and use thereof. Specifically, a vaccine polypeptide for novel coronavirus pneumonia is provided on the basis of analysis and study of the RBD sequence and structural information of the S protein of SARS-CoV-2. Said vaccine polypeptide comprises the following elements connected in series: a generic Th epitope sequence, a B cell epitope sequence and a T cell epitope sequence. The B cell epitope and the T cell epitope have an amino acid sequence from the RBM region of the S protein of SARS-CoV-2. Provided are a vaccine composition containing said vaccine polypeptide and use thereof. Experiments show that the vaccine polypeptide of the present invention can enable cynomolgus monkeys to initiate strong cellular and humoral immunity, and to generate neutralizing antibodies that block the binding of RBD and ACE2, and can be used for preventing and treating novel coronavirus pneumonia.

5.20230338490CANINE CANCER VACCINE

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18331475 Solicitante Arizona Board of Regents on behalf of Arizona State University Inventor/a Stephen Albert Johnston
Provided herein are vaccine compositions for use in immunotherapy for canine cancers, and methods of canine cancer immunotherapy using said compositions. The compositions and methods provided herein include DNA vaccines having two plasmids that encode thirty-one peptide antigens, plus a plasmid that encodes canine GMCSF.

6.20230338513CORONAVIRUS DISEASE (COVID-19) VACCINE
US - 26.10.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18186874 Solicitante Thomas Jefferson University Inventor/a Matthias Johannes Schnell
The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

7.20230338503PARENTERAL NOROVIRUS VACCINE FORMULATIONS
US - 26.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18322679 Solicitante Takeda Vaccines, Inc. Inventor/a Charles RICHARDSON
The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.

8.20230340387METHODS AND SYSTEMS FOR VACCINE PRODUCTION
US - 26.10.2023
Clasificación Internacional C12M 1/00 Nº de solicitud 17997711 Solicitante ADVA Biotechnology Ltd. Inventor/a Ohad KARNIELI
A decentralized distributed vaccine manufacturing systems and methods thereof provide a cost effective, simple to operate, automated, and small-scale development and manufacturing process by automated computer-controlled devices. The devices and methods disclosed that allows localized vaccine development and manufacture. The bioreactor systems can include at least one bioreactor chamber, at least one reservoir, a plurality of sensors, and a fluid circuit. The operational methods disclosed herein are directed towards growing cells or tissue while measuring various parameters, and a controlled operation of the various parameters during the operation of the bioreactor systems.

9.WO/2023/201881USE OF LENTINAN IN PREPARING SARS-COV-2 RESPIRATORY MUCOSAL VACCINE
WO - 26.10.2023
Clasificación Internacional A61K 31/716 Nº de solicitud PCT/CN2022/101512 Solicitante NAVAL MEDICAL UNIVERSITY, PEOPLE'S LIBERATION ARMY Inventor/a ZHAO, Ping
The present invention relates to the technical field of pharmaceutics, and particularly, to use of lentinan in preparing an SARS-CoV-2 respiratory mucosal vaccine. The SARS-CoV-2 respiratory mucosal vaccine is a vaccine using lentinan as the only immunologic adjuvant or using a composite adjuvant comprising lentinan administered by means of nasal drop or nasal spray to prevent SARS-CoV-2 infection.

10.20230338495Vaccine Compositions and Antibodies For Lyme Disease
US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18022087 Solicitante Vitruviae LLC Inventor/a Mahiuddin AHMED

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present invention relates to vaccine compositions comprising lipid antigens, antibodies targeting lipid antigens, pharmaceutical compositions comprising such and their use in diagnosing, monitoring, treating, and preventing infectious disease, such as Lyme disease. In one aspect, administered is a therapeutically effective amount of a vaccine composition comprising a lipid antigen, an antibody or fragment thereof binding a lipid antigen, and/or a pharmaceutical composition comprising an antibody or fragment thereof binding a lipid antigen. Other aspects are described.

11.20230338518Metal Aluminum Nano-Adjuvant, Vaccine Composition And Preparation Method Therefor And Use Thereof
US - 26.10.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 17728382 Solicitante Jilin University Inventor/a Kun LIU
Disclosed are a metal aluminum nano-adjuvant, a vaccine composition and a preparation method therefor and a use thereof. The vaccine adjuvant comprises metal aluminum nanoparticles, and can be used as a candidate adjuvant for preventive vaccines and therapeutic vaccines for various diseases such as infections, autoimmune diseases and tumors. The combined use of the vaccine adjuvant provided by the present disclosure and antigen can effectively enhance the humoral immune response and the cellular immune response of the vaccine, and the enhancement effect is significantly better than that of the commercially available aluminum hydroxide adjuvant.

12.4265272VERWENDUNG VON IMPFSTOFFZUSAMMENSETZUNGEN AUF BASIS EINER SARS-COV-2-REZEPTOR-BINDUNGSDOMÄNE BEI DER VERABREICHUNG VON SCHUTZIMMUNITÄT
EP - 25.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21854867 Solicitante INST FINLAY DE VACUNAS Inventor/a VEREZ BENCOMO VICENTE GUILLERMO
This invention relates to the field of Biotechnology and Medicine. It describes the use of vaccine compositions based on the receptor binding domain of SARS-CoV-2 virus in the treatment of patients recovered from COVID-19 and in subjects vaccinated with vaccine platforms other than subunit vaccines, who fail to develop effective protective immunity or where immunity has decreased over time and a booster with the same vaccine used in primary vaccination is not recommended. Particularly, this use is described for vaccine compositions comprising a covalent conjugate of the receptor binding domain (RBD) and a carrier protein such as tetanus toxoid, diphtheria toxoid and diphtheria toxoid mutant CRM197, vaccine compositions having the RBD as antigen, with or without the immunopotentiator outer membrane vesicles of serogroup B Neisseria meningitidis.

13.2618000Temperature stable nucleic acid method for preparing vaccine
GB - 25.10.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 202311520 Solicitante DOUGLAS T GJERDE Inventor/a DOUGLAS T GJERDE
Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.

14.WO/2023/203238STREPTOCOCCUS SUIS VACCINE COMPOSITION COMPRISING IMMUNOGENIC FUSION POLYPEPTIDES

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

WO - 26.10.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/EP2023/060533 Solicitante INTERVACC AB Inventor/a FROSTH, Sara
The present disclosure relates to immunogenic fusion polypeptides, immunogenic compositions and vaccine compositions comprising said fusion polypeptides and use thereof for immunization of mammals susceptible to *Streptococcus suis* infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.

15.WO/2023/201786IMMUNOLOGICAL ADJUVANT COMPOSITION AND CANCER VACCINE BASED ON COMPOSITION AND APPLICATION THEREOF
WO - 26.10.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/092201 Solicitante SUZHOU ERSHENG BIOMEDICAL CO., LTD. Inventor/a LIU, Mi
The present invention relates to an immunological adjuvant composition and a cancer vaccine based on the composition and an application thereof. The immunologic adjuvant composition at least comprises a combination of (1) and (2) in the following components: (1) Poly(I:C) or Poly(ICLC); (2) CpG-ODN, wherein the CpG-ODN is at least two of A-type CpG-ODN, a B-type CpG-ODN, and a C-type CpG-ODN, and at least one of the two is a B-type CpG-ODN or a C-type CpG-ODN; and (3) an amino acid, a polypeptide, a lipid, a saccharide, a protein, or an inorganic salt. A cancer vaccine based on the immunologic adjuvant composition is provided, comprising nanoparticles or microparticles, and an antigen component and an immunologic adjuvant composition loaded onto the nanoparticles or microparticles. The provided immunologic adjuvant composition can fully exert the efficacy of enhancing the adjuvant to activate the cancer-specific T cell reaction, and better assist the vaccine in exerting functions.

16.20230340535NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM
US - 26.10.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 18318325 Solicitante INTERNATIONAL AIDS VACCINE INITIATIVE, INC. Inventor/a Christopher L. PARKS
The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

17.4263811UNIVERSELLE BAKTERIOPHAGEN-T4-NANOPARTIKELPLATTFORM ZUM ENTWURF VON MULTIPLEX-SARS-COV-2-IMPFSTOFFKANDIDATEN DURCH CRISPR-ENGINEERING
EP - 25.10.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 21905936 Solicitante UNIV AMERICA CATHOLIC Inventor/a RAO VENIGALLA B
The present disclosure relates to a system for and a method of incorporating SARS-CoV-2 genes and proteins into T4 phages. The present disclosure also relates to vaccine against SARS-CoV-2 containing recombinant T4 phages created using the method provided in the present disclosure.

18.20230338493DECTIN-1 (CLEC7A) SINGLE NUCLEOTIDE POLYMORPHISM AS A BIOMARKER FOR PREDICTING ANTIBODY RESPONSE WHEN USING BETA-GLUCAN AS A VACCINE ADJUVANT
US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18001246 Solicitante MEMORIAL SLOAN KETTERING CANCER CENTER Inventor/a Irene Y. Cheung
The present disclosure relates generally to methods for determining whether a patient will show an enhanced immunogenic response to vaccines when using β-glucan as a vaccine adjuvant. Kits for use in practicing the methods are also provided

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

19.20230338491METHOD FOR SCREENING INDIVIDUAL TUMOR NEOANTIGEN PEPTIDE, AND VACCINE FORMULATION THEREOF
US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18338605 Solicitante HANGZHOU NEOANTIGEN THERAPEUTICS CO., LTD. Inventor/a Fan MO
A screening method of individualized tumor neoantigen peptide and a vaccine preparation thereof are provided. The screening method includes: Step 1, collecting and collating variable information for mutation producing a neoantigen and an antigenic peptide; Step 2, calculating according to a formula to obtain a score of each antigenic peptide; Step 3, arranging the antigen peptides in a descending order according to iNeo_Score, and selecting the antigen peptides from top to bottom successively; Step 4, continuing to select an antigenic peptide until enough candidate antigenic peptides are obtained or all of candidate antigenic peptides are selected so as to obtain screened antigenic peptides; and Step 5, grouping the screened antigen peptides into preparation groups. The designed individualized tumor neoantigen peptide is screened and prepared into a preparation in the disclosure, which includes screened antigen peptide, inorganic salt and an excipient. The preparation can be made into small-volume injection.

20.20230338500A COMBINATION OF VACCINES TO PROPHYLACTICALLY TREAT A PIG
US - 26.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17918006 Solicitante Intervet Inc. Inventor/a Maarten Hendrik Witvliet
The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of *Mycoplasma hyopneumoniae*, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with *Mycoplasma hyopneumoniae* and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.

21.20230338530COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME
US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17791685 Solicitante LG CHEM, LTD. Inventor/a Joon Ho SHEEN
Provided are a vaccine composition for preventing or treating cancer, the vaccine composition comprising antigen-presenting cells, on the cell surface of which a complex of a major histocompatibility complex (MHC) and a tumor antigen is overexpressed, and cancer treatment using the same.

22.WO/2023/201434VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS
WO - 26.10.2023
Clasificación Internacional C12N 15/63 Nº de solicitud PCT/CA2023/050537 Solicitante ENGINEERED ANTIGENS INC. Inventor/a MORAES, Trevor
Disclosed are novel veterinary vaccine compositions comprising a P. multocida PmSLP protein or an immunogenically equivalent portion thereof. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections of food production animals, such as bovine and porcine animals, caused by Pasteurella multocida. Related methods and uses are also disclosed.

23.WO/2023/201433VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

WO - 26.10.2023
Clasificación Internacional C12N 15/63 Nº de solicitud PCT/CA2023/050536 Solicitante ENGINEERED ANTIGENS INC. Inventor/a MORAES, Trevor
Disclosed are novel veterinary vaccine compositions comprising a *P. multocida* PmSLP protein or an immunogenically equivalent portion thereof. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections of food production animals, such as bovine and porcine animals, caused by *Pasteurella multocida*. Related methods and uses are also disclosed.

24.20230338511SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES
US - 26.10.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18023891 Solicitante University of Houston System Inventor/a Ke-He Ruan
Recombinant protein coronavirus antigens and vaccine compositions using the same, include a recombinant protein that is a single-chain (SC) viral membrane protein complex derived from the spike (S), envelop (E) and membrane (M) protein of a coronaviruses such as SARS-CoV-2, the causal agent for COVID-19. Methods for immunization of a subject using the vaccine compositions treats or prevents clinical signs caused by coronaviruses infection.

25.4265271VAKZINIMMUNOGENE
EP - 25.10.2023
Clasificación Internacional A61K 39/015 Nº de solicitud 23184802 Solicitante FUND OSWALDO CRUZ FIOCRUZ Inventor/a HILL ADRIAN VIVIAN SINTON
An immunogenic composition comprising: a) one or more plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in Figure 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in Figure 2 or Figure 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are plasmodium-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

26.WO/2023/201787CANCER-SPECIFIC T CELL-BASED CELL SYSTEM, LYMPHOCYTE DRUG AND USE THEREOF
WO - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2022/092331 Solicitante SUZHOU ERSHENG BIOMEDICAL CO., LTD. Inventor/a LIU, Mi
Provided are a cancer-specific T cell-based cell system, a lymphocyte drug and the use thereof. The cell system comprises cancer-specific T cells activated by a cancer vaccine, wherein the cancer vaccine comprises delivery particles and cell components loaded on the delivery particles, the delivery particles are nanoparticles or micron particles, and the cell components are water-soluble components and/or water-insoluble components in cells obtained by separating cancer cells and/or tumor tissues. Cancer-specific T cells can be activated by cancer vaccines or activated by injecting DC cells into the body after stimulation of DC cells in vitro by means of the cancer vaccines. An immune response is activated by means of an allogeneic body, innate immune cells and activated adaptive immune cells are transplanted into a receptor at the same time, and the clinical problem that a patient having poor immunocompetence cannot generate an effective immune response to a vaccine is solved.

27.20230338504Compositions for Booster Vaccination Against Dengue

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

US - 26.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18328403 Solicitante Sanofi Pasteur Inventor/a Diana Coronel
The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue naïve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4. The invention is also directed to a method of inducing in a human subject a neutralizing antibody response comprising the administration of a vaccine composition, or to a vaccine composition for use in such a method, said composition comprising a dengue antigen of each of serotypes 1 to 4, or a nucleic acid construct capable of expressing in said subject a dengue antigen of each of serotypes 1 to 4; wherein said composition is administered as a primary vaccination, followed by a booster vaccination, and wherein the human subject is initially dengue naïve.

28.WO/2023/201862ORTHOHEPEVIRUS SPECIES A PANGENOTYPE ORF3 PROTEIN AND USE THEREOF
WO - 26.10.2023
Clasificación Internacional C07K 14/10 Nº de solicitud PCT/CN2022/098150 Solicitante XUZHOU MEDICAL UNIVERSITY Inventor/a WANG, Wenshi
Disclosed are an Orthohepevirus species A (HEV-A) pangenotype ORF3 protein and use thereof. The HEV-A pangenotype ORF3 protein can be used for detecting the content of IgG and IgM antibodies in serum of a patient with hepatitis E, and still can detect the IgG and the IgM in the serum after the serum is respectively diluted by 500 times, thereby having high sensitivity. Since an ORF2 polypeptide serves as a main component of an HEV vaccine, an ORF2 antibody detection kit cannot distinguish between vaccine immune people and infected people. HEV positive cases detected according to an ORF3 protein detection kit can all be determined as people naturally infected with HEV.

29.WO/2023/205810NANO-ENHANCED VACCINE
WO - 26.10.2023
Clasificación Internacional A61K 9/127 Nº de solicitud PCT/US2023/066134 Solicitante UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor/a KESTER, Mark
Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART- 1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.

30.WO/2023/204559HIGH-TITER JAPANESE ENCEPHALITIS VIRUS GENOTYPE 5 AND USE THEREOF
WO - 26.10.2023
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/KR2023/005204 Solicitante KOREA NATIONAL INSTITUTE OF HEALTH Inventor/a SHIM, Sang Mu

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present invention relates to high-titer Japanese encephalitis virus genotype 5 and use thereof and, more particularly, to a high-titer virus produced using subculture and cerebral inoculation of mice, and a vaccine composition including same.

31.WO/2023/204148TREATMENT OF INFLAMMATORY CONDITIONS
WO - 26.10.2023
Clasificación Internacional C12N 7/04 Nº de solicitud PCT/JP2023/015132 Solicitante CYN-K, LLC Inventor/a UENO, Ryuji
The present disclosure provides a method for treating an inflammatory condition, especially an age related inflammatory condition in a mammalian subject in need thereof, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin-3 antigen, a composition or vaccine comprising for the purpose thereof.

32.4265637FÜR RESPIRATORISCHES SYNZYTIALVIRUS SPEZIFISCHES BINDUNGSMOLEKÜL
EP - 25.10.2023
Clasificación Internacional C07K 16/10 Nº de solicitud 21905720 Solicitante ZHUHAI TRINOMAB PHARMACEUTICAL CO LTD Inventor/a ZHENG WEIHONG
The present disclosure relates to a respiratory syncytial virus (RSV)-specific binding molecule and an application thereof. The present disclosure also provides a preparation method of the above molecule, and an application of the molecule in the preparation of a product that specifically binds to the RSV surface fusion glycoprotein and the preparation of an RSV vaccine, etc.

33.4262758VERFAHREN ZUR QUANTIFIZIERUNG VON CPG-HALTIGEN OLIGONUKLEOTIDEN IN ALAUNHALTIGEN FORMULIERUNGEN
EP - 25.10.2023
Clasificación Internacional A61K 9/19 Nº de solicitud 21908029 Solicitante DYNAVAX TECH CORP Inventor/a GOHLKE MARTIN
The present disclosure relates to methods for characterizing formulations comprising aluminum hydroxide particles (alum), an antigen bound to the alum, and an unmethylated cytidine-phospho-guanosine-containing oligodeoxynucleotide (CpG ODN). In particular, the present disclosure provides methods for determining concentration of CpG ODN in a vaccine formulation through use of a colorimetric assay for measuring total phosphorus.

34.20230338519FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY
US - 26.10.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 17998693 Solicitante Transmed Gothenburg AB Inventor/a Nils Lycke
The present invention relates to a fusion protein, a nucleotide sequence encoding such a fusion protein, the use thereof as an adjuvant or vaccine. The fustin protein comprises a bacterial exotoxin and a single chain antibody fragment (scFv) that specifically binds to a surface marker on dendritic cells. The fusion protein is advantageously administered intranasally, orally or intrapulmonarily.

35.4262854RNA-KONSTRUKT
EP - 25.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21836221 Solicitante IMPERIAL COLLEGE INNOVATIONS LTD Inventor/a SHATTOCK ROBIN
The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

36.4225351SAMMENSÆTNING OG FREMGANGSMÅDE TIL BEHANDLING AF KRÆFT UNDER ANVENDELSE AF EN VACCINE SOM EN FØRSTE TERAPEUTISK AKTIV INGREDIENS I KOMBINATION MED EN ANDEN AKTIV INGREDIENS
DK - 23.10.2023
Clasificación Internacional A61K 38/19 Nº de solicitud 21880926 Solicitante HPVVAX, LLC Inventor/a IOANNIDES, Tim
A method for treating or reducing the incidence of recurrence of cancer, benign tumors, or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering to a patient one or more doses of HPV recombinant vaccine as a first active therapeutic agent in combination with a second active therapeutic agent administered concomitantly or as a fixed-dose combination composition.

37.4262855RNA-KONSTRUKT
EP - 25.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21836222 Solicitante IMPERIAL COLLEGE INNOVATIONS LTD Inventor/a SHATTOCK ROBIN
The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

38.WO/2023/204693COMPOSITION FOR REDUCING SIZE OR VOLUME OF TARGET TISSUE OR KIT INCLUDING SAME
WO - 26.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/KR2023/005580 Solicitante SK BIOSCIENCE CO., LTD. Inventor/a KIM, Eun-som
The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

39.4262842KATH2-DERIVATE ZUR STIMULIERUNG DES ANGEBORENEN IMMUNGEDÄCHTNISSES
EP - 25.10.2023
Clasificación Internacional A61K 38/10 Nº de solicitud 21834957 Solicitante UNIV UTRECHT HOLDING BV Inventor/a HAAGSMAN HENDRIK PETER
The invention relates to methods for activating, inducing or promoting innate immune memory in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof. The invention further relates to methods of improving antimicrobial treatment in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof and to a use of CATH2 or a derivative thereof as an adjuvant for a pathogen-specific vaccine.

40.4262862IMMUNOGENES PEPTID
EP - 25.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21831097 Solicitante UCL BUSINESS LTD Inventor/a REEVES MATTHEW BRYAN

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

P120670PCT 56 ABSTRACT Immunogenic peptide The invention provides a human herpesvirus immunogenic peptide comprising a novel antigenic domain (AD) of glycoprotein B, termed AD-6. The invention also provides a nucleic acid sequence encoding said immunogenic peptide and an inhibitor that binds to said 5 immunogenic peptide. Also provided are an immunogenic composition, a pharmaceutical composition and a vaccine comprising said immunogenic peptide, nucleic acid sequence or inhibitor, and methods of treating or preventing a human herpesvirus infection.

41.20230338501LIVE-ATTENUATED RNA HYBRID VACCINE TECHNOLOGY
US - 26.10.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18024703 Solicitante ACCESS TO ADVANCED HEALTH INSTITUTE Inventor/a Neal VAN HOEVEN
This disclosure provides ribonucleic acid (RNA) polynucleotides encoding replication-competent viral genomes that, when introduced to a subject, induce an active viral replication. The RNA may be provided naked or with an artificial RNA delivery system. The viral genome may be a full-length genome of an attenuated viral strain. For example, the RNA may encode an attenuated Chikungunya or yellow fever virus. The artificial RNA delivery system may be a lipid particle such as a lipid nanoparticle (LNP), a nanostructure lipid carrier (NLC), or a cationic nanoemulsion (CNE). This disclosure also provides methods of inducing an immune response, including protective immunity, by administering to a subject an RNA polynucleotide that encodes a replication-competent viral genome in an amount sufficient to cause viral replication in the subject. The immune response may include inducing the production of neutralizing antibodies at a level comparable to inoculation with a live-attenuated virus.

42.WO/2023/205627ENTEROCOCCUS FAECALIS VACCINE AND USES THEREOF
WO - 26.10.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/US2023/065878 Solicitante VAXCYTE, INC. Inventor/a FAIRMAN, Jeffery C.
The present disclosure provides immunogenic compositions comprising at least one recombinant polypeptide antigen derived from an *Enterococcus* bacterium (e.g., *E. faecalis, E. faecium*, *E. durans*). The disclosure further provides methods, and uses of the immunogenic compositions, for protecting or treating a subject from infection by an *Enterococcus* bacterium. Such infections may cause, or worsen, conditions such as root canal failure, endocarditis, bacteremia, urinary tract infections, prostatitis, intraabdominal infection, cellulitis, dysbiotic gastrointestinal tract, prosthetic joint infection, or wound infections.

43.20230338251METHOD OF TREATING CANCER
US - 26.10.2023
Clasificación Internacional A61K 8/34 Nº de solicitud 18336379 Solicitante Intensity Therapeutics, Inc. Inventor/a Lewis H. BENDER
The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

44.4263838VERFAHREN UND ZUSAMMENSETZUNGEN ZUR HEMMUNG VON ÜBERSCHÜSSIGEM NUKLEINSÄUREFÄLLUNGSNACHWEIS
EP - 25.10.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 21831366 Solicitante PFIZER Inventor/a KALLA NEHA

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present disclosure describes improved methods for use in purifying biological products made by host cells. In some embodiments, the improved methods comprise one or more steps of lysing host cells, such as with a detergent, to release the biological product, precipitating host cell DNA,such as with domiphen bromide, and then inhibiting precipitation of residual host cell DNA in a supernatant containing the biological product by adding a salt to a sufficient final concentration. In some embodiments, the biological product is a vaccine, or a viral vector for gene therapy, such as an AAV vector or a lentiviral vector.

45.20230340046NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 26.10.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 18314878 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

46.WO/2023/204252NON-REPLICATING BOVINE INFECTIOUS LYMPHOMA VIRUS (BLV) AND CELLS FOR PRODUCING SAME
WO - 26.10.2023
Clasificación Internacional C12N 15/48 Nº de solicitud PCT/JP2023/015633 Solicitante THE UNIVERSITY OF TOKYO Inventor/a AIDA Yoko
The purpose of the present invention is to provide: a novel non-replicating bovine infectious lymphoma virus (BLV); and a cell for producing the same. According to the present invention, provided is a bovine infectious lymphoma virus (BLV) in which at least part of the function of pol genes is lost. Moreover, according to the present invention, provided is a non-replicating BLV-producing cell which contains genes of the BLV in which at least part of the function of pol genes is lost. The present invention is advantageous in that a BLV vaccine having high immunogenicity and high safety in which replication does not occur in an infected subject can be provided.

47.20230338489NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
US - 26.10.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18323577 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

48.WO/2023/202607POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE COMPONENT AND APPLICATION THEREOF
WO - 26.10.2023

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clasificación Internacional A61K 39/116 Nº de solicitud PCT/CN2023/089161 Solicitante SHANGHAI REINOVAX BIOLOGICS CO., LTD Inventor/a ZHU, Xianchao
The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

CUBA